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Abstract 
Abstract 
The high number of cancer deaths in the western world is of growing concern. 
There were an estimated 2.6 million new cases of cancer in Europe in 1995, 
representing over one-quarter of the world burden of cancer despite Europe's 
inhabitants comprising only one-eighth of the world's population. The 
corresponding number of deaths from cancer was around 1.6 million. These 
figures demonstrate the very substantial burden of cancer in Europe, and since a 
lot of cancer mortality is, at least in theory, highly preventable, more research is 
needed into where cancer mortality poses the strongest threat and what 
preventative interventions are needed. 
This thesis attempts to provide accurate estimates of cancer mortality rates 
throughout Europe by using appropriate modelling methods to produce smoothed 
disease maps of the true distribution of the disease. Since this study is on a large 
scale geographically, mortality data and risk factor exposure data are not available 
at an individual level. However, different forms of aggregated data are available 
allowing this ecological study to be carried out. Incorporating differing levels of 
exposure to various risk and protective factors reduces the variation in the disease 
risk estimates and allows the effects such factors have on European cancer 
mortality patterns to be quantified. 
Poisson spatial multilevel modelling techniques are used to explore the 
distribution of all cancer mortality. The models are fitted using both empirical 
Bayes and fully Bayesian approaches and the effects of incorporating a spatial 
factor and of adding a higher geographical level are explored. The Poisson spatial 
multilevel model with correlated covariance structure was compared to other 
models which are commonly used for disease mapping purposes; the conditional 
autoregressive (CAR) model and the multiple-membership multiple-classification 
(MMMC) model. The most suitable method for modelling aggregated mortality 
Abstract 
data proved to be the spatial multilevel model which allows for correlated random 
effects and is fitted using Monte Carlo Markov Chain (MCMC) methods. 
This model is then used to explore the spatial mortality patterns of specific 
cancers, namely, lung, colorectal and oesophageal cancer, in the EU. Variability 
within and between countries was evident for each of the cancer groups examined. 
Much of this variation could be accounted for by risk factors such as smoking and 
diet, which had strong yet differing effects on each of the cancers. Accounting for 
spatial patterning of the disease was also shown to reduce variation in cancer 
mortality substantially across the EU. Cancer 'hotspots' were identified providing 
evidence that urgent preventative public health intervention on tobacco and diet 
modification is required in many European regions. 
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Chapter 1 Introduction 
Chapter 1 
1 Introduction 
1.1 Motivation 
The World Health Organisation recently published an atlas of mortality in Europe 
(1). Population and mortality information was collected for the periods 1980/1981 
and 1990/1991, co-ordinating with two recent censuses. The atlas was attempting 
to identify differences in trends in mortality from various causes at the sub-
national level in Europe and also to indicate areas in which more study is needed 
to determine both reasons for these differences and the most appropriate action to 
reduce them. The data collected by WHO have been made available and provided 
the initial motivation and main source of information for this study. 
Using subsets of this data set and developing existing spatial modelling 
methods, the aim of this thesis is to provide an accurate account of the spatial 
patterning of cancer mortality across Europe. 
1.1.1 Cancer Mortality 
The high number of cancer deaths in the western world is of growing concern. 
There were an estimated 2.6 million new cases of cancer in Europe in 1995, 
representing over one-quarter of the world burden of cancer despite Europe's 
inhabitants comprising only approximately one-eighth of the world's population. 
The corresponding number of deaths from cancer was around 1.6 million (2). It 
has been predicted that in 2020, 3.4 million new cases of cancer will occur in 
Europe (3). These figures demonstrate the very substantial burden of cancer in 
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Europe, and the scope for prevention and has motivated the research for this 
thesis. 
Studies of continuity of mortality rates across national borders and an 
evaluation of the distribution between national and regional variations in health 
status have revealed large spatial mortality variation both within and between 
countries in Europe (1). This thesis aims to show such patterns but specifically in 
relation to cancer mortality. More accurate estimates of mortality rates are 
obtained by incorporating additional information that has been gathered with 
regards to potential risk and protective factors for cancer mortality. Variation in 
cancer mortality often reflects differences in demographic structure, socio-
economic conditions or lifestyle factors. It is of particular interest to quantify the 
effect of such factors on cancer mortality patterns and also to examine any 
relationships that exist after taking these factors into account. 
1.1.2 Disease Mapping 
A common method used to investigate the spatial variability of a disease such as 
cancer is to map mortality rates. Producing accurate disease maps of cancer 
mortality is of key importance in the field of public health as it draws experts in 
the area closer to understanding the true geographical distribution of a potentially 
fatal disease which is becoming ever more common. 
Disease mapping has been a growing area over recent years (4) with the 
main aim being to produce a map 'clean' of random noise and any natural 
variation in the human population, allowing the identification of areas with high 
or low rates. This research aims to develop existing disease mapping methods to 
produce accurate maps of cancer mortality allowing the assessment of the true 
underl ying distribution of the disease. 
2 
-·---r---· --- Introduction 
1.1.3 Spatial Multilevel Modelling 
To produce accurate disease maps of cancer mortality, accurate estimates of 
disease rates have to be calculated. The method proposed in this thesis is to 
provide estimates by Poisson spatial multilevel modelling techniques. 
Geographically distributed data such as counts of cancer deaths within 
regions within countries take on a natural hierarchical structure and exemplifies 
the type of data appropriate for a multilevel analysis. The observations within 
these clustered units are likely to be more similar than observations from different 
clusters, due to shared social and geographical environments. It is therefore 
important to take account of this underlying structure and the correlation that 
exists between observations from the same cluster. Along with taking into account 
the multilevel structure of the data this method gives a convenient and efficient 
way to overcome problems which arise from traditional methods of modelling and 
mapping disease rates. It allows the extra-Poisson variation, that often exists in 
observed counts of cancer deaths, to be modelled. Also, areas geographically 
close to one another share similar disease rates and common factors which 
influence the incidence and outcome of a disease, and this spatial patterning of 
disease can be taken into account through multilevel modelling. Using this type of 
modelling to estimate risks of disease mortality allows potential ecological 
covariates to be incorporated into the models, hopefully giving a more accurate 
picture of disease patterns across the map. Modelling these ecological covariates 
also gives the opportunity to quantify the associations they have with cancer 
mortality across Europe. 
The research that exists in Poisson spatial multilevel modelling concentrates 
mainly on fitting models with two levels. This research extends existing models 
(5, 6) to incorporate further levels such as country at a higher level. 
Earlier disease mapping applications tended to focus on fitting models using 
empirical Bayes approaches. However, more recently, with the growmg 
availability of Markov Chain Monte Carlo methods in packages such as 
WinBUGs (7), there has been much development in fully Bayes approaches. Both 
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methods are explored in this thesis in terms of fitting Poisson spatial multilevel 
models with a correlated variance structure. These methods are compared, along 
with two other MCMC methods that have been proposed as reliable approaches to 
modelling such multilevel data; the multiple membership model and the 
conditional autoregressive model. 
1.2 Objectives 
The main objectives of this thesis are to explore the patterns of cancer mortality in 
Europe and to develop Poisson spatial multilevel models to provide accurate 
estimates of mortality risks. Since this study is on such a large scale 
geographically, mortality data and risk factor exposure data are not available at an 
individual level. However, different forms of aggregated data are available 
allowing this 'ecological study' to be carried out. 
Despite this type of analysis being fairly crude it can play an important role 
in epidemiology. For example, detecting areas or clusters with extreme disease 
rates could influence geographical assessment of health resource allocation; or 
significant relationships that are shown to exist between rates of a disease and the 
prevalence of a risk factor in given populations while analytically controlling for 
the prevalence of other confounding factors and for spatial autocorrelation may 
lead to the formulation of aetiological hypothesis which can then be examined 
further on an individual level. 
1.3 Summary of Thesis 
In the following Chapter, a summary is gIven of existing literature that has 
explored cancer mortality risk and protective factors. This review identifies the 
relationships that are known to exist between four specific cancers and lifestyle 
factors such a diet, smoking and socio-economic status. 
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In Chapter 3 a description and summary of the European population and 
cancer mortality data is given. The problems associated with data that has been 
collected on such a wide scale, such as data quality and missingness, are 
discussed. Data was also obtained that represents exposure to the various risk 
factors discussed in Chapter 2. Descriptions of these data sets, along with their 
summaries and problems are also given. 
Chapter 4 reviews existing methods of disease mapping. The main focus is 
on modelling Poisson distributed counts of deaths and the development of the 
methods used to model relative risks of disease are explored. This involves 
looking at more recent spatial methods from both empirical Bayes and fully 
Bayesian approaches. 
In Chapter 5, the European cancer mortality data are modelled usmg 
multilevel models. Variance components models are fitted and estimated using 
iterative generalised least squares procedures and quasi-likelihood methods. This 
model is extended to incorporate a spatial component and the resulting estimates 
are discussed. Disease maps of the relative risks from the models are examined. 
Chapter 6 explores fitting the spatial multilevel model to the European 
cancer mortality data using Markov chain Monte Carlo. Aspects of using this fully 
Bayes method are discussed including fitting the model using WinBUGS, choice 
of priors, different sampling methods and convergence properties. Again, results 
are discussed and estimates explored through disease maps. The model is then 
extended to incorporate a further country level and differences in the results are 
discussed. 
In Chapter 7 two other approaches to fitting spatial multilevel models are 
explored. Using MCMC, a multiple membership model and a correlated 
autoregression model are fitted to the cancer mortality data. Results from these 
methods are compared to the empirical Bayes' variance components and spatial 
multilevel models fitted in Chapter 5 and to the MCMC spatial multilevel model 
fitted in Chapter 6. Point estimates, confidence intervals and the diagnostic 
information criterion are used to compare the models. One model is then chosen 
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to explore specific cancer mortality rates further. In Chapter 8 lung, colorectal and 
oesophageal cancer mortality rates are examined separately using the MCMC 
three-level spatial multilevel model. The focus in this Chapter is mainly on 
identifying any 'hot spots' of cancer mortality from the disease maps and to 
quantify the causal relationships that exist between the specific cancer mortality 
rates and risk factors. 
Finally, Chapter 9 discusses the limitations of the research carried out, both 
from a statistical modelling perspective and from a public health point of view. 
General conclusions about the thesis as a whole are drawn. 
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Chapter 2 
2 Cancer Mortality Risk Factors 
2.1 Introduction 
Prevention of cancer is an increasingly important and integral part of public 
health. The first steps in preventing this disease are to understand its causes and 
attempt to quantify the proportion of cases due to each cause. Previous studies of 
geographic variation in cancer rates have provided important clues to the role of 
lifestyle factors and cancer risk. 
2.2 Diet 
The relationship between dietary components and cancer is not fully established; 
however, the overall impact of diet on cancer mortality appears to be significant. 
Evidence that diet is a determinant of cancer risk comes from several sources, 
including the following: correlation between national and regional food 
consumption data and the incidence of cancer in the population; studies on the 
changing rates of cancer as they migrate from a region or country of one dietary 
culture to another; case-control studies of dietary habits of individuals with and 
without cancer; prospective studies; intervention studies. While it is not yet 
possible to provide quantitative estimates of the overall risks, it has been 
estimated that 35 percent of cancer deaths may be related to dietary factors (8). 
The association between dietary components and cancers differs among different 
cancers or groups of cancers. 
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A recent study into the estimates of cancer incidence and mortality in 
Europe (2) showed that the most common cause of death in Europe in 1995 
among cancers was lung cancer with 330,000 deaths, representing about one fifth 
of the total number of cancer deaths. Deaths from cancer of the colon and rectum 
(189,000) ranked second. Breast cancer was the most common cause of cancer in 
females, representing 17% of all female cancer deaths and lung cancer the most 
common in males (29%). Most countries in Europe have shown a rising trend in 
oesophageal cancer over the last thirty years, especially in males (9). In 1990, 
oesophageal cancer accounted for 3% of male cancer deaths (10). The rising trend 
and poor prognosis (five-year survival in Europe is less than 10 percent (11», 
makes this disease of growing concern in cancer research. Further details of the 
specific relationships in these cancer groups (breast, colorectal, oesophageal and 
lung) are summarised in Table 2.1. Note that the blank areas in the table indicate 
that there is insufficient evidence of a relationship. 
Table 2.1 Association between dietary components and selected cancers 
Dietary 
Site of Cancer 
Component Breast Colorectal Oesophageal Lung 
Animal Fats + + + 
Vegetables 
Fruit 
Fish/Fish Oil 
Alcohol + + + + 
Coffee 
Cheese + 
+ = positive association; increased intake with increased cancer mortality 
negative association; increased intake with decreased cancer mortality 
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2.2.1 Breast Cancer and Diet 
Breast cancer is a common cause of death in woman throughout Europe. The 
EUROCARE IT study recently estimated survival rates of incident cases between 
1985 and 1989 in 17 countries in Europe (11) in which breast cancer was shown 
to have a five-year survival rate of 75%. One of the most often studied cancer 
associations is breast cancer risk and dietary fat. Earlier studies have supported 
the causal association between dietary fat and breast cancer; however, many 
recent studies have been uncertain. Research suggests that these conflicting results 
are due to concentration on dietary fat as opposed to a more specific focus on 
content of saturated fat in the diet along with fruit and vegetable consumption 
(12). Saturated fat, found mainly in animal fats, has been found to be positively 
related to risk of breast cancer. A recent ecologic study conducted using breast 
cancer mortality rates and dietary supplement data confirmed results from other 
studies showing that animal products are associated with risk for breast cancer and 
that fish intake and vegetable consumption are associated with risk reduction (13). 
There is strong and consistent evidence that increased consumption of fruit and 
vegetables is associated with reduced risks of many common forms of cancer 
including breast cancer (14, 15). A meta-analysis of studies on breast cancer risk 
and diet confirmed the association between intake of vegetables and, to a lesser 
extent, fruits and breast cancer risk (16). There has been much research focusing 
on dairy foods specifically. However, the only conclusive results regarding breast 
cancer risk appears to be a positive association with cheese intake (17). Many 
case-control and cohort studies (18, 19) and meta-analyses (20) have found a 
positive association between alcohol use and breast cancer. A study found risk of 
breast cancer was increased by 40-45 % for woman ever drinking versus never 
drinking (21). The ecologic study, mentioned above, that examines breast cancer 
mortality rates (13) found alcohol to be an associated risk factor. It has been 
suggested that fibre intake decreases the risk of breast cancer. However, 
epidemiological studies have not consistently supported such a relationship. A 
meta-analysis of ten case-control studies (22) showed dietary fibre was inversely 
associated with the role of breast cancer, but, Willet at al (23) discussed that, in a 
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large number of prospective studies, inverse associations have generally not been 
shown to exist. 
2.2.2 Colorectal Cancer and Diet 
Colon cancer is the third most common form of cancer in Europe with particularly 
high incidence rates in Western Europe. Colorectal cancer is a leading cause of 
cancer mortality in the industrialised world. More literature is available examining 
relationships between diet and colon cancer incidence rather than mortality, but 
incidence should be a resonable measure of colorectal cancer mortality rates as 
survival of cancer of the colon is fairly poor because most cases are diagnosed at 
an advanced stage (24). The EUROCARE II project (11) showed colorectal 
cancer to have a five-year survival rate of 50%. Almost all the specific risk factors 
of colorectal cancer are of dietary origin. International comparisons indicate diets 
low in dietary fibre (low in vegetable and fruit consumption) and high in animal 
fat increase the risk of colon cancer (25). The large majority of studies in humans 
has found a protective effect of fibre from vegetables and possibly fruits (26, 27). 
Willett et al showed that animal fat from red meat intake was positively associated 
with colon cancer but dairy foods which contributed to total animal fat intake 
were not significantly related to the risk of colon cancer (28). High fat intake has 
been shown to be positively associated with the risk of colorectal cancer (26, 29). 
Fernandez et al suggested that fish consumption has a protective effect against 
colon cancer (30). Tavani et al confirmed coffee to be a risk factor showing an 
inverse association between coffee intake and risk of cancer of the colon (31). A 
prospective study of cancers of the colon and rectum confirmed a positive 
association between alcohol use and cancer of the colon (32). 
2.2.3 Oesophageal Cancer and Diet 
Cancer of the oesophagus is generally characterised by relatively low mortality 
rates in Europe with incidence in most Western European countries also being low 
(33). Several studies have demonstrated a positive association between 
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oesophageal cancer and several dietary factors including low intakes of vitamin A, 
C, riboflavin, nicotinic acid, calcium and zinc (34). In dietary terms the 
associations are with low intakes of lentils, green vegetables, fresh fruits and 
animal protein. Fernandez et al found a significant negative relationship with fish 
consumption and oesophageal cancer (30). Alcohol appears to playa major risk in 
many of the epidemiological studies examining risk factors for oesophageal 
cancer with intake of alcohol appearing to be an independent risk factor (34). A 
fairly recent study looking at oesophageal cancer mortality in Spain found similar 
results to other studies, supporting a role of alcohol in causation of oesophageal 
cancer (35). 
2.2.4 Lung Cancer and Diet 
Lung cancer is the most common cause of cancer mortality among men in Europe, 
and is becoming an increasingly important cause of cancer mortality among-
women (2). During the last 25 years it has become apparent that diet is the other 
major cause of cancer, but theories have moved steadily from a search for causal 
agents (eg, too much fat) to protective agents (eg, too little fruit and vegetables) 
(36, 37). Mortality studies have shown excess risk to be associated with 
consumption of saturated fats (red meat) (38, 39) and protective effects associated 
with the intake of vegetables (40) and fruit (41). Lung cancer incidence has also 
been shown to have an inverse association with high intakes of plant foods (42). A 
comprehensive search of the literature available on relationships between diet and 
lung cancer showed that a diet rich in fruit and vegetable reduces the incidence of 
lung cancer by approximately 25% (43). Evidence of dairy fats having a particular 
effect on lung cancer is inconclusive (17). Many of the suggested relationships 
between alcohol and lung cancer are actually confounded, or at least can be 
explained, by smoking. However, overall, the existing evidence suggests a small 
increase in the risk of lung cancer from alcohol drinking that does not appear to be 
fully explained by tobacco smoke (44). 
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2.3 Lifestyle Factors 
Other lifestyle factors such as smoking and socio-economic status are commonly 
associated with the risk of cancers. It has been shown that people with high socio-
economic status are at a greater risk from some cancers; however, evidence of an 
association with cancer mortality is sometimes inconclusive. Smoking is well 
known to be a major risk factor for many common cancers. The relationship 
between such lifestyle factors and the four cancers previously discussed are 
shown in Table 2.2. 
Table 2.2 Association between other lifestyle factors and cancer mortality 
Lifestyle Factor 
Smoking 
High socio-
economic status 
Breast 
Site of Cancer 
Colon Oesophageal 
+ 
2.3.1 Breast Cancer and Lifestyle Factors 
Lung 
+ 
Earlier evidence that breast cancer risk is unlikely to be affected by cigarette 
smoking continues to be challenged by recent findings. Although no defmite 
conclusions can be made, several recent studies have reported findings that 
strongly hinted at such a relationship. A recent survival study found smoking to be 
a significant risk factor for breast cancer mortality (45). However, a recent 
collaborative reanalysis of individual data from 53 epidemiological studies (46) 
showed smoking has little or no independent effect on the risk of developing 
breast cancer. Some recent studies have established passive exposure to 
environmental tobacco smoke (ETS) as a risk factor for breast cancer (47), yet 
another study looking at breast cancer mortality found no relationship with ETS 
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(48). It appears that results from studies into the effect cigarette smoking has on 
breast cancer mortality are equivocal and need further examination. 
Socio-economic status is thought to influence the risk of breast cancer (49). 
A study of breast cancer in young women showed that, compared with controls, 
cases were significantly more educated (50), with breast cancer incidence being 
most frequently reported in those with greater than thirteen years education. Few 
studies have shown such a relationship with breast cancer mortality, and many 
conflicting results have appeared. However, a recent study showed a clear 
gradient in survival, with better survival for women with higher socio-economic 
status (51). There is also an increasing amount evidence to suggest a positive 
association between risk of breast cancer and obesity (52-54). 
2.3.2 Colorectal Cancer and Lifestyle Factors 
Colorectal cancer also appears to be clearly affected by socio-economic status. 
Tavani et al showed that the number of years of education was strongly associated 
with colorectal cancer incidence with a significant trend in risk when comparing 
those with the highest level of education to those with less than seven years' 
education (50). There is little evidence to suggest that this association is also 
apparent with colorectal cancer mortality but incidence, again, may be viewed as 
an indicator of mortality due to the poor survival rates. There also appears to be 
little evidence of an association between cigarette smoking and colorectal cancer 
mortality. However, an increased risk of colorectal cancer with early onset and a 
long history of cigarette smoking has been suggested (55), but no association was 
seen in a large case-control study (56) or in a study of male construction workers 
in Sweden (57). 
2.3.3 Oesophageal Cancer and Lifestyle Factors 
Many studies have consistently identified smoking as a risk factor for oesophageal 
cancer. A recent mortality study confirmed this by showing the role of cigarette 
consumption on causation of oesophageal cancer (35). Nyren and Adami (58) give 
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a comprehensive review of the evidence suggesting a positive association between 
tobacco smoking and oesophageal cancer. There is little evidence of an 
association between socio-economic status and deaths from oesophageal cancer. 
In recent years obesity has emerged as a major risk factor for this disease with a 
positive association being shown to exist between BMI or relative weight and 
oesophageal cancer (59-63). 
2.3.4 Lung Cancer and Lifestyle Factors 
It is well known and accepted that tobacco smoking is the main risk factor for 
lung cancer. The risk among smokers relative to the risk among never-smokers 
lies between 8 to 15 in men and 2 to 10 in woman (44). These risks reflect the 
contribution of the different aspects of tobacco smoking, namely, average 
consumption, duration of smoking, time since quitting, age at start, type of 
tobacco product, and inhalation pattern. Evidence of a causal relationship between 
cigarette smoking and lung cancer mortality has been accumulating since the 
1950s. In recent years more attention has been focused on the potential health 
effects of ETS. Numerous studies have now led to the expectation that exposure to 
ETS also entails some increase in lung cancer risk (64). There is little evidence of 
a relationship between socio-economic status and lung cancer mortality. The 
prognosis of lung cancer is generally poor due to the carcinomas being diagnosed 
at an advanced stage. In Europe, the 5-year survival from 1985-1989 is reported to 
be 10% for woman and 9% for men (65), and therefore there is less scope, in 
terms of time, for inequalities in survival by socio-economic group to occur. 
However, due to the poor prognosis, relationships with lung cancer incidence and 
socio-economic status are likely to reflect mortality rates as well. In most 
countries, lung cancer incidence in men and woman shows a social class gradient, 
with those from higher social classes having lower incidence than lower social 
classes (66). 
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3.1 Mortality and Population Data 
One of the main goals of cancer control is to reduce mortality from the disease. 
Hence, examining mortality as an outcome is an important method to use when 
attempting to quantify the burden of cancer in a given population. 
There are various measures of disease burden, namely incidence, cumulative 
incidence, prevalence, survival, life-years lost and disability-adjusted life years. 
However mortality is widely considered the most important indicator of the 
burden of cancer. Cancer mortality rates measure, at a given population level, the 
risk of dying from specific cancers or from all cancers. 
3.1.1 Source of Data 
The World Health Organisation recently published an atlas of mortality in Europe 
(1). Along with providing national averages for all the main causes of death 
within the WHO European Region, it aims to provide a geographical presentation 
of variations in gender and cause specific mortality across the WHO European 
Region. Information has been collected for the periods 1980/1981 and 1990/1991 
to attempt to identify differences in trends in mortality at the sub-national level in 
Europe. The atlas also indicates areas in which more study is needed to determine 
both the reasons for these differences in mortality rates and the most appropriate 
action to reduce them. The information provided by WHO attempts to serve as a 
background against which to generate hypotheses and to formulate programmes 
15 
Chapter 3 Data 
for epidemiological studies to explain the differences found within and between 
countries. The data collected by WHO have therefore been made available and 
will provide the main source of information for this project. 
Data were only available from official national sources in European Member 
States. Collection of data was finalised in 1995 and up until this date there were 
49 countries who were member states of the WHO European region. Data for the 
Federal Republic of Yugoslavia are included but this country is not a WHO 
Member State. A list of these countries and the years they became member states 
is given in Table 3.1. A map of the areas covered by the WHO European region is 
given in Figure 3.1 
3.1.2 Population Data 
Population data were requested from time points that co-ordinated with two recent 
censuses, providing information on the number of residents, according to midyear 
estimates, per region of residence for the years 1980, 1981, 1990 and 1991. The 
data have been broken down into 5-year age bands (up to the 80-84 age band and 
then all aged 85 and over) for both sexes. Region of residence was defined 
according to the EUROSTAT nomenclature of administrative units in the 
countries of the European Union (EU) or corresponding administrative 
equivalents in other countries. Where available, the units of analysis were level II 
NUTS (standard nomenclature of territorial units for statistics) or an equivalent 
level (sub-national) just below the country level (such as county in the UK, 
department in France, voivodship in Poland and oblast in the Russian Federation). 
Population data are available for 36 countries in the WHO European Region 
for the period 1980/81 and for 44 countries in 1990/91. The total population for 
these 36 countries in 1980/81 (averaged over the 2 timepoints) is 677,057,315 
with a mean of 18,807,148 and a range from 229,482 (Iceland) to 139,221,495 
(Russian Federation). In 1990/91 the total population for the same 36 countries is 
722,727,899 with a mean of 20,075,775 and a range from 256,377 (Iceland) to 
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Table 3.1 Countries in the WHO European Region 
Country Date of becoming party to WHO Constitution 
Albania 
Armenia 
Austria 
Azerbaijan 
Belarus 
Belgium 
Bosnia & Herzegovina 
Bulgaria 
Croatia 
Czech Republic 
Denmark 
Estonia 
Finland 
France 
Georgia 
Germany 
Greece 
Hungary 
Iceland 
Ireland 
Israel 
Italy 
Kazakhstan 
Kyrgyzstan 
Latvia 
Lithuania 
Luxembourg 
Malta 
Monaco 
Netherlands 
Norway 
Poland 
Portugal 
Republic of Moldova 
Romania 
Russian Federation 
San Marino 
Slovakia 
Slovenia 
Spain 
Sweden 
Switzerland 
Tajikistan 
The Former Yugoslav Republic of 
Macedonia 
Turkey 
Turkmenistan 
Ukraine 
United Kingdom 
Uzbekistan 
Yugoslavia, Federal Republic of 
26 May 1947 
4 May 1992 
30 June 1947 
2 October 1992 
7 April 1948 
25 June 1948 
10 September 1992 
9 June 1948 
11 June 1992 
22 January 1993 
19 April 1948 
31 March 1993 
7 October 1947 
16 June 1948 
26 May 1992 
29 May 1951 
12 March 1948 
17 June 1948 
17 June 1948 
20 October 1947 
21 June 1949 
11 April 1947 
19 August 1992 
29 April 1992 
4 December 1991 
25 November 1991 
3 June 1949 
1 Feb 1965 
8 July 1948 
25 April 1947 
18 August 1947 
6 May 1948 
13 February 1948 
4 May 1992 
8 June 1948 
24 March 1948 
12 May 1980 
4 February 1993 
7 May 1992 
28 May 1951 
28 August 1947 
26 March 1947 
4 May 1992 
22 April 1993 
2 January 1948 
2 July 1992 
3 April 1948 
22 July 1946 
22 May 1992 
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Figure 3.1 Map of the WHO European Region 
(Israel , Kyrgyzstan and Tajikistan are not shown on this map) 
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149,749,900 (Russian Federation). The total population in these countries has had, 
on average, a 7% increase during this ten year time period. Data were available at 
a sub-national level for 24 countries in 1980/81 and 31 countries in 1990/91. The 
mean population for a region (using only the 24 countries available over both time 
periods) is 1,545,474 with a range from 12,807 (Appenzell-Inner Rhoden in 
Switzerland) to 1,7044,864 (North Rhine-Westphalia in Germany) in 1980/81. In 
1990/91, the mean is 1,558,570, ranging from 13,593 to 17,328,180 (same regions 
as 1980/81). Table 3.2 summarises the population data for each country. 
3.1.3 Mortality Data 
Cause-specific death data by gender and region of residence were provided for all 
ages and for the groups aged 0,1-14,15-34,35-64,65-74,75-79,80-84 and 85 
and over. Again the data were provided for the time periods 1980/1981 and 
1990/1991. The causes of deaths were based on the Ninth Revision of the 
International Classification of Diseases (ICD-9). There are 19 specific diagnostic 
categories within 8 main groups of causes of deaths (see Table 3.3). These causes 
of death categories account for around 80% of all deaths and constitute the most 
important causes of death in the European population. 
Mortality data are available for 36 countries in 1980/81 and 43 in 1990/91. 
In the 35 countries with data available over both time periods, there were a total of 
6,988,156 deaths recorded in 1980/81 and 7,576,797 in 1990/91. Total deaths 
have, on average, increased by 8% over the ten year period. Taking into account 
population size at a regional level, crude death rates were calculated for each 
country and region. A summary of these is given in Table 3.4. Thirty-four 
countries have the crude death rates available for both time periods. For these 
countries, the mean crude death rate for 1980/81 is 1012 (per 100,000), ranging 
from 540 (Armenia) to 1354 (Hungary). For 1990/91 the mean crude death rate is 
1017, with a range from 633 (Armenia) to 1404 (Hungary). Regional crude death 
rates are available within 21 countries in 1980/81, ranging from 620 (Madrid, 
Spain) to 1850 (Copenhagen and Frederiksberg (city), Denmark). In 1990/91 
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Table 3.2 Summarised population data 
If regional data available: 
Country Year Total Mean regions with extreme values No. of 
for all Min (region) Max (region) regions 
regions 
Albania 
Armenia 1980/81 3126741 
1990/91 3578200 
Austria 1980/81 7557031 839670 269958 (AT01) 1535279 (AT09) 9 1990/91 7771755 863529 270571 (AT01) 1522251 (AT09) 
Azerbaijan 1980/81 3 1990/91 7097008 2365669 334753 (AZ03) 5028272 (AZ01) 
Belarus 1980/81 9663343 1380478 1134454 (BY02) 1619560 (BY03) 7 1990/91 10217277 1459611 1182179 (BY02) 1650042 (BY0401) 
Belgium 1980/81 9859111 3286371 1000983 (BID) 5632209 (BEl) 3 1990/91 9967450 3322484 962350 (BID) 5753850 (BEl) 
Bosnia & 1980/81 
Herzegovina 1990 4480790 
Bulgaria 1980/81 8876326 986259 697860 (BG04) 1241679 (BG05) 9 1990/91 8688071 965341 642515 (BG04} 1238950 (BG05} 
Croatia 1980/81 4599213 
1990/91 4779427 
Czech 1980/81 10447972 1289375 690496 (CZ02) 2042959 (CZ03) 8 
ReQublic 1990/91 10335711 1291964 699487 (CZ02) 2054631 (CZ03) 
Denmark 1980/81 5122300 341487 47534 (DK023) 624780 (DK012) 15 
1990/91 5147618 343175 45705 (DK023} 601853 (DK012} 
Estonia 1980/81 
1990/91 1570665 
Finland 1980/81 4789756 399147 22789 (FlO 1) 1128844 (FIll) 12 
1990/91 5000199 416683 24580 (FI01} 1248909 (FIll} 
France 1981 54284652 2467484 240038 (FR83) 10053563 (FR01) 22 
1990/91 56895248 2586148 250156 (!<'B83} 10737070 (FR01} 
Georgia 1980/81 5067173 
1990 5417600 
Germany 1980/81 61616978 5601543 693543 (DE4) 17044864 (DPS) 11 
1990/91 79723463 4982717 680175 (DE4} 17328180 (DPS} 16 
Greece 1980/81 9686279 745099 182325 (GR22) 3343654 (GR3) 13 
1990/91 10144347 780335 193305 (GR22} 3451335 (GR3)} 
Hungary 1980/81 10711481 535574 239724 (HUB) 2061095 (HU05) 20 
1990/91 10355441 517772 225732 (HUB} 2017200 (HU05) 
Iceland 1980/81 229482 
1990/91 256377 
Ireland 1980/81 3424609 
1990/91 3521754 
Israel 
Italy 1980/81 56433883 2821694 112329 (IT12) 8872566 (IT2) 20 
1990 57576429 2878821 115270 (!f12} 8911995 (IT2} 
Kazakstan 1980/81 20 
1990/91 8334889 416745 153028 (KZ16} 927897 (KZ03} 
Kyrgystan 1980/81 7 
1990/91 4391366 627338 197739 (KG07} 1315872 (KG06} 
Latvia 1980/81 2515561 
1990/91 2666542 
-----~ 
Lithuania 1980/81 3423077 
1990/91 3726225 
Luxembourg 1980/81 364688 
1990/91 384475 
Macedonia 
------~--
Malta 1980/81 319000 
1990/91 355900 
------
Monaco 
~-----~-----
1183325 351383 (NL74) 3105220 (NL73) 12 Netherlands 1980/81 14199897 
___ 1990/91 15013980 1154922 221893 (Nl25} 32~364 (NL7:3l 
-(Continued over page) 
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Norway 1980/81 4092657 227370 78331 (NOO3) 821676 (NOlO) 18 1990/91 4251601 236200 74629 (NOO3) 880318 (NOlO) 
Poland 1980/81 35739989 729388 230989 (PL05) 3741807 (pL13) 49 1990/91 38181654 779218 247169 (PL05) 3988987 (!,L13) 
Portugal 1980/81 9858400 7 1990/91 9982037 1426005 240596 (PT2) 3510567 (Pf11) 
Republic of 1980/81 4033407 
Moldova 1990/91 4361105 
Romania 1980/81 22277011 543342 215365 (R016) 2060237 (ROlO) 41 1990/91 23195902 565754 236249 (R016) 2328932 @OlO) 
Russian 1980/81 139221495 1907144 272972 (RUl005) 8298614 (RU0314) 79 
Federation 1990/91 149749900 1874418 158592 (RU1109) 8899639 (RU0314) 
San Marino 
Slovakia 1980/81 5000682 1250171 381957 (SK01) 1687363 (SK04) 4 
1990/91 5290589 1322648 443240 (SK01) 1722077 (SK04) 
Slovenia 1980/81 1889871 
1990/91 1999929 
Spain 1980/81 37750844 2097269 118893 (ES63) 6464996 (ES61) 18 
1990 38924600 2162478 124800 (ES63) 6903000 (ES61) 
Sweden 1980/81 8320485 346687 55485 (SE05) 1531870 (SE19) 24 
1990/91 8641322 360055 57343 (SEO~ 1655755 (SE19) 
Switzerland 1980/81 6372691 245104 12807 (CH03) 1124037 (CH26) 26 
1990/91 6752248 259702 13593 (CH03) 1151264 (CH2§) 
Tajikistan 1980/81 6 
1990/91 5367875 894647 168000 (fJ02) 1637532 (fJ05) 
Turkey 
Turkmenistan 1980/81 5 
1990/91 3703631 740726 413334 (fM01) 923170 (fM05) 
Ukraine 1980/81 49960794 1921569 904387 (UA0103) 5180225 (UA0302) 26 
1990/91 51663235 1987048 941343 (UA0103) 5324226 (UA0302) 
United 1980/81 56340950 1006089 110330 (UK914) 6828083 (UK55) 56 
Kingdom 1990/91 57680993 1030018 117698 (UK914) 6871241 (UK55) 
Uzbekistan 1980/81 13 
1990/91 10210082 785393 286827 (UZ11) 1176162 (UZ09) 
Yugoslavia 1980/81 9879486 4939743 582706 (YU01) 9296781 (YU03) 2 
1990 10529295 5264648 644302 (yu01) 9884993 (YU03) 
Table 3.2 gives the WHO codes for the regions with extreme rates within each 
country. Appendix A1.2 gives the corresponding region names (and also gives 
region names for Tables 3.4 and 3.5) 
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regional crude death rates are available for 30 countries, ranging from 302 
(Dahalal-Abad, Kyrgystan) to 1775 (Mikhaylovgrad, Bulgaria). 
For the purpose of this thesis, we are interested in examining a subset of 
these data. Since the main focus is on European spatial patterns of cancer 
mortality, all malignant neoplasms (ICD-9, 140- 208) are summarised in Table 
3.5. Cancer mortality data are available for 41 countries in 1980/81 and 40 in 
1990/91. Taking account of population size at a regional level, crude death rates 
were calculated for each country and region. Thirty-one countries have the crude 
death rates available for both time periods. For these countries, the mean crude 
death rate for 1980/81 is 191 (per 100,000), ranging from 75 (Armenia) to 309 
(Denmark). For 1990/91 the mean crude death rate is 214, with a range from 99 
(Armenia) to 348 (Denmark). Regional crude death rates are available for 19 
countries in 1980/81, ranging from 73 (Montenegro, Federal Republic of 
Yugoslavia) to 541 (Copenhagen and Frederiksberg (city), Denmark). In 1990/91 
regional crude death rates are available for 31 countries, ranging from 21 
(Dahalal-Abad, Kyrgystan) to 487 (Copenhagen and Frederiksberg (city), 
Denmark). 
3.2 Data Issues 
When collecting data on such a wide scale globally, inevitably certain problems 
will occur resulting in limitations to the final dataset. 
3.2.1 Missing Data 
The full data set should ideally contain information on the sub-national level from 
all Member States of the WHO European Region. This was not possible for many 
reasons resulting in deviations in the availability of data, including not only lack 
of data of a certain type or from a certain year but also cases in which data were 
supplied for different years or with different age aggregations from those 
requested. 
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Table 3.3 Specific cause mortality data 
Causes of death according to ICD-9 
Infectious and parasitic diseases 
Malignant Neoplasms 
Malignant Neoplasm of oesophagus 
Malignant Neoplasm of colon, rectum rectosigmoid junction and anus 
Malignant Neoplasm of liver, specified as primary 
Malignant Neoplasm of trachea, bronchus and lung 
Malignant Neoplasm of female breast 
Malignant Neoplasm of bladder 
Leukaemia 
Diseases of the circulatory system 
Ischaemic heart disease 
Diseases of the pulmonary circulation and other forms of heart disease 
Cerebrovascular disease 
Atherosclerosis 
Diseases of the respiratory system 
Pneumonia 
Chronic obstructive pulmonary disease and allied conditions 
Diseases of the digestive system 
Chronic liver disease and cirrhosis 
Disease of the urinary system 
Congenital anomalies 
Accidents, injury and poisoning 
Motor vehicle traffic accidents 
Other transport and self-inflicted injury 
Suicide and self-inflicted injury 
code 
001- 138 
140 - 20S 
150 
153 - 154 
155 
162 
174 
188 
204 - 208 
390 - 459 
410 - 414 
415 - 429 
430 - 438 
440 
460 - 519 
480 - 486 
490 - 496 
520 - 579 
571 
5S0 - 599 
740 -759 
ESOO-E999 
E810-E819 
E800-E807, 
E826-E845 
E950-E959 
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Data collection involved making individual requests from national statistical 
offices. This process coincided with major political, economic and social changes 
in the region. For example, during the period of data collection, 16 new Member 
States were acquired, most of them newly independent states of the former USSR, 
together with the unification of Germany. This sometimes led to a difficulty in 
access to information and also could have complicated communication with the 
national statistical offices. To reduce complications, data for the same 
administrative areas have been used over the decade, but sometimes under new 
names and within the borders of new countries. 
Also, due to the wide range of countries, data collection was constrained by 
the availability of databases as well as their quality and completeness. The 
requested resolution of the region of residence was not always obtained. 
Sometimes data were only available on a national level or a level lower than 
NUTS II. For such countries the higher level of data has been used. 
Often data for certain years were missing, with some countries only being 
able to provide data for one decade rather than two. For example, in countries 
where population data are collected only by census, data may be available only for 
the years when the census was made. Trends can still be examined as long as one 
year is available out of each of the two consecutive years. In these instances the 
data summaries use one year instead of the mean over the two years. 
The number of residents (midyear estimates) and data for all-cause mortality 
by gender and region of residence were collected for all ages and for specific age 
groups. Not all countries, however, could supply the data in the requested format. 
For example in some countries such age divisions could not be achieved for 
elderl y people or sometimes groups aged under 1 year were aggregated with those 
for the group ages 1-4 years. When population and mortality data were obtained in 
age categories that were slightly different from those requested, account was taken 
of these exceptions in the standardisation of rates by grouping the age categories 
of the standard population similarly to the categories of the index population. 
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Table 3.4 Summarised mortality data 
Country Year Total 
Crude Death If reg!0nal data available 
Rate reg!0ns with extreme values No. of Deaths (per 100000) Min (region) Max (region) regions 
Albania 
Armenia 1980/81 16892 540 
1990/91 227(J7 633 
Austria 1980/81 92568 1225 781 (AT08) 1648 (AT09) 9 
1990/91 83190 1070 753 (AT08) 1369 (AT09) 
Azerbaijan 1980/81 3 
1990/91 43735 616 508 (AZ03) 670 (AZ04) 
Belarus 1980/81 94325 976 7 
1990/91 112083 1098 686 (BY0401) 1415 (BYO~ 
Belgium 1980/81 113012 1146 1038 (BEl) 1325 (BID) 3 
1990/91 
Bosnia & Herzegovina 1980 13048 
1990 15174 678 
Bulgaria 1980/81 96696 1090 9 
1990/91 109516 1262 1050 (BGOZ) 1775 (BG04) 
Croatia 1980/81 50760 1104 
1990/91 53512 1120 
-~---~ 
Czech Republic 1980/81 132972 1274 8 
1990/91 126728 1226 1105 (CZ05) 1385 (CZO~ 
-
Denmark 1980/81 56149 1096 741 (DK014) 1850 (DKOll) 15 
1990/91 60254 1171 864 (DK014) 1751 (DK011) 
Estonia 1980/81 
1990/91 19585 1247 
Finland 1980/81 44521 929 804 (FIll6) 1105 (FIll7) 12 
1990/91 49697 994 857 (FL08) 1198 (FL07) 
France 1981 554823 1022 833 (FR1) 1430 (FR63) 22 
1990/91 525443 924 731 {E!!1) 1324 (FR63) 
Georgia 1980/81 43654 861 
1990 46473 858 
Germany 1980/81 718155 1166 1008 (DEB) 1826 (DEBW) 11 
1990/91 916345 1149 992 (DEB) 1399 (DEE) 16 
Greece 1980/81 86752 896 799 (GR3) 1435 (GR41) 13 
1990/91 94825 935 834 (GRI2) 1356 (GR41) 
Hungary 1980/81 145056 1354 1175 (HU12) 1526 (HU15) 
1990/91 145237 1404 1230 (HUOZ) 1513 (HU15) 
Iceland 1980/81 1597 696 
1990/91 1750 684 
Ireland 1980/81 33201 869 
1990 31457 893 
Israel 
Italy 1980/81 549901 974 780 (IT91) 1296 (IT13) 20 
1990 543708 944 733 (IT91) 1324 (IT13) 
Kazakstan 1980/81 20 
1990/91 64309 772 672 (KZ03) 1177 (KZO~ 
Kyrgystan 1980/81 7 
1990/91 30684 699 302 (KG03) 960 (KG04) 
Latvia 1980/81 32095 1276 
1990/91 34781 1034 
Lithuania 1980/81 
1990 39713 1070 
Luxembourg 1980/81 4109 1128 
1990/91 3759 978 
Macedonia 
Malta 1980/81 3219 1009 
1990/91 2791 784 
Monaco 
Netherlands 1980/81 114897 809 676 (NL51) 
939 (NL74) 12 
1990/91 129391 862 495 (NU~ __ 968 (NL111~ 
Norway 1980/81 41618 1017 847 (NOO3) 
1161 (N004) 18 
1990/91 45432 1069 _~7 (N012) 1269 ~(04) 
-----
_ .. ----
(Continued over page) 
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Poland 1980/81 339563 950 714 (pL19) 1178 (p136) 49 1990/91 396196 1038 817 (PL19) 1361 (PU1) 
Portugal 1980/81 --95432 968 7 1990/91 103738 1039 913 (PT11) 1376 (PT14) 
Republic of 1980/81 40974 1016 
Moldova 1990/91 44138 1012 
Romania 1980/81 228256 1025 799 (R025) 1484 (ROO2) 41 1990/91 249423 1075 830 (ROO8) 1455 (ROO2) 
San Marino 
Russian Federation 1980/81 1525021 1095 79 1990/91 1670959 1128 387 1522 
(RU1109) (RU0203) 
Slovakia 1980/81 50106 1002 904 (SK01) 1104 (SK04) 4 1990/91 54619 1032 882 (SK01) 1128 (SK04) 
Slovenia 1980/81 18777 994 
1990/91 18940 947 
Spain 1980/81 291365 772 620 (ES3) 931 (ES43) 18 
1990 333142 856 680 (ESl) 1012 (ES12) 
Sweden 1980/81 91917 1105 967 (SE20) 1372 (SE07) 24 
1990/91 95182 1101 899 (SE20) 1337 (SEOl) 
Switzerland 1980/81 59484 933 684 (CH04) 1278 (CH05) 26 
1990/91 63187 936 693 (CH25) 1420 (CH05) 
Tajikistan 1980/81 6 
1990/91 33001 615 541 (fJOl) 684 (fJ01) 
Turkey -----
Turkmenistan 1980/81 5 
1990/91 26536 716 683 (fM05) 759 (fM04) 
Ukraine 1980/81 568516 1138 834 (UA0114) 1370 (UA0304) 26 
1990/91 649413 1258 898 (UA0114) 1533 (UA0102) 
United Kingdom 1980/81 661619 1174 866 (UK522) 1658 (UK531) 56 
1990/91 645942 1120 832 (UK522) 1505 (UK562) 
Uzbekistan 1980/81 13 
1990/91 61713 604 506 (UZ03) 792 (UZ13) 
Yugoslavia 1980/81 90118 912 634 (YU01) 930 (YU03) 2 
1990 97665 928 611 (YU01) 948 (YU03) 
Table 3.5 Summarised cancer mortality data 
Crude Death IT re~onal data available 
Country Year Total Rate reg!ons with extreme values No. of Deaths ~~rl00000) Min (region) Max (region) regions 
Albania 
Armenia 1980/81 2330 75 
1990/91 3526 99 
Austria 1980/81 19224 254 170 (AT08) 352 (AT09) 9 
1990/91 19324 249 190 (AT08) 309 (AT09) 
Azerbaijan 1980/81 3 
1990/91 4804 68 55 (AZ03) 88 (AZ04) 
Belarus 1980/81 12155 126 7 
1990/91 17771 174 147 (BY0401) 231 (BY06) 
Belgium 1980/81 26537 269 263 (BEl) 310 (BE3) 3 
1990/91 
Bosnia & Herzegovina 
Bulgaria 1980/81 12839 145 120 (BG02) 192 (BG04) 9 
1990/91 30551 175 142 (BG06) 222 (BG04) 
Croatia 1980/81 8538 186 
1990/91 10611 222 
Czech Republic 1980/81 26415 256 8 
1991 28102 273 249 (CZ05) 310 (CZ01) 
---- -----
Denmark 1980/81 15811 309 226 (DK013) 541 (DK011) 15 
1990/91 17899 348 288 (DK013) 487 (DK011) 
_.-----
1980/81 Estonia 
1990/91 3331 212 
- --------
.. ------
.. 
(Continued over page) 
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Finland 1980/81 8998 188 155 (Fl06) 235 (Fl01) 12 1990/91 9718 194 161 (FI08) 221 (FI102 ____ 
France 1981 126632 233 210 (FRS1) 318 (FR63) 22 1990/91 138629 244 203 (FR1) 323 (FR63~ ____ 
Georgia 1980/81 
1990 5645 104 79 (GE02) 126 (GE05) 
Germany 1980/81 157662 256 218 (DEB) 360 (DEBW) 11 
1990/91 207843 261 201 (DEC) 314 (DE2) 16 
Greece 1980/81 16418 169 136 (GE43) 232 (GE41) 13 1990/91 19689 194 162 (GE42 230 (GE22) 
Hungary 1980/81 27720 259 193 (HU16) 334 (HU05) 20 1990/91 31139 301 253 (HU01) 364 (HU05) 
Iceland 1980/81 349 152 
1990/91 450 176 
Ireland 1980/81 6254 183 
1990 7217 205 
Israel 
Italy 1980/81 122776 218 125 (IT93) 323 (IT33) 20 1990 145036 252 152 (IT93) 365 (IT33) 
Kazakstan 1980/81 20 1990 22595 136 93 (KZ03) 214 (KZ06) 
Kyrgystan 1980/81 7 1990/91 3361 77 21 (KG03) 146 (KG01) 
Latvia 1980/81 
1990/91 5535 208 
Lithuania 1980/81 
1990 6956 187 
Luxembourg 1980/81 955 262 
1990/91 963 250 
Macedonia 
-
Malta ~ -
Monaco 
-
~~ ~ -
Netherlands 1980/81 31134 219 159 (Nl.51) 258 (NL74) 12 
1990/91 35409 236 163 (NI25) 268 (NUl) 
Norway 1980/81 8809 215 147 (N003) 247 (NOlO) 18 
1990/91 9819 231 185 (NOO3) 256 (NOll) 
Poland 1980/81 60269 169 130 (PU6) 218 (PU1) 49 
1990/91 73436 192 152 (PU4) 255 (PU1) 
Portugal 1980/81 14266 145 7 
1990/91 18204 182 154 (Pf11) 234 (Pf14) 
Republic of Moldova 1980/81 3989 99 
1990/91 5751 132 
Romania 1980/81 28782 129 88 (ROO4) 194 (R01O) 41 
1990/91 32853 142 87 (R039) 207 (ROO2) 
San Marino 
Russian Federation 1980/81 225689 162 79 
1990/91 287362 194 68 (RUll09) 270 (RU0204) 
Slovakia 1980/81 8600 172 
1990/91 10377 196 
Slovenia 1980/81 3506 186 
1990/91 4206 210 
--~~- . - ------ -
Spain 1980/81 58862 156 120 (ES3) 192 (ES12) 18 
1990 76823 197 157 (ES63) 244 (ES12) 
Sweden 1980/81 19659 236 184 (SE14) 270 (SE07) 24 
1990/91 20369 236 194 (SE14) 284 (SE04) 
Switzerland 1980/81 14887 234 116 (CH22) 348 (CH05) 26 
1990/91 16473 244 159 (CH25) 392 (CH05) 
Tajikistan 1980/81 6 
1990/91 2637 49 28 (TJ04) 97 (TJ01) 
Turkey 
Turkmenistan 1980/81 5 
1990/91 2325 63 49 (fM04) 96 (fMOll_n_ 
-------
Ukraine 1980/81 76210 153 26 
1990 101352 196 125 (UA01l2) 225 (UA0308)_ 
- -
United Kingdom 1980/81 146712 260 200 (UKS11) 357 (UKS31) 56 
1990/91 162026 281 217 (OKS21 L __ 371 (lJKS62l 
---~- ~ -
Uzbekistan -
--~-- -- --
12385 125 73 (YU01) 129 (YU03) 2 Yugoslavia 1980/81 
1990 15568 148 94 (YU01} 151 (YU01} 
27 
Chapter 3 Data 
The data sometimes had missing mortality counts for specified ICD groups 
or the data were aggregated otherwise than defined. This had minimal effect on 
total mortality counts. If countries had specific mortality groups with different 
definitions in terms of ICD codes they were classified as missing. 
3.2.2 Data Quality 
Data reliability is obviously of concern when collecting mortality statistics on 
such a large scale. This depends somewhat on how accurately causes of death 
have been classified. For instance, often a patient has a known cancer diagnosis, 
however, it is not always simple to classify whether the disease was irrelevant, an 
underlying cause or a contributing cause of death. In less developed countries, 
where there is less public awareness of early cancer signs, poor access to health 
care and/or low autopsy rates, there will be many more opportunities for 
misclassification of cause of death (67). 
Despite the rather large amount of data requested by WHO, 90% of the 
approached Member States returned data. When a considerable amount of data are 
collected from several sources and almost 50 countries, inevitably some errors and 
misunderstandings will occur. In order to ensure a high standard of data quality, 
numerous checks on quality and plausibility were carried out. Most data sets were 
forwarded to NCBS (Netherlands Central Bureau of Statistics) for checks. Some 
data were sent directly to the ECEH (European Centre for Environment and 
Health). They were checked by the ECEH and RIVM (International 
Environmental Data Service). If the analysis of final data sets revealed 
inconsistencies, these were corrected after consulting with NCBS . 
. The procedures for data quality and plausibility included verification of the 
completeness of the data received, arithmetic checks and comparison of crude 
mortality rates (comparing regional level data with a specified reference line). If 
data appeared incomplete or contained errors, additional or revised data were 
requested from Member States. If further requests to countries did not yield 
improvement, the section of the data was classified as missing. Also, population 
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and mortality data at a national level were verified with statistics published in the 
editions of the World Health Statistics Annual for the years 1980, 1981, 1990 and 
1991. The final verification of all national level data did not reveal major 
differences and the final survey of the contents of the regional level data gave a 
good overall impression of the plausibility of the data. 
3.2.3 Sources of Bias 
Mortality data are widely considered to have the highest degree of international 
comparability in developed countries because deaths are mostly reported in 
accordance with international reporting standards and therefore counts are fairly 
accurate. However, as with most data collection and processing, the risks of bias 
and random error are still highly probable. Reasons for the bias occurring in this 
type of data are that countries, and sometimes regions within countries, differ in 
their training of medical staff and their use of diagnostic technologies and 
autopsies to confirm causes of deaths. Also, the accuracy of death certificates 
differs between countries in Europe. This could be due to the level of health care 
services, numbers of specialists or use of screening tests for detection of diseases. 
International differences in mortality data also depend on methods of data 
collection and procedures of coding (eg the procedure used for nationals or 
residents dying abroad). 
Migration in and out of regions can also affect mortality rates as this often 
changes the size and composition of the population dwelling in particular areas. 
However, most member states should have avoided this affecting the accuracy of 
their rates due to population censuses being carried out every ten years and with 
birth and death counts being carried out in between censuses. 
Certain cancers are not meaningfully represented by mortality rates. It 
should be noted that the burden of cancers with favourable prognosis, such as the 
common non-melanoma skin cancer and endometrial cancer or the more rare 
thyroid and testis cancer, are not reflected by mortality rates. For those cancers 
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that remain almost inevitably fatal such as lung, oesophagus, liver and pancreas, 
mortality rates are actually good approximations of incidence rates. 
The high standards of the World Health Organisation should reflect the 
quality of the data. All data collection and processing procedures have been 
carried out thoroughly so the reliability and plausibility of the data should be rated 
highly. In view of factors outwith the control of WHO that may have affected the 
data, some caution should be made when making international comparisons of 
cause-specific mortality rates. To minimise the influence of random fluctuations 
and give clear pictures of patterns of mortality, modelling techniques are 
necessary to analyse these data. 
3.2.4 Mortality Data Advantages 
Despite the use of population-level mortality data having drawbacks, they do have 
overriding advantages. As previously mentioned and as can be seen from the vast 
amount of cancer mortality literature, cancer mortality rates are widely accepted 
as important measures of the burden of cancer. 
One of the main advantages of examining mortality data, and the probable 
reason for its common usage is that it is the most widely available measure of 
cancer burden. This is because the compilation of cancer mortality statistics is a 
simpler task than that of cancer incidence, prevalence or survival. In economically 
developed countries, such as many of those within the WHO European region, the 
coverage of mortality statistics collection was close to 100% in 1990 (68). 
3.3 Cancer Mortality Data in the ED 
In subsequent Chapters a subset of the main mortality dataset will be explored. 
Malignant neoplasms (ICD-9, 140- 208) are examined for the EU countries in the 
time-period 1991. These data are summarised in Table 3.6. 
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Taking account of population size at the regional level, crude death rates 
have been calculated for each country and region. These are given for each 
country in Table 3.6 and corresponding extreme rates are given for regions within 
these countries. The mean crude cancer death rate in 1991 is 257 (per 100,000) 
ranging from 157 (Norte, Portugal) to 487 (Copenhagen and Frederiksberg (city), 
Denmark). Data are missing for 4 of the 15 EU countries in 1991 and regional 
crude death rates are available for 10 of the remaining 11 countries. 
Table 3.6 Summarised cancer mortality data in the EU in 1991 
Total Crude If regional data available 
Country Deaths Death Rate regions with extreme values No. of 
Min Max regions {2er 100000) {region~ {region~ 
Austria 19317 247 193 304 9 
(V orarlberg) (Vienna) 
Belgium missing 
Denmark 17764 345 290 487 15 
(S~nderjylland) (Copenbaen and 
Frederiksberg (city» 
Finland 9626 192 165 234 12 
(Gulu) (Fahvenanmaa) 
France 138778 243 203 322 22 
(lIe de France) (Limousin) 
Germany 210537 263 207 320 11 
(Brandenburg) (Hamburg) 
Greece 19945 196 168 236 13 
(Aegean North) (Ionian Islands) 
Ireland mzsszng 
Italy missing 
Luxembourg 957 247 
Netherlands 35640 237 169 273 12 
(Flevoland) (Groningen) 
Portugal 18203 185 157 2323 7 
(Norte) (Alentejo) 
Spain missing 
Sweden 20406 235 201 305 24 
(Norrbotten) (Gavleborg) 
UK 161555 280 219 377 56 
(Northern Ireland) {!sle of Wight) 
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3.4 Risk Factor Data 
Ecological studies aim to ascertain associations between a disease and exposure to 
risk or protective factors for groups or populations. It is therefore necessary to 
analyse data that reflect levels of exposure to such factors along with population 
and mortality data. 
In Chapter 2 we discussed existing literature on cancer mortality risk and 
protective factors. Evidence suggests that the main factors affecting some of the 
most common cancer groups are diet, specifically fruit, vegetable and animal fat 
consumption, alcohol intake, smoking level and socio-economic status. 
3.4.1 Source of Data 
Data were obtained from various sources to reflect exposure levels to these risk 
and protective factors. 
3.4.1.1 Diet 
Data reflecting levels of consumption of fruit, vegetables and animal fat were 
obtained from the Food and Agriculture Organisation of the United Nations. 
F AOSTAT is their online statistical database (69) and they compile information 
and data on various aspects of food and agriculture from all countries. In this 
instance, country level information was used from food balance sheets. This 
comprises the average amounts of fruit, vegetables and animal fat available for 
human consumption during the period 1991, and are measured in kilograms. 
Alcohol consumption for each European country was also available from 
FAOSTAT in kilograms for the year 1991. 
3.4.1.2 Smoking 
Data to reflect levels of smoking within European countries were obtained from a 
World Health Organisation global status report. The Tobacco or Health report 
(70) was carried out in 1997 and the details are provided on the internet as a 
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service by the Office on Smoking and Health of the National Centre for Chronic 
Disease Prevention and Health Promotion (71). The annual adult (age over 
fifteen) consumption of manufactured cigarettes per capita was obtained for each 
country for the time period 1990-1992. 
3.4.1.3 Socio-Economic Status 
Socio-economic status (SES) is some description of a person's position in society 
such as income, educational level attained, occupation or value of dwelling place. 
A good indicator of SES on a population level is Gross Domestic Product (GDP) 
which is a relative measure of wealth of individual regions or countries. GDP data 
were obtained from the World Health Organisation (72) and are available for each 
country in Europe. It is measured in US dollars per inhabitant in 1995. GDP was 
available at a sub-national level for EU countries only from Eurostat (73); these 
data will be summarised, along with the other EU risk factors data in Chapter 5. 
3.4.2 Data Summaries 
Risk factor data are summarised in Table 3.7; for each risk or protective factor the 
median, minimum and maximum and the countries with extreme levels of these 
factors are given. 
3.4.3 Data Issues 
Various risk factor data have been collected on a large global scale, which again 
may cause occasional discrepancies. 
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Table 3.7 Summarised risk factor data 
Risk/protective 
Median Minimum factor Maximum 
Fruit 74.5 24.6 142.6 
kg/year/capita (UK) (Estonia) (Greece) 
Vegetables 88.2 34.5 300.4 
kg/year/capita (UK) (Israel) (Greece) 
Animal Fat 14 1.3 29 
kg/year/capita (Russian Federation) (Armenia) (Hungary) 
Alcohol 76.2 9.3 173.9 
kg/year/capita (Sweden) (Armenia) (Germany) 
Smoke 1920 910 3620 
cigarettes/year/adult (Italy) (Azerbaijan) (Poland) 
GDP (region level) 12670 2180 21780 
US$/inhabitant (Spain) (Tajikistan) (Switzerland) 
3.4.3.1 Time Periods 
The time periods used for each of the risk/protective factors might not be ideal. It 
is difficult to determine at which time period each exposure should be measured, 
for example at which period in a person's life their diet most affects their risk of 
cancer. For a population it is clearly impossible to consider accumulated lifetime 
exposure to such factors. Also, there is sometimes a lack of availability of 
risk/protective factor data at specific time periods. For these reasons, data that 
exist for approximately the same period as our mortality data have been obtained 
and are used in subsequent Chapters for the modelling in an attempt to reflect the 
cultures of the different countries or regions. However, it is important to remain 
aware that, if the change over time in patterns of exposure to risk or protective 
factors has differed substantially between these regions or countries, then this will 
have an impact upon both the estimated relationship with such risk factors and the 
estimated adjusted risk of mortality in these countries. 
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3.4.3.2 Country Level 
All the data collected to reflect the levels of risk or protective factors are at the 
country level except for GDP in the EU. It would obviously be more informative 
for all the data to be at the less aggregated level. However, since it was necessary 
to obtain different types of data from different countries this was not possible. 
These data are still very useful as they should represent the country's dietary and 
lifestyle habits. When we are interpreting the results of analysing such data it 
should be clear that differing levels of exposure to risk factors within countries 
have not been taken into account. 
3.4.3.3 Data Quality 
Similar issues of data quality and reliability arise with the risk factor data as did 
with the mortality and population data. For example, the country-level 
consumption data were collected by various methods: tailored questionnaires sent 
to member countries, magnetic tapes, diskettes, FfP transfers and accessing 
websites of the countries, national and international publications, country visits 
made by the Food and Agriculture organisation (FAO) statisticians and reports of 
F AO representatives in member countries. Therefore maximum effort was made 
to gather accurate statistics on factors such as food consumption, but F AOSTAT 
comment that data reliability, especially in developing countries, may in some 
cases be questionable. These problems cannot be overcome and one should just 
remain aware when drawing any conclusions that the type of data under 
examination means that any form of analysis is fairly crude. 
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4 Disease Mapping Review 
4.1 Introduction to Disease Mapping 
Understanding the geographical distribution of disease mortality or incidence is of 
key importance in the field of public health. Mapping incidence or mortality rates 
from diseases such as cancer is one of the primary tools used to investigate the 
spatial variability of risk from specific diseases. The main aim in doing so is to 
produce a map 'clean' of random noise and any natural variation in the human· 
population, and which allows identification of areas with high or low rates. These 
maps play an important role in epidemiology allowing, for example, the 
geographical assessment of health resource allocation and the formulation of 
aetiological hypotheses. 
4.1.1 Standardised Mortality Ratio 
Disease mapping initially involves the choice of an epidemiological measure 
which shall be displayed on the map. Traditionally the measure used is a 
standardised mortality/morbidity ratio (SMR). This gives a geographical picture 
of the disease rates expected in a given area compared to the observed rate. For 
example, if we consider a population of regions, i, i = 1, ... ,I, with observed (Oi) 
and expected (Ei) counts of deaths. The Ei are often calculated through 
standardisation based on the number of deaths in the population N i • This 
standardisation is conducted for age and sex strata k, and if stratum k has Oile out 
of a population Nile, the expected number of events is given by 
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The standardised mortality ratio for the disease of interest is therefore 
o· SMR i = _I xiOO. E· l 
To produce maps of the SMRs, the chloropleth method (74) is often used 
which involves specifying the SMRs into class intervals and assigning to each 
interval a specific colour, shade or pattern. The choice of interval categorisation 
can be of importance as it can fundamentally change the geographical picture of 
the disease. A common approach is that of equal-interval classification in which 
the range of data values is divided into a fixed number of classes whereby each 
class represents an equal range of SMRs. A problem with this method is that, if 
we have a highly skewed data distribution, the majority of areas will probably fall 
into 1 or a small number of classes. The map will therefore show little spatial 
variation with the majority of SMRs being classified as similar when in fact they 
are not. Another traditional approach is based on the percentiles of the SMR 
distribution, such as quartiles, quintiles or sixtiles. This method ensures that each 
class is equally represented on the map. However, this method can also be 
misleading because areas with similar SMRs may be assigned to different classes. 
Some areas will appear to be very heterogeneous on the map when in fact they are 
not. Another method used to determine class intervals is to search for natural 
divisions in the distribution of SMRs. These classes would represent clusters of 
SMRs and the approach differs from the two previous methods, as it does not 
arbitrarily assign observations that have similar values into different classes. To 
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use this method some form of cluster analysis would probably be performed so 
clusters are determined statistically that minimise within-class variation. Since the 
map is often used to determine groups of areas with similar disease, this method 
may over-emphasise any clusters that exist. The choice of classification method is 
important but does depend on specific data distributions. Muehrcke et al (75) 
gives a fuller discussion of ways of defining disease mapping class intervals. 
Once the SMRs are displayed on a map the intention is to allow 
interpretation of the geographical variation in the disease. However, this method 
has limitations and has been criticised by various authors, particularly Clayton and 
Kaldor (76). When examining SMRs, the ratios for small or sparsely populated 
areas have large variability, and therefore often dominate the map, as there are 
few or no observations. An alternative method that has been commonly used, but 
is also open to criticism, is to display the statistical significance levels for a test of 
the difference between the risk in a specific area and that from the overall rate on 
the map. This type of map ignores the size of the effect in that two areas with 
identical SMRs may appear to be quite different if they are of unequal population 
sizes, and the most prominent areas may simply be those with the largest 
populations. Also, risk factors often play an important role when studying a 
disease's geographical variation, and traditional methods do not allow potential 
risk factors to be taken into account. 
4.1.2 Poisson Model 
To overcome such problems modem approaches use interpolation methods to 
improve on the raw rates. A multiplicative model originally proposed by Breslow 
and Day (77) allows the standardised rates to be mapped based on Poisson 
inference. Estimating the parameters using maximum likelihood and mapping the 
modelled standardised rates has the advantage of providing estimates of the 
parameters, namely the disease rates (78). This assumes that the observed cases Oi 
follow a Poisson distribution (79) with 
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(4.1) 
where Oi are the unknown area-specific relative risks of mortality from the 
disease. The likelihood of the relative risk Oi is 
e -«()iEi) (B E )Oi 
g(O.IB.) = i i 
I I O.!' 
I 
(4.2) 
where again Ei denotes the expected number of cases in region i. The maximum 
likelihood estimate (MLE) of Oi is the SMR for the ith area: 
B. =O/E. I I I , 
with estimated standard error 
s. = re./E .. I '\j tli I 
However, this again leads to the most extreme SMRs tending to be based on 
counts from small or sparsely populated areas. On the other hand, p-values can be 
calculated under the null hypothesis 0 = 1 or the adjusted null hypothesis which is 
based on 
where n is the number of areas (80), which compares the SMR to other areas on 
the map. In the event of no deaths in a region, which commonly occurs in small 
populations and for rare diseases, the probability is estimated as 0 (81). On the 
contrary, areas with extreme p-values are often only identifying areas with large 
populations. Although modelling methods have been used, the maps of estimates 
of SMRs and p-values can still be difficult and often misleading. 
For sparsely populated areas and rare diseases, the observed counts fluctuate 
about the mean within each area more than would be expected from a Poisson 
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distribution. If this extra-Poisson heterogeneity (82) is ignored, the overdispersion 
can create the impression of artificial geographic variation in the disease rates. 
Another problem in using conventional Poisson based methods is that they do not 
take account of any spatial pattern of disease, i.e. they ignore the fact that areas 
geographically close to one another share similar disease rates and common 
factors which influence the incidence and outcome of disease. A further 
disadvantage of methods discussed so far is that they do not allow the inclusion of 
ecological covariates. Inclusion of such variables would allow the construction of 
disease maps that take into account risk factors that are known to affect a specific 
disease. Methods that overcome these problems produce more accurate maps of 
disease mortality ( and incidence) and allow a closer assessment of the true 
underlying distribution of a disease. 
4.2 Bayesian Methods for Disease Mapping 
Bayesian methods are now widely used to overcome such problems and there 
have been vast developments in the area recently. Lawson et al (4) discusses in 
detail many of the recent methodologies for the statistical evaluation of disease 
mapping. Such methods allow the production of smoothed estimates of relative 
risks and maps 'clean' of random noise, influential spatial factors and any natural 
variation in the human population. 
4.2.1 Bayesian Approaches to Relative Risks 
The various Bayesian statistical smoothing techniques assume that the relative 
risks (}i are random effects that arise from a probability distribution of risks (76, 
83). A random effects model can be fitted in which the relative risks have prior 
distributions and these prior distributions have hyper-parameters, which can have 
hyper-distributions also. The fully Bayesian approach bases inference on sampled 
parameters from the joint posterior distribution. The empirical Bayes approach 
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involves estimating the parameters of the prior distribution and inference can then 
be made conditional on these estimated parameters (78). 
Mollie (79) outlines the approaches to Bayesian inference for relative risks. 
Disease mapping data combine two types of information, namely the information 
provided in each area by the observed deaths described by the Poisson likelihood 
g(910), and prior information on the relative risks specifying their variability in 
the overall map, summarised by their prior distribution (9). 
Bayesian inference about the unknown relative risks 9 is based on the 
marginal posterior distribution 
g(0IO,1) oc g(OIO) f (011), (4.3) 
where 0 is the observed data and 1 are the hyper-parameters. The prior 
probability density function of the relative risks is given by f (Bi). 
The likelihood function of the relative risks 9 for the data (observed number 
of deaths) 0 is the product of n independent Poisson distributions and can be 
written as 
g(OI 9) = TI g(Oil ()i), (4.4) 
l 
(4.5) 
The prior distribution (9) reflects prior belief about variation in relative risks over 
the map and should be parameterised by hyperparameters y and denoted f (91 "(). 
Equation (4.3) can be used as an approximation of the marginal posterior 
distribution of the relative risks given the observed data g(910). Empirical Bayes 
methods use estimates of the hyper-parameters and typically these are maximum 
likelihood estimates derived from the marginal likelihood of 1, 
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g(OI y) = f g(O 10)/(0 I y)dO. (4.6) 
If areas are independent then the marginal posterior distribution IS also 
independent and can be written as 
(4.7) 
A point estimate of the relative risks is given by a measure of location of this 
distribution, typically the posterior mean E(OIO) or the posterior median. 
However, direct evaluation of these parameters through analytical or numerical 
integration is not generally possible. 
Another measure of location of this posterior is the posterior mode or 
maximum a posteriori (MAP) estimate that maximises g(OIO;y). MAP estimation 
can be performed using penalised likelihood maximisation (84) and has been 
applied to disease mapping (81, 85). 
Standard Bayesian analysis, considering a completely specified pnor 
distribution f (01 y) with known hyper-parameters y, is seldom used in practice. 
The empirical Bayes (EB) approach assumes that hyper-parameters are unknown 
and are drawn from an unspecified distribution. The fully Bayesian formulation 
comprises a three-stage hierarchical model in which the hyper-prior distribution 
(y) is specified. 
4.2.2 Empirical Bayes 
The empirical Bayes method was the first approach to disease mapping that 
attempted to overcome some of the problems encountered when examining SMRs 
and simple SMR models. Marshall (86) provides a good thorough review of 
various methods for statistical analysis of patterns of disease, induding a review 
of spatial empirical Bayes methods. The early approaches that have been used to 
map geographical distributions of specific diseases have been shown to be 
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unsatisfactory at clearly identifying extreme rates, especially for rare events or for 
small populations. To overcome such problems, empirical Bayes estimation was 
developed in the area. Efron and Morris (87) appear to be the first to have used 
such methods to pool information across areas, reducing the total mean-square 
error. These methods were further developed by Tsutakawa (88) and Clayton and 
Kaldor (76) by taking into account the variation in the estimation precision across 
the map. The stability of rare estimates is increased by combining the Poisson 
variation in each area with a global model of the rates. Tsutakawa (88) initially 
derived improved estimates of mortality rates using an EB approach that treats 
true rates as samples from an unknown prior distribution that needs estimation. A 
normal distribution for the logit of the probability of disease in each geographical 
area was used in this early exploratory analysis. This approach is similar to 
Leonard's method for estimating binomial proportions (89). 
As previously shown, our likelihood function derives from the Poisson 
distributed number of observed cases occurring within the geographical areas, and 
classical statistical analyses of relative risks are representative of the data. Also, 
we stated that we know the distribution of relative risks conditional on the 
distribution within each area. Therefore, the prior beliefs to be incorporated into 
Bayes theorem is the information we have on the relative risks eg that small 
populations are more likely to have extreme relative risks and the probability that 
relative risks obtained from larger populations are more reliable (76). The 
posterior distribution of risks can then be calculated using prior beliefs. Empirical 
Bayes methods always seek to approximate the posterior distribution. Any other 
method used to calculate the posterior distribution would be classified as full 
Bayes (90). 
4.2.2.1 Poisson-Gamma Model 
Along with incorporating an estimate of reliability through prior beliefs, a prior 
distribution of the overall relative risks can be specified, reflecting the distribution 
of relative risks between areas. The Gamma distribution was originally suggested 
by Clayton and Kaldor (76) for this purpose and has been further used and 
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developed by others (91-96). They considered a Gamma distribution for the 
relative risks described by the hyper-parameters, a and v, where a is a scale 
parameter and v is a shape parameter. 
V()V-l -aBo () I a. e I 
I( i r) = ~(V) (4.8) 
This choice of model involves describing the probability of disease mortality or 
incidence occurring within given areas by the Poisson distribution, and the 
Gamma distribution describes the denominator populations required for the 
observed cases to occur (94). Therefore, as shown by Clayton and Kaldor (76), 
conditioning on the true relative risk (Bi), the number of deaths (or incidence 
counts) (Oi) in the ith geographical unit follows a Poisson model where Ei is the 
expected number of deaths. 
The relative risks are assumed to follow a Gamma distribution with the 
marginal distribution of the Oi being negative binomial. The shape and scale 
parameter of the negative binomial model are estimated by maximum likelihood. 
It follows that the empirical Bayes estimate of the posterior expectation takes the 
form: 
where the distribution of ~ conditional on the observed count is also Gamma. 
This is a compromise between the observed SMR (O;/Ei) and the general mean 
(v / a). Since Oi have a negative binomial distribution, the unconditional 
expectation of the Oi is given by 
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In the model suggested by Clayton and Kalder (76) the adjustment for age has 
been achieved internally from overall age-specific rates over all the areas. Manton 
et al (97) suggested that age adjustment can be accomplished from a set of 
external age-specific standard rates. 
Manton also suggested that this modelling can account for covariates by 
making the prior mean a function of the covariates. Clayton and Kaldor (76) 
suggest extending the distribution of ()i to allow for covariates, Zi. They give an 
example suggesting that the estimate for an area with relatively few observed or 
expected cases should not be drawn towards the overall mean relative mortality, 
but towards an estimated value consistent with the area's level of the given 
covariate. Clayton and Bernardinelli (84) differentiate between covariates at an 
area-level and those measured on individuals. Area-level or ecological covariates, 
Zi, can be included by modelling the logarithm of the relative risks as a linear 
function of these covariates. This is effectively a separate scale parameter for the 
prior f (~ ICXi,Vi): 
E[log(B,)] = IO~ :, ) = z,' jJ, 
then the prior in equation (4.8) can be written as 
V()V-l -a.(). a . . e II f(Bilai'v)= I I • 
rev) 
Marshall (98) extended the Gamma-Poisson model and proposed a non-
iterative-distribution free approach using weighted moments to estimate a prior 
mean and variance. Marshall points out the difficulties arising in iterative methods 
of estimation and non-iterative ANOVA style estimators for the prior mean and 
variance. Tsutakawa (91) used the Poisson likelihood and Gamma framework to 
estimate relative risks for geographic regions with an additional random effects 
component. 
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4.2.2.2 Log-Normal Model 
Various other forms of prior distribution have been considered. Clayton and 
Kaldor (76) also proposed that the rates follow a multivariate log-normal 
distribution. Here the normal prior hyper-parameters J1 and a; were specified for 
the logarithm of the relative risks: 
The posterior distribution for the relative risks is no longer tractable under such a 
model and parameters can be estimated using the EM algorithm. 
Tsutakawa (91) proposed a log-normal model which is an alternative to 
standardising the data: 
where the observed data in stratum k and area i are assumed to follow a Poisson 
distribution. Then the area and stratum specific relative risks Jr ik were modelled 
in terms of area-specific relative risks fh and stratum-specific risks (A such that 
Here, the residuals uik are distributed with mean 0 and variance a;. This has the 
structure of a classic mixed effects model with fixed effects (A and random 
effects (}i. The (}i are assumed to come from a one parameter inverted Gamma-1 
distribution with hyper-parameter a: 
a -a/B. a e I 
!«(}i I a) = r(a) (}t . 
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Maiti (99) develops this log-normal EB method into a hierarchical Bayes 
estimation procedure for estimating mortality rates for disease maps. Bemardinelli 
and Montomoli (85) compared parametric (normal prior) EB estimates with Bayes 
estimates. Penalised log-likelihood maximisation was used for the EB estimation 
of the relative risks. 
4.2.2.3 Non-Parametric Model 
Clayton and Kaldor (76) suggested estimating a pnor distribution non-
parametrically using a method suggested by Laird (100). This assumes that 8i are 
iid random variables with density, f (8), of unspecified parametric form. f (8) can 
be estimated nonparametrically using an EM algorithm. This method has the 
advantage of imposing few constraints. Heisterkamp et al (93) developed the non-
parametric approach further. The prior distribution is replaced by a number of 
support points a h such that 
and the probability of each value can be written as 
The actual number of support points, H, gives an indication of the number of 
different values for the true SMR in the data, whereby H = 1 would suggest that 
all areas have the same true SMR up to a maximum of H = n unique SMRs. The 
conditional likelihood for a mixture of Poisson distributions (80) can be written as 
The posterior empirical Bayes estimates are a weighted average of the estimated 
support points a h : 
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H 
~ ahithe-ahE; (ahEJo; 
E(Bi IOi'EJ=~H----­
~ ithe-ahE; (ahEJo; 
Schlattman (101) suggests using mixture models to identify population 
heterogeneity and map construction within an empirical Bayes framework. This 
assumes that Oi comes from a nonparametric mixture density. Estimation is done 
using a maximum likelihood approach. 
4.2.2.4 Multilevel Models 
Multilevel models can also be used to provide empirical Bayes estimates for 
disease mapping (6, 102-104). The simplest Poisson multilevel model fits one 
"level" to model the Poisson variation and the extra Poisson variation is fitted at 
the higher level. Referring to any covariates as Zi, the logarithm of the relative 
risks can be written as 
log( ~) = z/ P + Ui , (4.10) 
with an assumed normal distribution for the residuals Ui: 
(4.11) 
Changing the prior for log(Bi) in (4.9) to one dependent on an area specific mean 
Ui gives 
(4.12) 
where 
(4.13) 
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This model can be extended to include higher levels of geographical aggregation 
(105). To fit a model with two levels, region i nested within country j, say, 
equation (4.1) becomes 
(4.14) 
then equation (4.9) can be written as 
(4.15) 
Here the logarithm of the relative risks for region i is modelled in terms of 
residuals at the levels of region and country. Each of these random effects are 
normall y distributed: 
(4.16) 
There is now non-independence in the relative risks since relative risks for two 
regions within the same country share the same country level random effect Vj. 
The prior in equation (4.12) can now be written as a joint prior for nj regions in 
country j: 
(4.17) 
The dispersion matrix for country j, ~j, has dimensions nj x nj with elements 
(J"; + (J"; on the diagonal and (J"; off-diagonal. 
Further levels can be added and is straightforward. Langford et al (106) 
showed that the model described in equation (4.14) and (4.15) can be extended to 
include random covariates. Langford et al (6) described how to include spatial 
correlation between the relative risks in the multilevel model. This will be 
discussed further in Chapters 5 and 6. 
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4.2.2.5 Spatial Models 
Ignoring spatial configuration of areas is often unjustifiable as areas close to one 
another in geographical space often share similar environmental, social or 
demographic factors which influence disease rates. An EB estimate which 
incorporates a spatial component can be thought of as a weighted average between 
the SMR, a local mean rate, and the global mean rate. 
Models of exchangeability (76) have been discussed so far, where area-
specific estimates are more or less displaced depending on the mean value. This 
displacement depends on the intrinsic stability of the estimates and not the areas' 
locations on the map (85). However, often the relative risk estimates are strongly 
influenced by the estimates of geographical areas, and only indirectly by the 
estimates from the rest of the map. Incorporating the geographical structure of the 
map results in a more complex prior model. This sets a conditional independence 
structure on the relative risks whereby each relative risk is conditionally 
independent of all other relative risks, given a small set of geographically adjacent 
areas. Most of the attention in the literature in this area has focused on this type of 
method, modelling spatial dependence of the prior ()i eg by modelling the mean of 
()i conditional on the ()/s of its neighbours. 
Another, less popular, approach for accounting for spatial location space is 
to make the prior on () position dependent whereby a trend is placed on the prior 
mean E«()). Marshall (98) proposed a method for empirical estimation of E«()i) for 
each i. It is assumed that the E«()i) do not vary greatly within neighbourhoods. An 
estimator shrunk towards a weighted neighbourhood average is obtained via a 
non-iterative distribution-free approach by a method of moments. The resulting 
degree of shrinkage depends on the local variability of the neighbourhood rates. 
Any of the EB methods results in estimates of relative risks being more displaced 
towards a local mean rather than a global value. 
Various different prior distributions have been developed for the alternative, 
more commonly used approach. A prior distribution that naturally allows for the 
possibility of spatial dependence between rates is the multivariate log-normal 
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prior. This was developed by Clayton and Kaldor (76) and has been a popular 
technique for mapping disease (96, 99, 107). The log-normal model was described 
previously and a spatial extension to this is to suppose that the log relative risks 
are correlated, where the correlation is dependent on geographical proximity. The 
dispersion matrix, L, may be expressed as a function of a small number of 
parameters. Clayton and Kaldor (76) used the conditional autoregression (CAR) 
procedure to model the mean conditional on its neighbours. This model has been 
further developed (84, 108-110) such that the logarithm of the relative risks is 
modelled as 
(4.18) 
where the Vi are unstructured heterogeneous effects such that 
(4.19) 
and the Ui are spatially structured effects through an intrinsic Gaussian 
autoregression 
(4.20) 
where u. is the mean of areas bordering area i: 
I 
(4.21) 
i' 
(4.22) 
i' 
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and W is the adjacency matrix of the map, defined by 
1 if i and i' are contiguous 
o otherwise. 
The Vi and Ui are assumed to be independent and if the Ui dominate then the 
relative risks show spatial structure. 
Yasui (96) develops this model slightly usmg a Gaussian spatial 
autoregression process which assumes that loge 0]), ... ,loge Oi) follows a 
multivariate Gaussian distribution with conditional moments. Yasui then goes on 
to evaluate empirically the various priors used in the EB estimation of small area 
disease risk by comparing mean squared errors and weighted mean squared errors. 
Mollie and Richardson (109) consider both the CAR and a simultaneous 
autoregression (SAR) prior model to attempt to smooth cancer mortality rates and 
discuss the differences between the models. The covariance structure of a SAR 
model implies that autocorrelations at a larger distance than for a CAR model are 
taken into consideration, without estimation of extra parameters. Besag (111) 
showed that a SAR model can be written as a CAR model of higher order. 
Bemardinelli and Montomoli' s (85) basic model is similar to that proposed 
by Clayton and Kaldor (76), but they go on to use a penalised log-likelihood 
maximisation for the EB estimation of relative risks. Bi is modelled as the sum of 
the global mean, denoted by Ji, that expresses the overall level of the log-relative 
risks throughout the map, and an area specific effect, denoted by ¢, representing 
the area risk effects, that is the difference between the log-relative risk for an area 
i and the global mean. For the ith area 10g(Oi) = 'Ii = Ji + ¢i and Oi follows the 
Poisson distribution given by 
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The aim is to combine the 'prior' belief about the risks, which is embodied in the 
prior [¢IA], [A] and [,u], with the 'new' information contained in the data {Y, E}. 
Here [¢I A] denotes the area effects and is viewed as a spatial process as it 
expresses the prior beliefs concerning the collection of unknown area effects; [A] 
denotes the prior for an unknown parameter which represents the geographical 
variability and which controls the amount of variation in risk distribution 
throughout the map; and [,u] denotes the prior for the global mean. The EB 
estimates of ¢ and ,u are obtained by maximising the posterior distribution 
[¢,,ul 0,E,1], which is equivalent to 
1* (¢,,u) = 10g[Y IE, ¢,,u] + log[ ¢ I i] 
" whereby A is a suitable estimate of the parameter A.. The first term on the right 
hand side for fixed Yand E is the log-likelihood of the data while the second term 
can be interpreted as a penalty function that penalises departure of ¢ from the 
prior model. Therefore, the above function can be interpreted as the penalised log-
likelihood. If we adopt the CAR prior model this becomes 
" N 
1 * (¢, 11) = I(¢, 11) - ~i ~ ¢;(¢i - ¢;). 
i=l 
The log-area effects that differ greatly from their respective neighbours receive 
high penalties. The penalties cause these estimates to shrink towards a local mean. 
The quantity 1 acts as a smoothing parameter and when it is large the penalty 
function receives more weight leading to smoother estimates of the effects {¢}. 
When this parameter is equal to 0, the penalty is given no weight, which leads to 
the ML estimates of the effects. 
53 
cnapter 4 Disease Mapping Review 
4.2.3 Fully Bayesian 
The fully Bayesian approach incorporates the distribution of the hyper-parameters 
fr ("() into the modelling. The joint posterior distribution of the relative risks e 
and the hyper-parameters "( given the data 0 is 
g(O,y I 0) oc g(OIO) f () (Oly) fly). (4.23) 
The marginal distribution for e given the data is then obtained by integrating out 
the hyper-parameters: 
g(OI 0) = f g(O,y I O)dy. (4.24) 
Fully Bayesian procedures, as with empirical Bayes, provide methods of variance 
reduction through the borrowing of information. The hierarchical structure leads 
to Bayes point estimates that are shrunk towards a value that is related to the 
distribution of all the parameters in the hierarchical structure. It is assumed that 
the prior structure is close to the 'true model', and consequently a different choice 
of priors will lead to different shrinkage. 
Various fully Bayesian disease mapping models are compared using 
goodness of fit criteria, by Lawson et al (112) and a comprehensive review of the 
main classes of spatial priors that have been proposed for fitting fully Bayesian 
disease mapping models is given by Best at al (113). A fully Bayesian approach 
that is commonly used (114, 115) as a model for disease mapping aggregated 
count data is a three-level hierarchical model. Again, Ei are the expected number 
of deaths, Pi represents the log relative risks (lOg(Bi» and Oi represents the 
observed number of deaths in area i. The Oi follow a Poisson distribution: 
0i ,.... Poisson (BiEJ ,i = 1, ... ,n 
(4.25) 
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(4.26) 
where pC· I A ) is an appropriate second-stage prior distribution for Pi and A are the 
hyper-parameters of this second stage model with hyper-distributions 7Z'(). 
4.2.3.1 Multivariate Normal Priors 
Correlated random variables are often represented by the multivariate normal 
distribution. The dependence structure can be structured in terms of an n x n 
covariance matrix 1:, and the second-stage prior can be written as 
(4.27) 
where P = {Pl, ... , Pnl = (log(fh), ... , 10g(Bn)} and represents the vector of area 
specific random effects from equation (4.24). 1: = t?n and Qij is the correlation 
between Pi and Pi (116). The elements of the correlation matrix are chosen to be a 
function of the relationship between the areas. This should be chosen so that the 
covariance matrix 1: remains positive definite. 
An alternative approach that follows on from this was proposed by Kesall 
and Wakefield (117) and is based on specifying a Gaussian random field for the 
underlying distribution of the log relative risk at the second stage of the 
hierarchical model. Integrating this model over i areas gives a multivariate normal 
model for 10g(Bi). 
Mollie (79) uses Gaussian Markov random fields (similar to CAR model) 
for mapping SMRs, which is a second stage model that was originally proposed 
by Besag et al (110), and discusses a compromise between a spatially structured 
prior and an unstructured prior (108). A convolution Gaussian pnor IS an 
intermediate distribution in the log-relative risks that ranges from prior 
independence to prior local dependence. The log relative risks in the prior are the 
sum of v, a normal variable with zero mean and variance A?, and u, an intrinsic 
Gaussian autoregression with conditional variances proportion to Tl. Again, v 
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describes the unstructured heterogeneity of the relative risks and u represents local 
spatially structured variation, so log( ~)= u + v. The conditional variance is 
2 
var[Pi I P j , j ¢ i, r] = var[Pi I P j , j E a i' K, A] = ~ + A? , 
Wi+ 
where ai denotes the set of areas adjacent to area i, the hyper-parameter A = 0; 
and Tl' corresponds to a total independence of the risks whereas ..1,2 = 0 leads to 
purely local dependence modelled by the intrinsic Gaussian autoregression. A 
small Tl'/A? reflects unstructured heterogeneity whereas a large Tl'/A2 indicates that 
a spatially structured variation dominates. 
For the multivariate normal priors for the log relative risks, a more general 
class of hyper-priors for the inverse variance is the conjugate Gamma distribution 
with specified parameters (79). Vague Gamma hyper-priors are often assumed for 
u and v when there is a lack of information about the importance of each 
component. It has been suggested (85) that it is reasonable to choose vague 
gamma priors with means 
2 for ..1-2 
var(log( ()i ) 
and 
2 
.s: -2 
.Lor K 
w var( (log( ()i » 
where w is the mean of Wi+ , Wi+ = L wij and wij is the ijth element of a 
j 
symmetric n x n weight matrix W similar to that described for equations (4.21) 
and (4.22). 
The Gaussian Markov random fields are the most commonly used second 
stage model. This model, which was further developed by Besag et al (110), can 
be written in general terms to coordinate with equations (4.25) and (4.26): 
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(4.28) 
[ ~ W .. U. 0 2 ) Vlu ~N L...Jj IJ J _u I ( -i) ,. Wi+ Wi+ (4.29) 
By setting the autocorrelation parameter, which reflects the overall strength of 
spatial dependence between locations, to its upper limiting value of 1 means the 
{Ui} follow an intrinsic autoregression. As previously discussed, this can be 
described as the spatial component of between-area variation of disease risk and 
the {Vi} represent the geographically unstructured heterogeneity effect. Posterior 
inference about the amount of spatial dependence that exists is based on the 
marginal variance of the U/s; this can be estimated using MCMC methods. 
Maiti (99) develops the CAR model for log-relative risks and assumes a 
hierarchical model. Non-informative priors for hyperparameters are used. This 
method was developed because unlike the EB method, the hierarchical Bayes 
method accounts for the uncertainty involved in the estimation of mean and 
variance of prior parameters by assigning the distributions of prior parameters. In 
the case of these models, the approximation to the variance of the MLE of 
parameters of the prior distribution is intractable. Mollie and Richardson suggest 
that an indication of the precision of these estimates can be based on the 
conditional expected information for the prior of the log rates. This is calculated 
from the expectation of the log of the prior density conditional on the observations 
and the current values of the parameter estimates, given in the EM algorithm. The 
CAR model appears to be a popular choice of model for examining spatially 
distributed disease data (79, 95). The Gaussian Markov random fields model is 
equivalent to specifying a multivariate normal model for the joint distribution of 
the area specific random effects but with the dependence structure parameterised 
in terms of the precision matrix, P, rather than the covariance matrix I = p-l. 
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Another multivariate normal model was proposed by McNab (118) which 
also parameterises in terms of the precision matrix. This model assumes 
where 
D = pP + (1- p)I . 
As discussed, P represents the precision matrix and I is the n x n identity matrix. 
p E [0 , 1] and can be interpreted as the measure of spatial dependence whereby if 
p = 0, the model reduces to the Gaussian independence prior (4.28) or if p = 1 it 
reduces to the intrinsic autoregression (4.29). 
4.2.3.2 Mixture Models 
Lawson and Clarke (119) propose an extension to the Gaussian Markov random 
fields model that includes a mixture of Gaussian and non-Gaussian conditional 
autoregressive components. The non-Gaussian is median based and aims to pick 
up discrete jumps in the relative risk structure which should hopefully avoid over-
smoothing the distribution of relative risks. 
Some of the models described in· this section run the risk of oversmoothing 
the distribution of relative risks. Mixture models have been proposed in an 
attempt to prevent this happening and are becoming more popular for disease 
mapping. They take a different approach, in that, instead of assuming that the 
structure of the map can be described with a global structure, they assume that the 
map consists of a number of components and the aim is to identify these 
components. Schlattmann and Bohning (101) classify each area of the map as 
belonging to one component but other models, which are not so specific, are 
available. 
Green and Richardson (120) proposed a mixture model where the allocation 
of p;'s for each area to a risk category follows a correlated process. They extend 
hidden Markov models to the spatial domain. It makes use of Potts model, which 
is frequently used in image processing, and involves fitting an interaction 
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parameter that controls the degree of spatial dependence and the number of 
'states' of the mixture is estimated as part of the model. This model can be written 
as 
exp(fii) = Ta. , 
• 
where a i is the allocation variable and a i E{l, ... ,c}; c,... Unif(l, cmax) and 
represents the number of components in the mixture. Then, 
T j ,.., Gamma(a,fi) , j = 1, ... ,c. 
The interaction parameter If.! is to be estimated and U(z) is the number of pairs of 
neighbouring areas. An area i is allocated to component j based on If.!; larger 
values of If.! suggests area i has more neighbours in component j and will therefore 
be favoured. This model uses a reversible jump algorithm because the number of 
components in the mixture, c, is uncertain. Fernandez et al (121) also suggested 
mixture models for spatially distributed data. Transformations of autoregressive 
Gaussian processes are proposed for the spatially dependent weights and 
reversible jump Markov Chain Monte Carlo algorithms for posterior inference are 
developed. 
4.3 Use of Disease Mapping Models 
In this chapter, the techniques available for fitting empirical Bayes and fully 
Bayesian models have been discussed. In the following chapters, iterative 
generalised least squares procedures and the linearising approximation, penalised 
quasilikelihood, will be described as a means of obtaining empirical Bayes 
estimates of the spatial multilevel model. Other methods, such as the EM 
algorithm and Fisher scoring can also be used to fit the models described in 
section 4.2.2. Estimation procedures for fitting the fully Bayesian models will also 
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be discussed. Markov Chain Monte Carlo (MCMC) procedures will be described 
in terms of fitting spatial multilevel models. However, this technique can be 
applied to all of the fully Bayesian models described in this chapter. 
60 
Chapter 5 Spatial Multilevel Modelling 
Chapter 5 
5 Spatial Multilevel Modelling 
5.1 Introduction to Multilevel Modelling 
Multilevel or hierarchically structured data are found in many areas of application 
and it is important that these structures are taken into account. An example which 
provides a clear case of such a structure is in education whereby we have a 
response from pupils who are assigned to levell, these pupils are clustered within 
classes at level 2, which are clustered within schools at level 3, and these can be 
grouped within authorities or boards at level 4. Multilevel models take into 
account how this structure affects the measurements of interest and ignoring a 
hierarchical structure, if present, has consequences. For example, if analysing a 
school dataset similar to that described above, the relationship between two pupil 
level variables could be modelled using a simple linear regression. The variation 
between schools could be taken into account by incorporating separate terms for 
each school but this is very inefficient as it involves estimating many more 
coefficients than the multilevel procedure. It also does not treat schools as a 
random sample and therefore provides no information on the proportion of the 
variation that is attributable to differences between schools in the population. A 
further disadvantage of ignoring clustering is that it will generally cause standard 
errors of regression coefficients to be underestimated. Multilevel modelling also 
provides a useful tool to develop more complex models and this will be discussed 
in this thesis, mainly by looking at how to model geographically distributed data 
and explore the effects of incorporating the spatial structure of the data as a level. 
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For the purpose of this thesis, the background to multilevel modelling will 
be described from the view of modelling Poisson distributed data. Goldstein et al 
(122) give details of how to model normally distributed multilevel data. 
5.2 Multilevel Modelling of Geographically Distributed Data 
As previously discussed, problems associated with using conventional Poisson 
based methods to model geographically distributed data can be overcome by using 
multilevel modelling techniques based on iterative generalised least squares 
procedures (6). The data that will be used for our preliminary analysis and model 
exploration are geographically distributed in that we have counts of cancer deaths 
within regions within countries and they exemplify the type of data appropriate 
for a multilevel analysis. 
5.2.1 European Cancer Mortality Data 
To begin modelling, cancer mortality in 540 regions in 38 countries in the period 
1991 will be used. The total population for the 38 countries was 690,308,858, 
ranging from 257,965 (Iceland) to 148,244,835 (Russian Federation). Population 
data are available at a sub-national level for 27 of the European countries. The 
mean population for a region was 1,295,139 with a range from 13,645 
(Appenzzell-Inner Rhoden, Switzerland) to 17,429,759 (North Rhine-Westphalia, 
Germany). The causes of deaths were based on the Ninth Revision of the 
International Classification of Diseases (ICD-9) (123) and the causes of death 
considered here are malignant neoplasms (ICD-9 140-208). The total number of 
recorded deaths from cancer in these countries was 1,614,293, ranging from 446 
(Iceland) to 290385 (Russian Federation). The mean number of deaths for a 
region was 2989, ranging from 29 (Appenzell-Inner Rhoden, Switzerland) to 
49137 (North Rhine-Westphalia, Germany). If population or mortality data were 
not available for the timepoint 1991, data were used from the closest available 
timepoint. Further summaries of the data were presented in Chapter 3. 
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5.2.2 European Risk Factor Data 
Since there is strong evidence of relationships between diet and other lifestyle 
factors and cancer mortality, it is important that we should adjust for these factors 
as necessary when examining spatial patterns of cancer mortality. We are also 
interested in quantifying what effect these factors have on mortality rates, and so 
need measures that reflect the population's diet and lifestyle. 
The risk factor data were summarised in Table 3.7. Average consumption 
data for animal fats, alcoholic beverages, fruit and vegetables were obtained for 
the period 1991. These cover the dietary components that appear to be related to 
the most common cancer mortalities. The data are measured in kilograms per year 
per head of population for each of the European countries being examined. 
Annual average consumption of manufactured cigarettes per adult (+ 15) is 
provided at a country level for the time period 1990-1992 and should reflect the 
average level of smoking in each of the European countries. To take into 
consideration the differences in socio-economic status between countries, gross 
domestic product (GDP) is available and is measured in US dollars per inhabitant 
in 1995. 
5.2.3 Variance Components Model 
Firstly, we consider a population of regions, i, i = 1, ... , 540, with observed (Oi) 
and expected (Ei) counts of deaths. The expected number of deaths in the ith 
region, Ei, has been calculated based on the 1990 European age and sex specific 
cancer mortality rates and on the number of deaths in the population N i • This 
standardisation is conducted for age and sex bands k and calculated as 
(5.1) 
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(5.2) 
The relative risk of the mortality from the disease of interest is then 
e. = °1 
I E. 
I 
(5.3) 
A single level Poisson model including all SIX explanatory variables can be 
written as (105): 
log(Jli) = log(Ei) + a 
+ fJ1Xli + fJ2 x 2i + fJ3 x 3i + fJ4X 4i + fJsxSi + fJ6x 6i (5.4) 
where log (Ei) is treated as an offset and is included to account for the different 
populations at risk of death from cancer in each area. a is a constant and XI& ••• ,X6i 
are the explanatory variables with coefficient PI, ... ,P6, representing the mean 
(fixed) effects of the factors fruit consumption, vegetable consumption, animal fat 
consumption, alcohol consumption, cigarette consumption and gross domestic 
product respectively. We assume that the number of counts within each region 
follows a Poisson distribution. The Ui represent heterogeneity effects between 
areas (94) which can be viewed as having extra Poisson variation caused by the 
variation among underlying populations at risk in the regions considered. 
A variance components model describes the random variation in the data by 
a set of variances. Looking at this model it can be seen that all of the variance is at 
a single level, i, which is region. There is only one random parameter, (J/. 
Potentially, and more appropriately, this model can be expanded by partitioning 
the variance into that which is attributable to random variation between countries 
and that which arises due to differences between regions within countries, i.e. 
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adding a further level. Equation (5.4) can be extended to include a second level, 
country, indexed by j, and can be written as follows: 
Dij .... Poisson (Ilij ) , 
10g(llij ) = 10g(Eij) + a 
+ fJI X lij + fJ2X2ij + fJ3 X 3ij + fJ4X4ij + fJ5 X 5ij + fJ6 X 6ij (5.5) 
+u·. +v· IJ J 
lvjJ .... N(O,Qv), Q
v 
= [a-;], 
lUij J .... N(O, Qu), Q u = [a-;]. 
The mam difference between the models is that the variance has now been 
partitioned into a-;, that which is attributable to differences between countries, 
and a-;, that which is attributable to differences between regions. 
5.2.4 European Cancer Mortality Results 
The results of the variance components models are shown in Table 5.1. Model A 
represents the null model with no explanatory variables included, model B is the 
full single level model (5.4) and model C incorporates country as a level (5.5). 
Firstly, looking at model B, the overall intercept, a; represents the 
logarithm of the average number of cancer deaths in all regions included in the 
study in addition to the (centred) logarithm of the expected cases, when all other 
fIxed coefficients are zero. The estimates of the intercept are not particularly 
informative in these models as they reflect an unlikely situation whereby an area 
has zero exposure to any of the risk or protective factors. Before examining the 
other fIxed parameter estimates it should be noted that for the purpose of 
interpretability the explanatory variables were re-based. The consumption 
variables were modelled in terms of 1000 kgs consumed per person per year, 
smoking was scaled to how many 1000 cigarettes were smoked per person per 
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Table 5.1 Results from variance components models: WHO European region 
Model A Model B Model C 
Estimate Estimate Estimate 
(95% CI) 
Fixed Part 
(95% CI) (95% CI) 
a 7.38 6.99 7.03 
(7.36 , 7.39) (6.92 , 7.06) (6.85 , 7.21) 
/31 (FRU) 
-3.63 
-2.90 
/h (VEG) 
(-4.42, -2.83) (-5.33, -0.47) 
0.99 0.36 
/33 (ANF) 
(0.46 , 1.53) (-0.99, 1.71) 
9.39 6.59 
(6.18 , 12.60) (-3.55 , 16.73) 
/34 (ALC) 1.39 1.99 
(0.90 , 1.88) (0.51 , 3.48) 
/35 (SMO) 0.05 0.09 
(0.02 , 0.08) (-0.01 ,0.18) 
/36 (GDP) 16.85 5.91 
(12.85, 21.85) (-1.86, 13.68) 
Random Part 
d u 0.049 0.027 0.013 
d v 
(0.043 , 0.055) (0.023 , 0.030) (0.011 ,0.015) 
0.014 
(0.006 , 0.022) 
year, and GDP was examined as millions of dollars per inhabitant per year. The 
estimate of /31 is the mean, or fIxed slope for the explanatory variable fruit and it 
can be seen the estimate is negative and, judging signifIcance by approximate 95 
per cent confidence intervals, signifIcant. This implies that when taking the other 
variables into account, an increase in fruit consumption decreases cancer mortality 
on average in the EU. The parameter estimate of -3.63 is a log relative risk of 
cancer mortality for each 1000 kg increase in fruit consumption per person per 
head. This suggests that every 10 kg increase in fruit consumption per person per 
year is associated with a decrease in the risk of cancer mortality of about 4% 
(RR=exp{ -0.0363} = 0.964). It can be seen that all of the other variables appear to 
significantly affect cancer mortality; vegetable consumption surprisingly has a 
positive association with cancer mortality in Europe, animal fat consumption and 
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alcohol are also shown to be significant risk factors, smoking is shown to 
significantly heighten the risk of cancer mortality, and a higher GDP appears to 
increase the risk of cancer mortality. 
The actual effect size of these variables will be discussed further on. There 
has been no partitioning of variance yet so all the variation here is due to 
differences between regions (CT; = 0.027). If we compare this value to the 
variance under model A (CT; = 0.049) it can be seen there has been a 45% 
reduction in variation after adding the explanatory variables. Due to the 
significant explanatory variables being at both region and country level, this 
shows that these factors are helping to explain the differences in cancer mortality 
between regions and countries. To show these differences visually, the estimated 
relative risks from models A and B have been mapped and are shown in figure 5.1 
and 5.2. 
There is definite clustering evident in Figure 5.1 and clusters of high cancer 
mortality rates can be identified in areas such as France, Denmark, parts of 
Russia, Hungary, UK and the Czech Republic. Cancer mortality rates in these 
regions are between 20% and 62% higher than expected if the European age and 
sex specific mortality rates had been applied to that area. Clusters of low mortality 
rates are most evident in regions Southern Europe, in particular Greece, Romania, 
Bulgaria and Ukraine. Overall, there is very high variability within and between 
many European countries. Figure 5.2, the map of the relative risks associated with 
living in these regions over and above the given risk factors, shows less 
variability; the relative risks now range from 0.59 to 1.51 (they ranged from 0.41 
to 1.62 in Figure 5.1). As was evident from the random parameter estimates, the 
risk factors have, therefore, explained some of the variation in cancer mortality 
rates in the Europe, suggesting that even these initial models have been effective 
at smoothing geographic variation. However, the clustering within countries 
suggests it may be useful to take account of the higher geographical level. 
Taking account of the fact that regions within a country are more alike than 
those from different countries, changes the parameter estimates somewhat (Table 
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5.1: Model C). The parameter estimates now appear more sensible with an 
increase in vegetable consumption and GDP not being associated with a 
significant increase in the risk of cancer mortality anymore. The variance has now 
been partitioned and it can be seen that a similar proportion can be attributed to 
2 d·" b . 2 () u' luerences etween regIOns, as to () v , differences between countries. From 
examining the map of relative risks from this model (Figure 5.3), it can be seen 
that there is much more clustering evident. There is a high amount of country 
level clustering as estimates for each region are drawn closer to the relative risks 
of the overall country. There are much more areas with very high (and very low) 
estimates which means the map is less useful for identifying regions as disease 
'hotspots' (or areas of very low risk) but is useful in identifying countries at high 
risk as compared to other European countries. 
Since the actual values of the fixed parameter estimates are not very 
informative, relative risks have been calculated which compare regions with high 
and low levels of exposure to each of the risk factors. The relative risks have been 
calculated for each of the variables from models Band C and are given in Table 
5.2. Firstly, for the consumption of fruit as estimated by model C, the table shows 
that Greece has the highest level of consumption in Europe and Estonia has the 
lowest. The relative risk of 0.71 shows that a population consuming, on average, 
the same amount of fruit as Greece has a risk of cancer mortality that is 29% 
lower than if consumption was on the same level as Estonia. The other significant 
covariate from model C is alcohol consumption; consuming the same level of 
alcohol as Germany leads to a risk of cancer mortality that is 1.4 times as high as 
if consumption was on the same level as Armenia. For model B, it can be seen 
that all the variables are having significant effects on cancer mortality in Europe 
and vegetable consumption and GDP are having an opposite effect than would be 
expected. Populations across Europe lead very varied lifestyles and the relative 
risks, before accounting for the non-independence of regions within countries, are 
likely to be inaccurate. It makes more sense to concentrate on the estimates from 
the model taking account of some of the geographical structure in the data. 
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Table 5.2 Variable effect size of risk factors from model B and C: WHO 
European Region 
Area with Relative Risk 
Variables Highest Lowest Model Consumption Consumption B C 
Fruit Greece Estonia 0.65 0.71 (1.13 , 1.50) (0.53 , 0.95) 
Vegetables Greece Israel 1.30 1.10 
(1.13 , 1.50) (0.77 , 1.58) 
Animal Fat Hungary Armenia 1.30 1.20 
(1.19 , 1.42) (0.91 , 1.59) 
Alcohol Germany Armenia 1.26 1.39 
(1.16 , 1.36) (1.09 , 1.77) 
Cigarettes Poland Azerbaijan 1.15 1.28 
(1.06 , 1.24) (0.97 , 1.63) 
GDP Switzerland Kyrgyzstan 1.73 1.21 
(1.52 , 2.04) (0.94 , 1.56) 
To give a graphical alternative to the maps, a plot of the predicted relative risks 
from model C is given in Figure 5.4. A measure of longitude (east to west 
positioning) has been plotted against the predicted relative risks for each region in 
Europe. This is an alternative to mapping the results and prevents the loss of 
information that occurs when grouping mortality rates in ranges. A relative risk of 
1 on the plot indicates a region where the number of cancer deaths is as expected. 
There is an indication of a negative slope in this plot, suggesting the farther west a 
region is, the higher the risk of cancer mortality. There is also the possibility of 
two separate slopes in the data (see lines imposed on plot), suggesting that 
analysing Europe as a whole is perhaps not the correct method. The lifestyles of 
populations across Europe are also very different as many eastern European 
countries are a lot less developed than Western Europe. It may make more sense 
to split the European data somehow before carrying out any further analysis. 
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Figure 5.1 Estimated Relative Risks from model A: all cancer mortality in the 
WHO European region 
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Figure 5.2 Estimated Relative Risks from model B: all cancer mortality in the 
WHO European region 
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Figure 5.3 Estimated Relative Risks from model C: all cancer mortality in the 
WHO European region 
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5.2.5 ED Cancer Mortality Data 
For subsequent modelling, a subset of the full dataset will be used. Only the EU 
will be examined as all its countries are in Western Europe and thought to be 
fairly comparable in terms of development and lifestyle habits. All of the 
countries in the EU contain regional data, with the exception of Luxembourg, 
which makes the dataset more suitable for exploring spatial multilevel models. 
The dataset only contains areas which have both population and mortality data 
available for the time period 1991. Therefore, we have all cancer mortality in 187 
regions in 11 EU countries. It should be noted that this dataset is based on the EU 
before the 10 new member states joined in 2004 (see Appendix Al.l ) and that 4 
of these 15 EU countries have missing data due to either the mortality or 
population data not being available for the time point being examined here . The 
total population for the 11 EU countries (Austria, Denmark. Finland. France. 
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Germany, Greece, Luxembourg, Netherlands, Portugal, Sweden and UK) was 
257,075,105 with a mean of 23,370,464, ranging from 387,100 (Luxembourg) to 
80,013,896 (Germany). The mean population for a region was 2,734,842 with a 
range from 24,734 (Ahvenanmaa in Finland) to 17,429,759 (North Rbine-
Westphalia in Germany). Again malignant neoplasms (ICD9 140-208) are 
consdiered. In 1991 the total number of recorded deaths from cancer in these 11 
countries was 654,126. The directly standardised mortality rates were calculated 
based on the standard European age and sex specific population. A summary of 
these is given in Table 5.3. The average standardised death rate for all countries is 
297 per 100,000, ranging from 163 (Finland and Sweden) to 267 (Denmark). At 
the regional level standardised death rates range from 125 (Epirus in Greece) to 
320 (Copenhagen and Frederiksberg city in Denmark). 
Table 5.3 Standardised death rates in the EU 
Country 
Austria 
Denmark 
Finland 
France 
Germany 
Greece 
Total 
deaths 
19317 
17764 
9626 
139310 
210537 
19945 
Luxembourg 957 
Netherlands 35645 
Portugal 18230 
Sweden 20406 
UK 162389 
Standardised 
Death Rate 
(per 100000) 
196 
267 
163 
212 
206 
164 
208 
209 
165 
163 
218 
If regional data available: 
Min Max No. of 
(region) 
181 
(firol) 
228 
(Sonderjylland) 
151 
(Kuopio) 
182 
(Midi-Pyrenees) 
187 
(Brandenburg) 
125 
(Epirus) 
197 
(Friesland) 
150 
(Centro) 
148 
(Kristianstad ) 
186 
(region) 
224 
(Burgenland) 
320 
(Copenhagen and 
Frederiksberg city) 
172 
(Ahvenanmaa) 
251 
(Nord-Pas-de-Calais) 
221 
(Bremen) 
192 
(Macedonia East and 
Thrace) 
223 
(Groningen) 
189 
(Azores) 
196 
(Gavleborg) 
264 
regions 
9 
15 
12 
22 
16 
13 
12 
7 
24 
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5.2.6 EU Risk Factor Data 
We are using subsets of the risk factor datasets obtained for the whole of Europe 
and these are summarised in Table 5.4. The risk factors are the same as those 
examined for the whole of Europe except GDP, which is available at the regional 
level (NUTS II) within each country in the ED. 
Table 5.4 Summarised ED risk factor data 
Risk/protective Median Minimum Maximum 
factor 
Fruit 100.8 74.5 142.6 
kg/year/capita (Sweden) (UK) (Greece) 
Vegetables 80.6 58.8 300.4 
kg/year/capita (Austria) (Finland) (Greece) 
Animal Fat 16.4 2.3 26.8 
kg/year/capita (France) (Greece) (Luxembourg) 
Alcohol 123.2 60.0 173.9 
kg/year/capita (UK) (Greece) (Germany) 
Smoke 2120 1550 3590 
cigarettes/year/adu (France) (Sweden) (Greece) 
lt 
GDP (region level) 17136 5611 44711 
ECD /inhabitant (Lorraine - France) (Ipeiros - Greece) (Copenhagen and 
Frederikberg city -
Denmark) 
5.2.7 EU Cancer Mortality Results 
The results of the variance components models are shown in Table 5.5. Model A 
shows the null model with no explanatory variables induded, model B is the 
results from the full model and model C is the full model with country added as a 
higher level. 
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Table 5.5 Results from variance components models: ED data 
Model A ModelB Modele 
Estimate Estimate Estimate (95% cn (95% cn (95% cn 
Fixed Part 
Po 7.53 6.83 6.87 
(7.50, 7.56) (6.68,6.99) (6.14, 7.46) 
Pi (FRU) 
-7.58 
-6.43 
Ih (VEG) 
(-8.65 , -6.50) (-11.08, -1.78) 
-1.12 
-1.06 
P3 (ANF) 
(-1.69, -0.55) (-3.09, 0.97) 
26.36 22.58 
P4 (ALC) 
(19.28 , 33.42) (0.94 , 44.22) 
0.64 1.25 
P5 (SMO) 
(-0.17 , 1.45) (-1.93 , 4.42) 
0.49 0.44 
(0.39 , 0.59) (0.09 , 0.78) 
P6 (GDP) 0.20 0.90 
Random Part 
(-4.61 ,5.01) (-2.231 ,4.02) 
d u 0.040 0.014 0.006 
d v 
(0.032 , 0.048) (0.011 ,0.017) (0.004 , 0.007) 
0.019 
(0.002 , 0.035) 
The parameter estimates can be interpreted as before, therefore using model 
B, the covariates significantly affecting cancer mortality in the ED are fruit and 
vegetable consumption which both have an inverse association with the risk of 
mortality, when taking the other variables into account, and animal fat 
consumption and smoking which are shown to have a positive association. Again, 
the actual effect size of these variables will be discussed further on. There has 
been no partitioning of variance yet so all the variation here is due to differences 
between regions (a; = 0.014). If we compare this value to the variance under 
model A ( a; = 0.040) it can be seen there has been a 66% reduction in variation 
after adding the explanatory variables. Due to the significant explanatory variables 
being at country level, this shows that these factors are helping to explain the 
differences in cancer mortality between regions and countries. The total variance 
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has been partitioned in model C and it can be seen that 76% of this is attributable 
to differences between countries. 
To examine the distribution of disease risk across the EU, the estimates of 
relative risks from models A, Band C have been mapped and are shown in 
Figures 5.5 to 5.7. The main features of Figure 5.5 indicate that France and 
Denmark have particularly high cancer mortality rates. Cancer mortality rates in 
these regions are between 20% and 54% higher than expected if the European age 
and sex specific mortality rates had been applied to that area. Greece, Portugal, 
Finland and Sweden appear to have the lowest rates. The pattern suggests that 
there is lower cancer mortality in the east and higher in the west with the 
exception of Portugal. However, data are missing for 4 EU countries, illustrated in 
white here, so it is difficult on the basis of these data to tell if this pattern is 
consistent across the whole EU. Figure 5.6 then shows the relative risks after 
taking into consideration the effects of the risk and protective factors that have 
previously been shown to have a significant effect on cancer mortality. This map 
shows less variability with the relative risks now only ranging from 0.77 to 1.36 
(they ranged from 0.59 to 1.54 in Figure 5.5). The risk factors have, therefore, 
explained some of the variation in the cancers mortality rates in the EU, 
suggesting that even these initial models have been effective at smoothing 
geographic variation. The map for model B is a lot smoother, hence allows easy 
identification of regions that could be labelled disease 'hotspots'. The disease map 
from model C is very similar to model B's. However, France noticeably has more 
high risk areas due to the country level relative risks for France being high and 
influencing the estimates for its regions. 
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Figure 5.5 Estimated Relative Risks from model A: all cancer mortality in the EU 
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Figure 5.6 Estimated Relative Risks from model B: all cancer mortality in the EU 
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Figure 5.7 Estimated Relative Risks from model C: all cancer mortality in EU 
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5.3 Estimating the Models 
The variance components models and subsequent models in this Chapter were 
fitted using a quasi-likelihood (frequentist) approach. This method involves 
finding pseudo maximum likelihood estimates for the unknown parameters in the 
model. The algorithm used here to find such estimates is known as iterative 
generalised least squares (IGLS) estimation or a restricted version (RIGLS). 
5.3.1 Iterative Generalised Least Squares 
The iterative generalised least squares method was introduced by Goldstein (124) 
to estimate normal response multilevel model. This procedure is based on a 
generalised least squares estimation that produces maximum likelihood (ML) 
estimates. Full details of how the algorithm fits multilevel models can be found in 
Goldstein (122). 
This two-stage process involves estimating fixed and random parameters 
(variances and covariances of the random coefficients) in successive iterations 
using IGLS. Goldstein (122) described the basic model of fixed and random 
effects. Considering this in vector notation, 
Y = Xj3 + ze, 
where Y is a vector of observations being modelled by explanatory variables X 
and associated fixed parameters fJ , and explanatory variables Z with random 
coefficients e. The fixed and random part design matrices X and Z need not be the 
same. e is assumed to contain a set of random error terms along with other 
random effects. 
Firstly, the fixed parameters are estimated using ordinary least squares 
regression, assuming higher level variance in the model to be zero. The vector of 
residuals produced from this model can then be used to construct initial values for 
the dispersion matrix V. The estimation procedure is iterative and it is firstly 
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applied usmg a generalised least squares estimation procedure to obtain the 
estimator for the fIxed coefficients 
(5.6) 
The residuals are calculated again, 
and by forming the matrix product of these residuals, y* = ITT and then stacking 
them into a vector produces Y * * = vec(ITT). The variance of the random 
coeffIents B, r = cov( B) , can then be estimated as, 
(5.7) 
Z* is the appropriate design matrix for the random parameters and V* is the 
Kronecker product of V, namely V* = V ® V, where 
v = E(YYT ) = E(Y*). (5.8) 
Now, assuming multivariate normality, the estimated covariance matrix for the 
fixed parameters can be written as 
Goldstein and Rasbash (125) showed that covariance for the associated random 
parameters can be written as 
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These random parameters and the associated variances can then be estimated from 
the model in a similar manner as the fIXed parameters and their variances. In 
comparison to ordinary least squares regression, the random part is modelled 
taking into account the structure of the data allowing us to estimate a set of 
parameters rather than having a single residual error term (6). 
5.3.1.1 Penalised Quasilikelihood Estimation 
As previously discussed, a Poisson distribution is being modelled, therefore the 
non-linear (logarithmic) relationship between the outcome variable and the 
predictor part of the model has to be taken into account. This has been done by 
making a linearising approximation to estimate the random parameters. Looking 
at a simple case of heterogeneity effects only (as in VC model equation (5.4», the 
residuals ui can be estimated from the model using penalised quasi-likelihood 
(POL) estimation with a second order Taylor series approximation (122, 125). 
Mter each iteration t, predictions H t are made from the model where 
Then these are used to calculate new predictions for iteration t + 1, so that 
f(Ht+l) = f(Ht) + Xi (Pt+l - PJf'(Ht) 
+ uif'(HJ + 11; f"(Ht)/2' 
(5.9) 
where f(e) is a link function. An updating function is provided for the flxed part of 
the model by the first two terms on the right hand side of equation (5.9). The third 
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term is made up of a linear random component that is created by multiplying the 
first differential of the predictions by the random part of the model while the next 
term in the Taylor expansion about Ht makes up the fourth term in (5.9). 
Following on from this, the Poisson distribution takes the form 
f(H) = f '(H) = f "(H) = exp(Xtpt + uJ, 
and at each iteration, estimates are made about the fixed part of the model plus the 
residuals. 
5.3.1.2 Marginal QuasilikeIihood 
This POL method described above generally gives better estimates than the MOL 
method but is more prone to convergence problems or with the estimates 'blowing 
up' if the residuals are too large. In such cases, a MOL model can be estimated by 
choosing H t to be the current value of the fixed part parameter only, that is 
omitting the estimated residuals from the linear component of the nonlinear 
function 
The MOL procedure does, however, tend to underestimate the values of both the 
fixed and random parameters, especially when the sample size is small (122). 
Also, to help overcome convergence problems the term involving the second 
derivative in (5.9) can be omitted giving a first order approximation. However, it 
is expected that its inclusion, in general, improves estimates, so a typical 
procedure, when facing convergence problems, is to estimate using MOL first 
order initially and if this succeeds attempt estimating using second order and POL 
procedures. The differences between the estimation procedures have been 
illustrated (126). 
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5.3.2 Restricted Iterative Generalised Least Squares 
As previously discussed, the IGLS procedure uses the current estimates of the 
fIxed and random parameters to iterate between equations (5.6) and (5.7). This 
procedure often produces biased estimates so Goldstein (127) shows how a simple 
modifIcation can lead to restricted iterative generalised least squares (RIGLS) 
which produces estimates that are unbiased. 
Using estimates of /J to rewrite (5.8) gives 
where 
given that, in the two-level model, the residual matrices, B1 and B2, have 
expectation as follows: 
(5.10) 
Equation (5.10) has taken account of the sampling variation of jJ and 
subsequently allows an unbiased estimate of V2 by adding the 'hat' matrix to y* at 
each iteration until convergence. This technique is similar to restricted maximum 
likelihood (REML) in normal response models. 
5.4 Spatial Multilevel Modelling 
The modelling so far does not take into account the geographical structure. Fitting 
the spatial model to the data takes into account the fact that areas close to each 
other in geographical space may share common factors that influence cancer 
mortality. 
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5.4.1 Spatial Model 
A spatial multilevel model can be formed by extending the variance components 
models. This involves adding further random effects and the full spatial model for 
the EU cancer morality data can be written as follows: 
log(JlJ = log(EJ + a i 
+ /31x1i + /32x2i + /33x3i + /34x4i + /3sxSi + /36x6i 
Vi = LZijv;, 
j*i 
(5.11) 
(5.12) 
(5.13) 
The model is as before but now there is the added parameter Vi. The Vi are spatially 
dependent random effects, and may have anyone of a number of structures 
describing adjacency or nearness in space (128). The spatial effects Vi are 
considered to be the weighted sum of a set of independent random effects Vi*. The 
v/ can be considered to be the effect of area upon other areas, moderated by a 
measure of proximity of each pair of areas Zij. There are many ways in which Zij 
can be formulated, in general it is written (129) 
(5.14) 
In this case the Wij are either 1 's or Os representing an adjacency matrix and 
The binary adjacency matrix is the most common spatial weight matrix; however, 
others can be used to define the spatial structure in the model. The adjacency 
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matrix cannot differentiate the strength of spatial effects between contiguous 
locations, therefore more complex spatial weight matrices are often proposed for 
more precise spatial control. 
The Vi* can then be estimated directly from the model and these are the 
residuals due to their independence. Therefore this multilevel model has within-
area effects which are modelled with a Poisson distribution and relative risks 
between regions which are considered as having a lognormal distribution. 
There is a more complex covariance structure present now. The variance has 
been partitioned with (Ju2 referring to the variance that arises due to heterogeneity 
between regions and (J/ referring to that which arises due to the spatial structure. 
The random effect has now been written as the sum of the heterogeneity effect, Ui, 
and a correlated spatially structured component, Vi. The model takes on similar 
structure to a simple autocorrelation model. The weights, Zij can be thought of as 
spatial explanatory variable, and represent a measure of the relevance of area j to 
area l. 
When fitting the model parameters, the spatial effects are more complex 
than the heterogeneity effects where there was simply a variance-covariance 
matrix with a variance term on the diagonal. Adding spatial effects requires off-
diagonal terms in the variance-covariance matrix. 
To consider the structure of the spatial part equations (5.11) to (5.13) can be 
rewritten in matrix notation 
1 
Y = {log(Ei) 1 Xli ••• X6i} ;, + [ZuZ; 1 [:;] , 
/36 
(5.15) 
where Zu is the identity matrix and Zv* = {zij}. The variance structure can be 
written as 
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(5.16) 
where () = {u.} and ()* = {v } 
u Z vi' 
which is equivalent to 
The overall variance, conditional on the fixed parameters, can be written as 
var(Y I XP) = n:eZT , 
where La is the variance of the random terms in B. Using the partitions from the 
spatial model (5.15) defined in () and Z and the variance structure of (5.16), it 
follows that: 
As mentioned above, the Zij can be formulated in different ways. In this example, 
as shown in (5.14), the variance of an area decreases as the number of neighbours 
Increases. 
Finally, using RIGLS estimation, the random effects for heterogeneity and 
the spatial effects are specified within a generalised linear modelling framework. 
Weights matrices associated with the random effects are constructed and fitted 
into the model. The model can now be expressed in terms of 3 design matrices 
and is generalisable to the non-linear model. 
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5.5 Results from Spatial Model 
The Spatial model was fitted to the ED cancer mortality data following the 
estimation procedure above. In this case model D is the model incorporating the 
spatial structure of the data and is fitted using second order POL and RIGLS; this 
is shown alongside the results from models A and B in Table 5.6. 
Table 5.6 Results from variance components and spatial models: EU data 
Model A ModelB ModelD 
Estimate Estimate Estimate 
(95% C.I.) (95% C.I.) (95% C.I.) 
Fixed Part 
Po 7.53 6.83 6.83 
(7.50 , 7.56) (6.68 , 6.99) (6.53 , 7.13) 
Pl (FRU) -7.58 -7.51 
(-8.65 , -6.50) (-9.67 , -5.36) 
P2 (VEG) -1.12 -1.11 
(-1.69 , -0.55) (-2.25 , 0.04) 
P3 (ANF) 26.36 25.98 
(19.28 , 33.42) (11.72,40.23) 
P4 (ALe) 0.64 0.71 
(-0.17 , 1.45) (-0.91 , 2.33) 
P5 (SMO) 0.49 0.49 
(0.39 , 0.59) (0.29 ,0.69) 
P6 (GDP) 0.20 0.33 
(-4.61 ,5.01) (-9.40 , 10.06) 
Random Part 
d u 0.040 0.014 0.002 
(0.032 , 0.048) (0.011 , 0.017) (-0.014,0.017) 
O"uv 0.011 (-0.001 , 0.023) 
d v 0.044 (0.011 , 0.077) 
Firstly, comparing the fixed parts results from the variance components 
model and this model, the estimates change very little after including the spatial 
component. However, looking at the standard errors, they almost double for each 
term in the spatial model. The probable reason behind this is that areas 
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geographically close tend to display positive dependence or positive 
autocorrelation, but when this is ignored as in the variance components model, 
incorrect inference will result, in particular standard errors of explanatory 
variables will be too small. Fitting the spatial model here has improved the 
accuracy of the model. U sing the variance terms, the total variance can be 
calculated. As can be seen from equation (5.12), a; is based on the residual, v ~. 
J 
To obtain the weighted residual, Vi, v; must be divided by the number of 
neighbours region i has, n .. Therefore, to obtain a weighted estimate of (J'2 it I v , 
must be divided by the average number of neighbours a region has, n. Hence, the 
total variance is a: + (J'; / n = 0.002 + 0.044/4.128 = 0.0127.85% of this variance 
now arises from spatial effects, confirming the importance of the spatial part in 
the model. 
We are also interested in quantifying the effect size of the risk or protective 
factors when examining cancer mortality. The relative risks have been calculated 
for each of the significant variables from model D and are given in Table 5.7. 
Firstly, for the consumption of fruit, the table shows that Greece has the highest 
level of consumption in these 11 countries and the UK has the lowest. The relative 
risk of 0.58 shows that a population consuming, on average, the same amount of 
fruit as Greece has a risk of cancer mortality that is 42% lower than if 
consumption was on the same level as the UK. Also, consuming the same level of 
vegetables as Greece leads to a risk of cancer mortality that is 28% less than if 
consumption was at the same level as Finland or Sweden. Luxembourg consumes 
the most animal fat in the EU countries being examined and this level of 
consumption leads to a RR over 2 times as high as if consumption was on the 
same level as Greece. Finally, the inhabitants of Greece, on average, smoke the 
most cigarettes. This level of smoking leads to a RR of cancer mortality 3 times as 
high as if cigarette consumption was at the same level as Sweden (where cigarette 
consumption is the lowest). 
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Table 5.7 Variable effect sizes: EU data 
Area with 
Variables Highest Lowest Relative Risk Consumption Consumption 
Fruit Greece UK 0.58 
Vegetables Greece Finland & Sweden 0.72 
Animal Fat Luxembourg Greece 2.03 
Cigarettes Greece Sweden 2.99 
To examine visually the apparent effect of risk factors and also to compare 
the different models fitted, plots of the predicted relative risks from all four 
models are given in Figure 5.8. Looking at the plot for model A, the variance 
components model with no explanatory variables included, it is obvious that there 
is definite clustering, with mortality rates for regions within each country being 
very similar. There also appears to be evidence of a negative slope, with the 
exception of Greece and Portugal, suggesting that rates tend to be highest in 
Western Europe and lowest in Eastern Europe. Examining the plot of model B, 
the variance component model including the explanatory variables, it can be seen 
that the spread decreases. The relative risks for countries with low relative risks 
are higher than in model A and those that previously had high relative risks are 
lower. This is because the risk or protective factors included are measured at the 
level of country and are therefore explaining differences between countries. The 
key features from fitting this model are that regions in Portugal, which were 
previously shown to have low cancer mortality rates, now appear to have a risk of 
cancer mortality that is higher that expected given the lifestyle factors. Portugal 
has fairly high consumption of fruit and vegetables and very low animal fat 
consumption, so after taking these into consideration they have above average 
mortality. Also, looking at Denmark, the cancer mortality risks are high under 
model A but under model B for most regions they are below average. So, taking 
into account the fact that Denmark has high animal fat consumption and low fruit 
and vegetable consumption, the rates are actually lower than expected. Moving 
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onto the estimates obtained from model D, there is less variability overall. In plot 
B they were clustered but showed more variation within each country and more 
overlap between countries. With the spatial model the relative risks are more 
tightly clustered within countries. This is due to the mean for each area being 
centred on the mean of its neighbours. Effectively this model is providing greater 
smoothing to a map. Finally, comparing the plot from model D to that of model C, 
which takes account of country as a level, it can be seen that model D provides the 
greatest amount of smoothing and reduces the variability the most. 
It should be noted here that there are some islands present in the data which, 
due to the level of data aggregation, have no regions bordering them. These 
regions have no neighbours so it may be assumed that they do not share common 
environmental and social factors with nearby areas, therefore island estimates 
would not be spatially smoothed. It is perhaps false to assume this, so each island 
was allocated two or three 'neighbours' based on the regions that were closest (ie 
smallest centroid to centroid distance). These regions were not necessarily all 
from the same country as the island but hopefully they provided some sort of 
smoothing based on the regions sharing similar spatial factors which may be 
influencing the rates. Also, as discussed in Chapter 3, missing data are inevitable 
in this type of study and when examining the EU, three countries have missing 
data for the time point of interest. This resulted in the regions which bordered 
areas with missing data being subject to a lower level of smoothing than regions 
which had information available for each of their neighbours. One should remain 
aware that the estimates for these areas are shrunk much less towards estimates 
from regions that share similar environmental and social factors. Also, areas at the 
boundary of the map have been smoothed to a lower degree. 
Further, a slightly different form of disease map can be used to identify the 
risk of mortality after including actual variable effects. This is done by mapping 
each region's relative risks plus the fixed effects from the model. Figure 5.9 does 
so for Model D's (spatial model) estimates. As can be seen, this map differs from 
those previously examined. The relative risks of cancer mortality are all very high 
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( > 1.4). This is because the risk factors have stronger effects that the protective 
factors, hence, they are having more overall influence on the relative risks and 
pulling them higher. There is a high amount of country level clustering evident 
due to the covariates being at the country level and drawing the risks within 
countries towards similar values. For this reason, this type of disease map is most 
useful for identifying differences in country level relative risks. However, it is 
noticeable that two regions in France have risk of mortality higher than the rest of 
the country (and most of the EU) after the addition of the effect size of the risk 
factors. Country level differences indicate that Denmark, overall, has the highest 
risk of cancer mortality and Portugal, Greece and Finland have the lowest after 
adding the fixed effects. 
Maps from four types of models have been explored in this chapter. In 
theory, further maps could be investigated that examine the risks that can be 
attributed to different parts of the model, eg regional, spatial, country level risks. 
Figure 5.3 combines the region and country effects to obtain overall estimates of 
relative risks; however these could have been mapped separately. For the purpose 
of producing smoothed disease maps and 'hotspot' identification, the overall 
relative risks are more appropriate and further disease mapping will focus on 
using this method. 
5.6 Further Spatial Modelling 
Empirical Bayes methods provide useful tools to fit spatial multilevel models. So 
far we have looked at two examples that incorporate the geographical structure of 
the data in to the model; one takes account of the non-independence of regions 
within countries by including a further hierarchical level and the other takes into 
account the fact that regions geographically close are more likely to share similar 
mortality rates and exposure to risk factors than regions far away from one 
another. The model with the spatial random effects appears to be more useful as it 
provides more smoothing and produces a disease map from which disease 
'hotspots' can be easily identified. However, it would useful to explore the effects 
93 
Chapter 5 Spatial Multilevel Modelling 
of adding country as a higher level to the spatial multilevel model. This will be 
carried out in the next chapter by fitting the models using fully Bayesian methods. 
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Figure 5.9 Estimated Relative Risks from model D plus fixed effects 
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6 Fully Bayesian Modelling 
6.1 Bayesian Estimation for Relative Risks 
There has been much development recently of Bayesian methods in relation to 
disease mapping applications. In simple terms, Bayesian approaches to disease 
mapping of mortality rates combine two types of information. The first for each 
region is the number of observed deaths, described by the Poisson likelihood 
g(O I iJ), and the second is the prior information on the relative risks specifying 
their variability in the overall map, summarised by their prior distribution (fJ) (78). 
As discussed in Chapter 4, a common assumption made when examining counts 
of deaths within an area is that Oi .... Poisson( elli) , and that Oi .... Gamma( a, fJ). The 
joint distribution can then be given by the product of the Poisson likelihood and 
the gamma distribution. This joint density is proportional to the posterior 
distribution for the parameters of interest. 
6.1.1 Posterior Distribution 
Prior beliefs about parameters of interest are combined with sample information to 
create updated, or posterior beliefs about the parameters. In the fully Bayesian 
approach, inference is based on the posterior distribution of fJ given the data and 
with the empirical Bayes approach the posterior distribution is approximated in 
some way. This chapter will focus mainly on the fully Bayesian approach, which 
has recently become widely available mainly because of the increased use of 
Markov chain Monte Carlo methods of posterior sampling. 
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Bayesian approaches to relative risks were discussed in section 4.2.1; the 
likelihood function of 0, the relative risks, were described in equations (4.4) and 
(4.5) and how to obtain the marginal posterior distribution was explained in (4.6) 
and (4.7), using empirical Bayes estimation, and in (4.23) and (4.24) using fully 
Bayesian methods. It was explained that, in general, the marginal posterior 
distribution cannot be solved analytically. 
6.1.2 Empirical Bayes 
The empirical Bayes approach was used to fit the spatial multilevel models in 
Chapter 5. This method assumed that the hyper-parameters are unknown and are 
drawn from an unspecified distribution. The parameters were then estimated using 
a technique such as iterative generalised least squares. As discussed, this is a two-
stage process which involves estimating fixed and random parameters in 
successive iterations. 
The spatial multilevel model (see equations (5.11) to (5.13)) can be written 
as 
Oi ,... Poisson ( ()iEi) (6.1) 
loge 0i) = zt P + Ui + Vi , (6.2) 
where the random effects have a joint normal distribution 
(6.3) 
The dispersion matrix L is a linear function of hyper-parameters "'( such that 
L = f(y)· 
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Therefore the algorithm alternates between an estimate of the fIxed parameters 
conditional on the estimates of the hyper-parameters [P I r = r] and an estimate 
of the hyper-parameters conditional on the fIxed parameters and estimates of the 
hyper-parameters after x iterations[r IP = P]. 
6.2 Fully Bayesian 
As previously discussed the empirical Bayes approach involves assuming the 
hyper-parameters are unknown and are drawn from an unspecifIed distribution, 
and estimates of the hyper-parameters are plugged in. Another method that was 
used to fit spatial multilevel models to the European cancer mortality data set was 
a fully Bayesian approach. This involves fItting a hierarchical model where the 
distribution of the hyper-prior [y] is specified. 
6.2.1 Prior Distributions 
The prior distribution for the relative risks (J is a probability distribution that 
explains all the information that is known about (J before the data have been 
collected. An informative prior distribution is used when information that is 
available before data collection is included in the analysis. A non-informative 
prior distribution is commonly used and expresses no knowledge about (J before 
data collection. They are also referred to as diffuse or flat priors and a common 
example is the uniform distribution over the range of sample space for (J. 
6.2.1.1 Spatially Structured Priors 
Prior knowledge of mortality rates indicates that areas geographically close to 
each other tend to have similar relative risks. To express the prior knowledge that 
there exists a local spatially structured variation in relative risks of cancer 
mortality in Europe, a spatially structured prior was used. Here the relative risks 
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have a locally dependent prior probability structure, whereby the conditional 
distribution of the relative risk in area i, given the values of the relative risks in all 
other areas j¢i, depends only on the relative risks of area i's neighbouring areas. 
Here we used a log-normal model which has a normal prior with hyper-
parameters Jl and ~ specified for the logarithm of the relative risks: 
where 
and ~ is the dispersion matrix given in equation (6.2). 
The prior model fitted results in the log relative risks being the sum of two 
independent components: 
log(~) = Ui + vt . (6.4) 
The random terms, Ui and Vi, have a joint prior distribution as described in 
equation (6.3) and the variance of loge Bi) is then dependent on the number ni of 
neighbours of that area, 
2 
e (J"v 2 Var[log( J] = --=- + (J" u , 
ni 
and the covariance between areas l and i' depends on the number njj , of 
neighbours they have in common, 
n .. , 2 (1 1 ) Cov[10g(8 i ),10g(8i ,)] = _ II 0v + -=- + ~ 0uv nini , ni ni 
n .. , 2 
-II-a 
v 
if i and i' are contiguous 
otherwise 
so that there is no covariance between areas with no common neighbours. 
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6.2.2 Hyperpriors 
The fully Bayesian approach was used to model the data and involved specifying 
the hyperprior distribution [y] and basing inference about the relative risks on the 
marginal posterior distribution (see equations (4.23) and (4.24». Specifying the 
hyperprior distribution and basing inference on the marginal posterior distribution 
allows the variability in the hyperparameters y to be incorporated. 
6.2.2.1 Hyperpriors for Fixed Effects 
A prior distribution for fixed parameters has to be defined over the whole real line 
allowing there to be no constraints and to take on any real value. Here, a flat prior 
has been used which is basically a uniform prior across the whole real line 
(- 00,(0) for each fixed effect coefficient. 
6.2.2.2 Hyperpriors for Random Effects 
Variance parameters must be constrained to have positive values. Here, a variance 
matrix is considered, as opposed to a single variance, and the prior used is a 
multivariate Wishart prior. The inverse variance matrix, ~-1, is given a Wishart 
distribution with 2 degrees of freedom and precision 2i: where i: is an estimate 
of the dispersion L: 
The Wishart distribution is used as prior for the inverse covariance matrix by 
giving it degrees of freedom equal to the order of the matrix, 2. Reasonable values 
for the precisions matrix were then chosen based on previous estimates from 
similar models. 
In this example, the marginal posterior distribution (4.24) is not tractable. To 
overcome this problem Monte Carlo methods are used which involve drawing 
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samples from the joint posterior distribution g(e,yIO) and hence from the marginal 
posteriors gee I 0) and g(y I 0). 
6.3 Markov Chain Monte Carlo 
Markov Chain Monte Carlo is a common method used for posterior sampling and 
consists of a range of algorithms designed for the iterative simulation of joint 
posterior distributions found in Bayesian modelling (130). Since the posterior 
distribution of the spatial multilevel model is complex and therefore intractable, 
MCMC simulation provides a useful method of posterior sampling. 
In simple terms, using current values of parameters, MCMC involves 
proposing new values, then a comparison of the posterior probability of the new 
and current values is made. These proposed values are generated from given 
distributions and subsequently new values are accepted based on a certain 
probability criterion. If these new values are accepted they replace the current 
values. Since these are simulation-based procedures, instead of simply producing 
point estimates, these methods are run for many iterations and at each iteration an 
estimate for each unknown parameter is produced. The aim is then to generate a 
sample of values from the posterior distribution of the unknown parameters. 
6.3.1 Sampling Methods 
Two algorithms are widely used to aid MCMC simulation; these are Gibbs 
sampling and the Metropolis Hastings algorithm. The aim is to generate a sample 
of points from the joint posterior distribution of the unknown parameters of 
interest. The spatial multilevel model would involve generating samples from the 
distribution [x, 11 0], where x is the log of the relative risks 0: 
[x, 1 I 0] ex: [0 I x][x I 1][1] = 0 [y, I x,l[x 17 ][7] 
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Although it is difficult to simulate from the joint posterior distribution, the 
conditional posterior distributions for the unknown parameters often have forms 
from which simulation is easy. Iterative sampling from these conditional posterior 
distributions is then equivalent to sampling from the joint posterior distribution, in 
the limit. 
6.3.1.1 Gibbs Sampling 
A common approach to this type of posterior sampling is Gibbs Sampling. 
Basically, this involves taking each parameter in turn and simulating a new value 
from its conditional distribution assuming the other parameters are true values. 
Starting values are then needed for each parameter and these are then updated in 
turn. 
For instance, since 
new values of Xi can be drawn, given the current values 
I d I X j,j .. i an 'Y , 
from the full conditional distribution 
[Xi I X'j' j ¢ i,'Y',O] ex: [Yi I X;] [Xi I Xj I, jEai,y']. 
Here the conditional distribution of the relative risk in area i, given values for 
relative risks in all other areas j i- i, depends only on the relative risk values in the 
neighbouring areas oi of area i. A new value of 'Y is drawn given the current 
values of x' from the full conditional distribution 
[l'lx ']oc[x'II']['Y] . 
The joint distribution of the sample values of (x, 'Y) should then converge to the 
joint posterior distribution [x, 'YI 0]. Therefore the distribution of the sample 
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values of x, respectively of ,,(, converges to the marginal posterior distribution 
[xIO], respectively of ["(10] (79). 
The Gibbs sample works well if the conditional posterior distributions have 
simple forms and are easy to simulate from but with the Poisson hierarchical 
model this is not the case. 
6.3.1.2 Metropolis Hastings Algorithm 
When the conditional posterior distributions do not have simple forms another 
MeMe method, Metropolis Hastings sampling, can be used. As previously 
discussed MeMe involves proposing new values and accepts or rejects this value 
as the new estimate for the next iteration. The conditional distribution is used as 
the proposal value for the Gibbs sampler. This is in fact a special case of the 
Metropolis Hastings sampler whereby every proposed value is accepted. This MH 
algorithm was used to fit the spatial hierarchical model, as easily-simulated full 
conditional distributions were not available. 
To explain the procedure in simple terms, a draw is made from a full 
conditional distribution of the kth component, say [(Xk 1 X-k, 0), which is not easy 
to draw from. Then, a Metropolis step can be used to carry out the update. 
Firstly select a proposal distribution, say q(. I 8), where 8 is its parameters 
fixed by the user. Theoretically this can be any compatible distribution eg it 
makes sense to choose a Normal distribution if your parameter can be any real 
number. 
Then, to sample a candidate point from [(Xk 1 X-h 0), draw Y - q(. 1 J) and 
compute 
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The new value of Xk is then set to be Y with probability minimum (1" , 1); 
otherwise we retain the current value of Xk. Many iterations are then run until the 
chain converges to a stationary distribution, which should be the required joint 
posterior distribution. 
6.3.1.3 Other Sampling Methods 
Often the distribution of interest, f(x) say, cannot be easily sampled from. 
However, if there exists a distribution g(x) such that 
J(x) < Mg(x) \j x, 
where M is a positive number, Ripley (131) described a technique where g(x) can 
be sampled from without problems. This method is called rejection sampling and 
involves thinking of g(x) as an envelope function that completely bounds the 
required distribution. An extension to this is used when there is a non-standard but 
log concave distribution of interest. The technique that can be used here is called 
adaptive rejection sampling (132). 
6.4 Fitting the Spatial Multilevel Model 
A similar model can be fitted to that described in the previous chapter (see 
equations (5.11) to (5.13» and is written as follows: 
log(,ui) = 10g(E i) + a + IPmXmi + Ua[i] + I Wi,j V j , (6.5) 
m jEa[i] 
where m is 1, ... ,6 and Pm represents each of the fixed effects covariates. a[i] is the 
area from which the observed count was taken from, and 8[i] is the set of 
neighbouring areas to the area from which the count is taken from. The weights in 
this model are such that L Wi,j = 1 V i and all neighbours are given equal weights 
JEa[i] 
so that wi,j = lIni, where ni is the number of neighbours to a[i]. Since there is a 
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one-to-one correspondence between the sets of area and neighbour residuals (Ui 
and Vj), a joint multivariate Normal distribution is fitted to these two sets of 
residuals. 
(6.6) 
The fully Bayesian spatial multilevel model was fitted in WinBUGS vI.3 
and the code is shown on the next page. Line 5 of the model specifies the 
response, namely the counts of cancer deaths, as Poisson distributed, and has a 
mean and variance Jli. The constant N used has a value that is input with the data 
and is the number of regions in the data. Lines 6-12 specify 10g(,Iii) as a linear 
additive function of the offset, which is the logarithm of the expected deaths, the 
intercept, PI, and 6 covariates, P2, ... ,/h. Line 13 adds the random effects that 
account for difference between regions. Region i is the region identifier (1 ... 187) 
for count of deaths i and is multiplied by u2[,1 ] (or u), which is a random variable. 
Lines 14-25 add the set of random effects to take account of spatial variability, 
u2[,2] (or v). The nearest neighbours are available and a region has at most 12 
nearest neighbours. A set of random terms is given for each neighbouring region 
identifier (neigh 1 [i], ... ,neighI2[i]). Each of these random terms is multiplied by a 
spatial weight (weightl[i], ... ,weight12[i]). Lines 28-29 specify the prior for our 
random terms which, as previously discussed, follow a multivariate normal 
distribution. Line 32 specifies the priors for the fixed effects to be flat. Lines 34 
and 35 define the hyper-prior for the variance matrix 't to be Wishart distributed 
with 2 degrees of freedom and precision matrix R2. The values for the precision 
matrix are declared with the data input and in this case, the values used were close 
to 2 i: where i: is an estimate of the dispersion matrix L obtained from the , 
variance matrix when the model is run using IGLS. 
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R2= . [
0.006 0.002] 
0.002 0.055 
The last part of the WinBUGS code (lines 36-40) generates the inverse of't. This 
was required to obtain 1:: since the precision matrix is the inverse of the variance. 
An example of the WinBUGS data file is given in Appendix A2.3. 
#----M 0 D EL Defin ition----------------
model 
{ 
# Level 1 definition 
for(i in 1 :N) { 
deaths[i] - dpois(mu[i]) 
log(mu[i]) <- offs[i] + beta[1] 
+ beta[2] * smoke[i] 
+ beta[3] * fruit[i] 
+ beta[4] * veg[i] 
+ beta[S] * animal[i] 
+ beta[6] * alcohol[i] 
+ beta[7J * gdp[i] 
+ u2[region[i],1] 
+ weight1 [i] * u2[neigh1 [i],2] 
+ weight2[i] * u2[neigh2[i],2] 
+ weight3[i] * u2[neigh3[i],2] 
+ weight4[i] * u2[neigh4[i],2] 
+ weightS[i] * u2[neighS[i],2] 
+ weight6[i] * u2[neigh6[i],2] 
+ weight7[i] * u2[neigh7[i],2] 
+ weight8[i] * u2[neigh8[i],2] 
+ weight9[i] * u2[neigh9[i],2] 
+ weight10[i] * u2[neigh1 0[i],2] 
+ weight11 [i] * u2[neigh11 [i],2] 
+ weight12[i] * u2[neigh12[i],2] 
} 
# Higher level definitions 
for G in 1 :N) { 
u2D,1 :2] - dmnorm(zero[1 :2],tau.u2[1 :2,1 :2]) 
} 
# Priors for fixed effects 
for (k in 1 :7) { beta[k] - dflatO } 
# Priors for random terms 
for (i in 1 :2) {zero[i] <- 0 } 
tau.u2[1 :2,1 :2] - dwish(R2[1 :2,1 :2],2) 
det <- tau.u2[1, 1]*tau.u2[2,2] - tau.u2[1 ,2]*tau.u2[2, 1] 
sigma2.u2[1,1] <- tau.u2[2,2]/det 
sigma2.u2[1,2] <- -tau.u2[1 ,2]/det 
sigma2.u2[2,1] <- -tau.u2[2, 1]/det 
sigma2.u2[2,2] <- tau.u2[1, 1]/det 
1 
(1 ) 
(2) 
(3) 
(4) 
(S) 
(6) 
(7) 
(8) 
(9) 
(10) 
(11 ) 
(12) 
(13) 
(14) 
(15) 
(16) 
(17) 
(18) 
(19) 
(20) 
(21) 
(22) 
(23) 
(24) 
(25) 
(26) 
(27) 
(28) 
(29) 
(30) 
(31) 
(32) 
(33) 
(34) 
(35) 
(36) 
(37) 
(38) 
(39) 
(40) 
(411 
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6.5 Convergence 
The aim of using the sampling methods described is to simulate a Markov chain 
whose equilibrium distribution is the desired distribution (130). The desired 
outcome is for the joint distribution of the sample values to converge to the joint 
posterior distribution. It is therefore common practice to run a sufficiently long 
bum-in of samples, which can then be discarded, and further dependent samples 
that are obtained can be assumed to come from the joint posterior distribution. 
Being interested in the log relative risks x, the marginal posterior distribution 
[xID] was approximated (ignoring the 'Y values). Then, for each region, point 
estimates can be obtained from the simulated values, for example the posterior 
mean from the sample mean, and interval estimation can be made by calculating 
Bayesian credible intervals. Therefore, it is important to be able to check when the 
Markov chain has reached a stationary distribution and so convergence to the 
posterior distribution has been obtained. 
6.5.1 Multiple Chain Monitoring 
The method used to assess convergence was to replicate the algorithm with 
different starting points and check that they show similar convergence behaviour. 
The reason for monitoring convergence in this way is that often a single sequence 
of Markov chain simulation appears to have converged, but when replicating the 
sequence independently it showed that within-sequence changes took too long to 
detect. Gelman and Rubin (133) give examples of applying Markov chain 
simulations of Bayesian posterior distributions where a single simulated sequence 
appears to have reached convergence, but when examining multiple independent 
simulations, poor convergence was evident. It has been suggested that with 
Bayesian posterior simulation, the added information obtained from replicating 
chains outweighs any additional costs required in multiple simulations (134). 
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6.5.1.1 Chain Trace Plots 
It makes sense to use a combination of convergence diagnostics and visual 
inspection of trace plots to help determine when the simulation appears to have 
stabilised. For models with many parameters it is often impractical to check 
convergence for every parameter. In this case the relevant parameters must be 
chosen to be monitored, and convergence can then be examined with reasonable 
confidence. One method is to examine trace plots or time-series plots and compare 
the parallel sequences. When the patterns from parallel chains start to overlap and 
stabalise, it can be assumed convergence has been reached. Figure 6.1 gives an 
example of sample traces of chains from the spatial multilevel model. It shows 
plots of the random terms, (Ju 2, (Juv and (Jv 2, where two parallel chains have been 
run from different initial values for 10,000 iterations. Looking at the plot for (Jv2, 
that is sigma2.u2[2,2], it can be seen that by 2500 iterations the chains 
(represented by separate blue and red lines) are not yet overlapping. This suggests 
that the sample traces of the Markov chains of the random terms have not yet 
reached convergence at this point. Assessing the chains for further iterations, it 
can be seen that by around 5000 iterations, the sample chains are overlapping 
somewhat and by 7500 they have almost completely merged together. The other 2 
plots, for (Ju 2 and (Juv, have also converged by this stage and, in fact, both converge 
much more quickly. This suggests that convergence has been reached for all of the 
random terms, and hence 7500 simulations would be a suitable burn-in period. 
However, it doesn't make sense to only examine the random terms. Assessing 
convergence of the fixed terms is also of importance. 
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Figure 6.1 Trace plots of random terms 
sigma2 u2[ 1 ,1 1 chains 1.2 
0 .2 
2 0 15 
all 
value 0 1 
0 .05 
0 0 
sigma2 .u2[ 1 ,21 chains 1 2 
0 .25 
a'"l 
value 0 .2 
0 .15 
0 .1 
0.05 
sigma2 .u2[2 ,21 chains 1.2 
2 
08 
av 0 .6 
value 
0 .4 
02 
00 
501 2500 5000 7500 
iteration 
6.5.1.2 Gelman-Rubin Test 
The Gelman and Rubin diagnostic test (135) is another method used to check the 
convergence of the MCMC algorithm. This method was initially inspired by the 
analysis of variance and the basic idea is to form an overestimate and an 
underestimate of the variance of the target distribution. When both these estimates 
are roughly equal, it can then be assumed convergence has been reached. 
The Gelman-Rubin test is again based on running parallel chains from 
different starting values. Its convergence condition is that the empirical 
distribution of simulations that are obtained from each sequence separate ly is 
approximately equal to the distribution that is obtained by combining all the 
sequences together. Before convergence the samples collected \vithin each si ngl e 
10000 
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sequence will be less variable than the samples collected from the combined 
sequences. 
Consider any parameters of interest and predictive quantities as separate 
scalar summaries. At a time point, consider a single summary 0), and assume m 
parallel simulations, each of length n. For each of these a numerical equivalent of 
simply visually comparing sample traces of chains (figure 6.1) is wanted. For each 
scalar summary 0), label the m parallel sequences of length n as O)ij, where j = 
1, ... ,n and i = 1, ... ,m. Then two quantities are computed; the between-sequence 
variance B 
m 
B - n I(- _ -)2 - OJ. OJ , 
-1 I. .. 
m i=l 
1 n 
where OJ i . = - IOJij and 
n j=l 
1 m OJ=-~OJ 
.. ~ I. 
and the within-sequence variance W 
1 m 2 
W=-ISi' 
m i=l 
m i=l 
2 1 In ( - )2 
where S = -- OJ -OJ • I -1 Ij I. 
n j=l 
The between-sequence variance B contains a factor of n because it is based on the 
variance of the within-sequence means, mi .. Each mi. is an average of n values of 
Using these two variance components, two estimates of the variance of OJ in 
the posterior distribution are constructed. Firstly 
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A n-l 1 
var(m)=--W+- B 
n n 
is an estimate of the vanance that is unbiased under stationarity, but is an 
overestimate under the more likely situation that the starting points are 
overdispersed. Therefore var( OJ) is a conservative estimate of the variance of OJ 
under overdispersion. 
On the other hand, the variance of OJ is likely to be underestimated by the 
within-sequence variance W, for any finite n. This is because the individual 
sequences do not have time to range over all of the target distribution resulting in 
them having less variability. As n increases, var(m) and W approach the true value 
of OJ, but from opposite directions. 
The scale reduction factor, or Gelman-Rubin statistic, can then be calculated 
to monitor the convergence of the Markov chain. This involves calculating the 
ratio between the estimated upper and lower bounds for the standard deviation of 
OJ, denoted by R: 
As the scale reduction factor reduces to 1, this indicates that the parallel Markov 
chains are overlapping therefore a sufficient bum-in period has been reached. If 
the Gelman-Rubin statistic is greater than 1 then convergence hasn't been reached 
and further simulations need to be run. 
In practice, the simulations are generally run until the values of R are less 
than 1.1 or 1.2 (134) for all the parameters. The R values can be examined 
numerically or a time series plot of them can be examined. The plots shown in 
Figure 6.2 are for the parameters PI to fh, and show the Gelman-Rubin scale 
reduction factor (in red) up to 20,000 iterations. Also shown is the estimate of the 
variance of OJ in blue and the average of the within-sequence variances, W, in 
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green. When the red line converges to around 1 and the green and blue lines are 
consistently overlapping, this indicates that the parameter has converged to 
stability. By 20,000 iterations it appears that convergence has not yet been reached 
as some of the fIxed parameters' R values are still greater than 1, eg P4 and P6. 
However, by 150,000 iterations (Figure 6.3) all the parameters appear to have 
converged to stability. Definite convergence was evident by 200,000 iterations so 
this was chosen to be the bum-in period when running these models. 
6.6 Further Iterations 
Once a suitable bum-in period has been determined, it is then necessary to run 
further iterations that will then allow accurate posterior estimates to be obtained 
from the resulting samples. The method that was used here to determine how 
many iterations were needed after convergence was to assess the Monte Carlo 
error for each parameter. The Monte Carlo error is an estimate of the difference 
between the mean of the sampled values and the true posterior mean. To enable 
accurate posterior inference, the Monte Carlo error should be small in relation to 
the posterior standard deviation. A rule of thumb that has been suggested (136) is 
that iterations should be run until the Monte Carlo error for each parameter of 
interest is less than 5% of the sample standard deviation. 
Table 6.1 reports the Monte Carlo error, sample standard deviation and the 
Monte Carlo error as a percentage of the standard deviation at 50,000 and 100,000 
iterations after a bum in of 200,000. As can be seen, at 50,000 iterations all of the 
fIxed and random terms have a percentage less than 5%. This indicates that 
running 50,000 iterations after convergence gives a suitable set of samples from 
which accurate posterior inference can be made. 
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Table 6.1 Monte Carlo error as percentage of posterior standard deviation 
Param- 50,000 iterations 100,000 iterations 
eters Me SD MCerroras Me SD MCerroras 
error %o/SD error %o/SD 
Po 0.00522 0.110S 4.7% 0.0042 0.1067 4.0% 
PI 2.4ge-06 0.0001 4.7% 2.47e-06 0.0001 4.0% 
P2 0.00003 0.0006 4.7% 0.0000 0.0007 3.9% 
P3 0.00002 0.0004 4.6% 0.0000 0.0004 3.9% 
P4 0.00014 0.0030 4.6% 0.0001 0.0036 3.9% 
P5 0.00002 0.0005 4.7% 2.13e-05 0.0005 3.9% 
P6 S.0ge-OS 0.0000 4.5% 6.64e-08 1.77e-06 3.8% 
cru
2 0.00003 0.0009 3.3% 2.46e-05 0.0009 2.8% 
cruv 0.00005 0.0016 3.0% 3.91e-05 0.0016 2.5% 
cr/ O.OOOlS 0.0055 3.3% 0.0001 0.0054 2.5% 
6.7 Model Results 
As previously discussed, numerical summaries of the posterior samples are used 
to examine the model results. The posterior samples can be assumed to be from 
the desired joint posterior distribution, and each parameter has a set of samples 
that can be thought to have arisen from the individual marginal distributions. 
6.7.1 Fixed and Random Effects Estimates 
Some results from running the spatial multilevel model defmed by equations (6.5) 
and (6.6) using MCMC are given in Table 6.2. The point estimates for each 
parameter from the null model and the full model are given. These are calculated 
by assuming the chain values are a sample from the posterior distributions and 
calculating the mean of these in the usual way. Credible intervals are also given 
for each of these point estimates, again for the null model and the full model. A 
credible interval is the Bayesian equivalent to the frequentist confidence interval. 
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Figure 6.2 Gelman-Rubin plots for fixed effects (at 20,000 iterations) 
beta[1] chains 1:2 beta[2] chains 1:2 
4.0 8.0 l 3.0 ~ 6.0 2.0 4.0 1.0 ~ 2.0 
------
0.0 0.0 
4001 10000 15000 4001 10000 15000 
iteration iteration 
beta[3] chains 1:2 beta[4] chains 1:2 
6.0 8.0 
4.0 6.0 ~ 4.0 2.0 2.0 0.0 0.0 
4001 10000 15000 4001 10000 15000 
iteration iteration 
beta[5] chains 1:2 beta[6] cha ins 1:2 
1.5 8.0 
1.0 6.0 L 4.0 0.5 2.0 
0.0 0.0 
4001 10000 15000 4001 10000 15000 
iteration iteration 
beta[7] chains 1:2 
6.0 
;~ ~ 
0.0 L..,...........-----r----.,----r 
4001 10000 15000 
iteration 
1 1 ~ 
Chapter 6 
Fu//y Bayes ian -\fode/ling 
Figure 6.3 Gelman-Rubin plots for fixed effects (at 150,000 iterations) 
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The quantiles of the samples can be used to produce credible intervals. The 
intervals given in Table 6.2 are 95% central Bayesian credible intervals, that is, if 
Oi is the ith quantile, the given intervals for each parameter are (00.025 , 00.975). 
The estimates are similar to those produced from the empirical Bayes 
method. A comparison of the estimates obtained from different modelling 
methods is given in Chapter 7. Interpretation of the fixed and random estimates is 
the same as in Chapter 5. Therefore, looking at the results from the fully Bayesian 
model (Table 6.2) we can see that significant covariates affecting risk of cancer 
mortality in Europe are fruit, vegetable, animal fat and alcohol consumption and 
cigarette smoking, while taking the others into account. Fruit, vegetable and 
alcohol consumption have an inverse association with cancer mortality rates while 
cigarette smoking and animal fat consumption show a positive relationship. 
Adding these explanatory variables has explained 50% of the variation in cancer 
mortality in Europe. It can be seen that 66% of the remaining variation is due to 
spatial patterning of disease. 
Table 6.2 Results from fully Bayesian spatial multilevel models 
Parameters Null Model Full Model 
Estimate Credible Interval Estimate Credible Interval 
Po 7.53 (7.49, 7.56) 7.09 (6.92, 7.26) 
PI (smoke) , 0.0005 (0.0005, 0.0006) 
P2 (fruit) , -0.0083 (-0.0089, -0.0080) 
P3 (veg) , -0.0013 (-0.0016, -0.0010) 
P4 (animal) 0.0293 (0.0225, 0.0355) 
Ps (alcohol) -0.0013 (-0.0020, -0.0006) 
P6 (Gdp) -1.97E-6 (-4.33E-6, 8.73E-7) 
au
2 0.0058 (0.0033, 0.0092) 0.0035 (0.0022, 0.0051) 
auv 0.0131 (0.0080, 0.0194) 0.0050 (0.0023, 0.0077) 
av
2 0.0593 (0.0422, 0.0804) 0.0275 (0.0175, 0.0378) 
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6.7.2 SMR Disease Map 
To gain a visual picture of the results of modelling cancer mortality using full 
Bayes estimation, relative risks have been mapped and are given in Figures 6.5 
and 6.6 (null and full model respectively). For comparison purposes, the 
standardised mortality ratios are mapped for each region in Figure 6.4. 
Recall that there were 652,728 deaths (254 per 100,000) in total from cancer 
in the 187 regions under investigation in 1991. The SMRs (Figure 6.4) vary 
around their mean of 1.02 (sd = 0.20) from 0.58 in Ipeiros, Greece to 1.54 in 
Copenhagen and Frederiksberg city, Denmark. Both these regions have fairly 
small population sizes and numbers of deaths. The ten highest SMRs and the ten 
lowest SMRs are presented in Table 6.3. The standard errors are also given in this 
table. Note here that the maximum likelihood estimate of the area-specific relative 
risks, Bi , is the standardised mortality ratio (SMR) for the ith area: 
OJ = SMR = OJ IEj with estimated standard error Si = -JO: I Ei • Due to the high 
variation in population sizes, these standard errors also have high variation. They 
range from 0.005 in North Rhine-Westphalia in Germany which has the largest 
population in the study to 0.111 in Ahvenanmaa, Finland which has the smallest 
population. Table 6.4 is similar but presents estimates for selected regions in order 
of increasing population size (ten smallest and ten largest given). 95% confidence 
intervals based on Poisson distribution have been computed for each SMR and are 
also presented in Table 6.3. Those that exclude unity have been presented in bold. 
Also included in the table are the posterior mean relative risks, as modelled 
in equation (6.4), and 95% credible interval estimates from the fully Bayes spatial 
multilevel model firstly with no covariates then with all the covariates included. 
Tables 6.3 and 6.4 include i, the number of the region; Oi, the observed 
number of deaths in the ith region; Ei, the expected number of deaths in the ith 
region' SMR the standardised mortality ratio in the ith region; Si, the standard , , 
error of SMR in the ith region; CI95%(SMR), confidence interval of the SMR in 
the ith region based on Poisson distribution; Mean, the posterior mean relative 
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risks from the fully Bayesian estimates of the spatial multilevel model; and PI95%, 
95% posterior ( credible) interval estimated from the spatial multilevel model. 
Figure 6.4 is a map of the SMRs, with regions displayed in red indicating 
areas with high SMRs and those in blue having low SMRs. Despite the majority 
of regions' population sizes being fairly high, there are still some regions with 
high or low SMRs displayed on the map which are based on the least reliable data. 
Since these regions have lower population sizes their SMRs do not differ 
significantly from 1, but this is not apparent from the map. For example, regions 
119 and 91 are numbered on the map of SMRs and, as can be seen from the size 
of these regions and from Table 6.4, they have small populations. The blue shade 
indicates they have relatively low SMRs, lying somewhere between 0.80 and 
0.89. However, Table 6.4 shows that despite having low SMRs these regions do 
not differ significantly from unity, demonstrating that using SMRs alone to map 
mortality can be somewhat misleading. It can also be seen that region 452 has a 
fairly high SMR but, since it also has a low population size, the confidence 
interval again includes 1. The lower half of this table contains estimates for the 
regions with the highest populations and it can be seen some SMRs are a lot 
closer to 1 but are actually significantly different from 100 (ie regions 75 and 76). 
It is clear these estimates are more reliable but this is not evident when examining 
SMRs alone or maps of SMRs. Therefore, to produce more reliable estimates 
models are fitted that take into account extra Poisson variation, spatial patterning 
of the data and covariates that may be affecting the risk of mortality. 
6.7.3 Relative Risk Disease Maps 
The fully Bayesian estimates of relative risks are given on the maps shown in 
Figure 6.5 and 6.6. Figures 6.5 shows the relative risks from the null model and it 
is evident that they show less variability than the SMRs (Figure 6.4). They vary 
from 0.63 in region 321, Norte in Portugal to 1.48 in region 85, Copenhagen and 
Frederiksberg city in Denmark with a mean of 1.01 (sd = 0.11). It can be seen that 
the extreme estimates (Table 6.3) are all closer to unity after modelling the data 
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with the effect of smoothing the map overall. The 95% credible intervals that 
contain unity are in bold in Table 6.3 and it can be seen that only five of the 
twenty regions with extreme SMRs have RRs that are significant. These are 
regions 133, Picardie in France and 161, 163, 167 and 168 which are all in Greece 
and are numbered on the map (Figure 6.5). It can be seen that these areas with 
significantl y high and low risks of cancer mortality also stand out on the map with 
many other regions taking on the purple colour (estimates close to 1). This type of 
modelling has smoothed the map because the mean for each region is centred on 
the mean of its neighbours. Therefore areas with extreme relative risks will tend to 
be shrunk towards a local mean, which is evident from Table 6.3. 
Looking at the estimates of the relative risks from the fully Bayesian spatial 
model including covariates (Figure 6.6), again it can be seen that there is less 
variability than in the previous two maps. The relative risks now vary from 0.85 in 
region 168 Aegean North in Greece to 1.29 in region 327 in Madeira in Portugal 
with a mean of 1.00 (sd = 0.07). The map is therefore a lot more smooth with the 
majority of the regions being purple (ie RR range from 0.90-1.09). Since the risk 
and protective factors included in the model have been measured at a country 
level (except GDP) the reduction in variability is due to the explanatory variables 
explaining some of the differences between countries. Only two of the twenty 
regions that had the most extreme SMRs are now significantly different from 
unity, regions 133, Picardie in France, and 168, Aegean South in Greece. These 
are again pointed out in the map (Figure 6.6) and it can clead y be seen that these 
regions stand out as having extreme areas of risk from cancer mortality. 
6.7.4 Disease Map Alternative 
There is an obvious disadvantage to disease mapping in that a loss of information 
occurs when grouping mortality rates in ranges. An alternative that overcomes this 
is to plot the relative risks against a measure of latitude, south to north 
positioning, or a measure of longitude, east to west positioning. In doing so, exact 
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values of relative risks can be examined and regions and or countries can be 
identified by their geographical positioning. 
The standardised mortality ratios and relative risks that were mapped in 
Figures 6.4-6.6 are plotted in Figure 6.7-6.10. Comparing Figures 6.7 and 6.8, 
again it is evident that the variability reduced somewhat. RRs in general move 
closer to unity as many extreme rates are shrunk toward a local mean based on 
their nearest neighbours' estimates. Figure 6.9 displays the full model estimates 
and it can be seen that the variability in the estimates is reduced even more, 
mainly between countries. This shows visually that the covariates are explaining a 
large amount of the variability, about 50% (see Table 6.2), at a country level. This 
plot is equivalent to a smoothed map and from this the extreme rates are more 
easily and reliably identified. Finally, Figure 6.10 is the same as Figure 6.9 but on 
a more natural scale. There appears to be evidence of a negative slope which in 
this case suggests that rates tend to be highest in the south and lowest in northern 
EU. Note here that, after taking into account the levels of exposure to the various 
risk factors, the region with the most extreme risk from cancer mortality is 
Maderia in Portugal (1.29). This island is very small and is not identifiable on the 
map (Figure 6.6). Other regions with particularly high relative risks after taking 
into account spatial patterning of cancer mortality and potential risk and protective 
factors are Copenhagen and Frederiksberg city and Nord-Pas-de-Calais. At the 
other end of the scale, regions that stand out with particularly low relative risks 
after adjusting for covariates and spatial autocorrelation are again various regions 
in Greece. Interestingly Norte in Portugal has a very low relative risk of cancer 
mortality showing that despite Portugal being a fairly small country it displays a 
very high amount of variability in cancer mortality rates. 
121 
Table 6.3 Estimates of SMRs/relative risks of mortality from cancer (selected regions shown, ordered by decreasing SMR) 
i Region Country OJ Ej SMR Sj CI95 % (SMR) MeanN PI95%(N) MeanF PI95%(F) 
85 Copenhagen * Denmark 2683 1743.1 1.54 0.030 (1.48, 1.60) 1.48 (0.98, 2.27) 1.20 (0.88, 1.72) 
138 Nord-Pas-de-Calais France 9992 6509.8 1.53 0.015 (1.50, 1.57) 1.36 (0.82, 2.32) 1.20 (0.89, 1.76) 
140 Alsace France 3975 2762.0 1.44 0.023 (1.39, 1.48) 1.17 (0.97, 1.45) 1.08 (0.92, 1.23) 
139 Lorraine France 5730 4008.5 1.43 0.019 (1.39, 1.47) 1.22 (1.06, 1.44) 1.12 (1.00, 1.25) 
134 Haute-Normandie France 4253 2988.1 1.42 0.022 (1.38, 1.47) 1.11 (0.94, 1.32) 1.06 (0.92, 1.22) 
143 Bretagne France 7689 5456.6 1.41 0.016 (1.38, 1.44) 1.06 (0.79, 1.43) 1.07 (0.85, 1.30) 
133 Picardie France 4389 3122.0 1.41 0.021 (1.36, 1.45) 1.23 (1.07, 1.41) 1.15 (1.02, 1.27) 
137 Bourgogne France 4570 3310.3 1.38 0.020 (1.34, 1.42) 1.03 (0.87, 1.22) 1.05 (0.91, 1.18) 
89 Vestsj aelland Denmark 1049 771.5 1.36 0.042 (1.28, 1.44) 1.21 (0.91, 1.62) 1.04 (0.81, 1.35) 
88 Roskilde Denmark 638 472.2 1.35 0.053 (1.25, 1.46) 1.09 (0.93, 1.29) 0.95 (0.83, 1.08) 
458 Kristianstad Sweden 669 928.4 0.72 0.028 (0.67, 0.78) 0.89 (0.73, 1.06) 0.92 (0.80, 1.06) 
449 Blekinge Sweden 344 478.6 0.72 0.039 (0.64, 0.80) 0.87 (0.68, 1.10) 0.94 (0.76, 1.15) 
322 Centro Portugal 3298 4602.2 0.72 0.013 (0.69, 0.74) 0.88 (0.76, 1.03) 1.03 (0.90, 1.19) 
163 Greece West Greece 1286 1845.5 0.70 0.020 (0.66, 0.74) 0.82 (0.69, 0.97) 0.88 (0.77, 1.01) 
167 Aegean South Greece 434 658.0 0.66 0.032 (0.60, 0.72) 0.79 (0.64, 0.98) 0.90 (0.77, 1.04) 
164 Greece Central Greece 1104 1722.5 0.64 0.019 (0.60, 0.68) 0.89 (0.77, 1.01) 0.92 (0.82, 1.03) 
168 Aegean North Greece 431 678.1 0.64 0.031 (0.58, 0.70) 0.80 (0.66, 0.97) 0.85 (0.74, 0.98) 
165 Peloponese Greece 1282 2097.2 0.61 0.017 (0.58, 0.65) 1.09 (0.82, 1.44) 1.10 (0.88, 1.36) 
169 Crete Greece 933 1585.0 0.59 0.019 (0.55, 0.63) 1.01 (0.72, 1.39) 1.05 (0.80, 1.38) 
161 Epirus Greece 588 1014.9 0.58 0.024 (0.53, 0.63) 0.82 (0.69, 0.97) 1.05 (0.80, 1.38) 
-----
N ~ t:stimates from null model, F - estimates from full model *Copenhagen and Frederiksberg (city) 
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Table 6.4 Estimates of SMRs/relative risks of mortality from cancer (selected regions shown, ordered by increasing population) 
i Region Country ~o~ OJ Ej SMR Sj CI95% (SMR) MeanN PI95%CNl MeanF PI95%(F) 
119 Ahvenanmaa Finland 24734 58 68.6 0.85 0.111 (0.64, 1.09) 0.93 (0.76, 1.14) 0.96 (0.80 , 1.15) 
452 Bornholm Denmark 45616 154 138.3 1.11 0.090 (0.94, 1.30) 0.89 (0.66, 1.21) 0.99 (0.78 , 1.29) 
91 Gotland Sweden 57578 150 172.3 0.87 0.071 (0.74, 1.02) 0.95 (0.74, 1.23) 1.01 (0.83 , 1.24) 
454 Powys UK 118590 344 361.0 0.95 0.051 (0.86, 1.06) 0.98 (0.85, 1.13) 0.93 (0.83 , 1.04) 
127 Isle of Wight UK 126338 476 448.6 1.06 0.049 (0.97, 1.16) 1.07 (0.84, 1.35) 1.01 (0.85 , 1.24) 
124 lamtland Sweden 135910 328 446.3 0.74 0.041 (0.66, 0.82) 0.89 (0.72, 1.10) 0.95 (0.80 , 1.12) 
559 Blekinge Sweden 151266 344 478.6 0.72 0.039 (0.65, 0.80) 0.87 (0.68, 1.10) 0.94 (0.76 , 1.15) 
449 Pohjois-Karjala Finland 177152 330 432.1 0.76 0.042 (0.68, 0.85) 0.93 (0.76, 1.13) 0.94 (0.80 , 1.09) 
246 Kronoberg Sweden 178961 441 554.4 0.80 0.038 (0.72, 0.87) 0.86 (0.71, 1.05) 0.95 (0.82 , 1.09) 
327 Ionian Islands Greece 194754 460 638.0 0.72 0.034 (0.66, 0.79) 0.77 (0.56, 1.08) 0.86 (0.68 , 1.10) 
82 Saxony Denmark 4721588 12630 12427.0 1.02 0.009 (1.00, 1.03) 1.03 (0.85, 1.28) 0.98 (0.87, 1.12) 
564 Scotland UK 5107000 14876 12636.0 1.18 0.010 (1.16, 1.20) 1.02 (0.88, 1.18) 1.01 (0.89, 1.13) 
148 Rhone-Alpes France 5418045 12075 9638.1 1.25 0.010 (1.23, 1.28) 1.06 (0.91, 1.24) 0.99 (0.87, 1.09) 
73 Hessen Denmark 5800320 16132 15289.0 1.06 0.008 (1.04, 1.07) 0.98 (0.83, 1.15) 0.97 (0.87, 1.08) 
536 Greater London UK 6889948 17648 16391.0 1.08 0.008 (1.06, 1.09) 1.07 (0.93, 1.24) 1.05 (0.94, 1.19) 
70 Lower Saxony Denmark 7431517 20009 19743.0 1.01 0.007 (1.00, 1.03) 1.02 (0.94, 1.12) 1.01 (0.96, 1.10) 
75 Baden-Wurttemberg Denmark 9911934 23636 24463.0 0.97 0.006 (0.95, 0.98) 1.01 (0.81, 1.26) 1.00 (0.89, 1.14) 
131 De de France France 10781499 21915 17399.0 1.26 0.009 (1.12, 1.28) 1.05 (0.90, 1.22) 1.01 (0.91, 1.11) 
76 Bavaria Denmark 11522397 28859 29274.0 0.99 0.006 (0.97, 1.00) 0.94 (0.82, 1.07) 0.93 (0.88, 0.99) 
72 North Rhine-Westphalia Denmark 17429759 49137 44408.0 1.11 0.005 (1.10, 1.12) 1.06 (0.92, 1.24) 1.02 (0.94, 1.12) 
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Figure 6.4 Map of SMRs 
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Figure 6.5 Map ofRRs from fully Bayesian model (no covariates) 
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Figure 6.6 Map of RRs from fully Bayesian model (all covariates ) 
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Figure 6.7 
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Figure 6.8 Plot of Latitude against Relative Risks from full y Bayesian null model 
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Figure 6.9 Plot of Latitude against Relative Risks from fully Bayesian full model 
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Figure 6.10 Plot of Latitude against Relative Risks from full y Bayesian full model 
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6.8 Adding a Further Level 
Spatial clustering effects can be incorporated into a multilevel model indirectly 
through the use of higher levels of geography as additional levels in the model. The 
European cancer mortality data set has a higher level, country, available and can be 
added as a third level to account for the fact that regions within a country are more 
likely to be homogeneous than regions from different countries. 
Equations (6.5) and (6.6) can be extended to include a further level by adding 
another variance parameter, Yk say, into the random part of the model, where k = 1, .. , 
11 are the country identifiers: 
0i .... Poisson(J.1J 
log(lli) = log(Ei) + a + Iflmxmi + Ua[iJ + L Wi,jV j + Yk' 
m jE8[i] 
The random effect Yk IS assigned a normal distribution with mean zero and 
. 2 
vananceO'y 
The hyper-prior for the inverse variance term, ~;1 , is defined to be Gamma 
distributed: 
~;1 .... Gamma (0.001,0.001) . 
The bum-in period was determined by examining trace plots from parallel chains 
and the Gelman-Rubin diagnostic test. Figure 6.11 shows the Gelman-Rubin test 
results for the full 3 level model from iterations 450,000 to 500,000. It can be seen 
that the R (red line) value is stabilising close to 1 and the estimates of the variance 
of OJ (blue line) and the average of the within-sequence variances, W (green line) are 
consistently overlapping. Before this, some of the parameters had not yet stabilised. 
This indicates that all of the parameters have converged to stability and 500,000 
iterations is therefore a suitable bum-in period for this model. 
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After a bum-in period of 500,000, the number of further iterations to run was 
decided by examining when the Monte Carlo error was small enough in relation to 
the posterior standard deviation. Table 6.5 shows that by a further 100,000 iterations 
the Monte Carlo error as a percentage of the sample standard deviation is less than 
5% for all the parameters. Therefore running 100,000 iterations after convergence 
gives a suitable set of samples from which accurate posterior inference can be made. 
The posterior estimates from the full model are given in Table 6.6. The results 
from the null model are also given. Smoking and fruit consumption are the onI y 
factors affecting the risk of cancer mortality after taking account of the non-
independence between regions within the same country. This is due to the width of 
the posterior credible intervals being wider than they are when fitting the two-level 
model (see Table 6.2). The introduction of the country level random effects has 
resulted in the covariate being measured with more uncertainty. Comparing the null 
model with the full model shows that adding the covariates reduces the total 
variance by around 40%, which is less of a reduction that we saw in the two-level 
model. In the two-level model, the covariates were effectively explaining the 
differences between countries, which has now been taken into account, hence, 
reducing their usefulness slightly. 
As can be seen from examining the random terms, there has been further 
partitioning of the variance; with a~ representing the amount of variation that is due 
to differences between countries. A high amount of the total variance (81%) is 
attributable to country level difference. This is due to the high amount of country 
level clustering and differences between countries that were evident from the initial 
disease maps. Comparing the total variance (= 0.03) to that of the two-level model 
(= 0.01 (see Table 6.2» it can be seen that there has been an increase in overall 
variation. This is somewhat surprising as, in practice, adding a further level to 
multilevel models does not tend to affect the total variance very much. The effect of 
adding a further geographical level, whilst already accounting for the non-
independence of region level risks through the spatial factor, will be discussed 
further in Chapter 8, after looking at further examples. It becomes evident that it is 
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likely that the three-level model is mainly describing the differences between 
countries, hence the increase in total variance, and that the two-level model is more 
useful for describing the differences between regions and the affects covariates have 
on these. 
Table 6.7 gives selected region's relative risk of cancer mortality. Comparing 
the two-level null model with the three-level null model shows some changes in the 
estimates; adding a higher country level has pulled the relative risks towards the 
country's overall relative risk. Some of the estimated relative risks change again 
after adjusting for the covariates; this is expected as the risk of cancer mortality is 
likely to change in some manner if the risk factors are having a significant effect. 
The width of the posterior credible intervals increases somewhat after the addition of 
covariates. The introduction of country-level random effects has resulted in the 
covariates being measured with more error which in tum has resulted in introducing 
uncertainty into the residuals and hence, the relative risks. This will be explored 
further in Chapter 8. 
Figure 6.12, the map of relative risks from the three-level model with no 
covariates, and Figure 6.14, the corresponding plot against latitude, shows a very 
high amount country level clustering. It is likely to reflect the true distribution of the 
country level risk of cancer mortality (before adjusting for risk factors). Figure 6.13 
shows the map of relative risks after adjusting for risk factors, and the corresponding 
plot is given in Figure 6.15, and it can be seen that country level clustering is still 
evident but to a lesser degree. Finland clead y have the lowest relative risk of cancer 
mortality after adjusting for all covariates and the spatial patterning of the disease. 
Some within country variation is evident across the map and regions in France and 
Austria are standing out as disease 'hotspots'. Other factors, which have not been 
taken into account in these models, are likely to be affecting these areas; such as 
health care provision (cancer treatments or availability of screening) or differing 
levels of the modelled risk factors within the countries. 
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Table 6.5 Monte Carlo error as percentage of posterior standard deviation 
Parameters 100,000 iterations 
Me error Posterior SD Me error as % of SD 
Po 0.3099 0.01395 4.5% 
PI 0.00016 0.00001 4.5% 
P2 0.00213 0.0001 4.5% 
P3 0.00109 0.00005 4.4% 
P4 0.01361 0.00061 4.5% 
P5 0.00209 0.00009 4.5% 
P6 1.60E-06 4.50E-08 2.9% 
(Ju 2 0.00059 0.00001 1.2% 
(Juv 0.00087 0.00001 1.0% 
(Jv2 0.00281 0.00004 1.4% 
0 2 y 0.02018 0.00056 2.8% 
Table 6.6 Results from fully Bayesian spatial multilevel models (three levels) 
Parameters Null Model Full Model 
Estimate Credible Interval Estimate Credible Interval 
Po 7.54 (7.42, 7.63) 6.93 (6.41, 7.51) 
PI (smoke) 0.0004 (0.0002, 0.0007) 
P2 (fruit) -0.0065 (-0.0108, -0.0020) 
P3 (veg) -0.0011 (-0.0029, 0.0014) 
P4 (animal) 0.0216 (-0.0136, 0.0462) 
P5 (alcohol) 0.0008 (-0.0041, 0.0058) 
P6 (gdp) 3.1E-7 (-2.7E-6, 3.4E-6) 
0/ 0.0028 (0.0018, 0.0042) 0.0029 (0.0019, 0.0042) 
Ouv 0.0009 (-0.0007, 0.0027) 0.0011 (-0.0005, 0.0029) 
0 2 v 0.0110 (0.0067, 0.0173) 0.0108 (0.0061, 0.0172) 
0 2 y 0.0446 (0.0174, 0.1094) 0.0246 (0.0061, 0.0775) 
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Figure 6.11 Gelman-Rubin plots at 500,000 iterations (note that only every tenth 
iteration is stored) 
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Table 6.7 Estimates of relative risks of mortality from cancer (selected regions shown, ordered by decreasing RR from three-level full model) 
Two-level null model Three-level null model Three-level full model 
i Region Country RRmean PI95% RRmean PI95% RRmean PI95 % 
2 Burgenland Austria 1.03 (0.76, 1.40) 1.02 (0.75, 1.40) 1.22 (0.90, 1.73) 
138 Nord-Pas-de-Calais France 1.36 (0.82, 2.32) 1.44 (0.98, 2.17) 1.21 (0.80, 1.74) 
133 Picardie France 1.23 (1.07, 1.41) 1.40 (1.14, 1.76) 1.21 (0.96, 1.45) 
3 Carinthia Austria 0.99 (0.81, 1.21) 1.01 (0.79, 1.30) 1.21 (0.95, 1.59) 
4 Lower Austria Austria 1.02 (0.88, 1.18) 1.00 (0.79, 1.26) 1.19 (0.95, 1.54) 
139 Lorraine France 1.22 (1.06, 1.44) 1.39 (1.13, 1.72) 1.19 (0.93, 1.43) 
158 Macedonia Central Greece 1.12 (0.90, 1.39) 0.88 (0.68, 1.17) 1.18 (0.92, 1.52) 
244 Overijssel Netherlands 1.03 (0.90, 1.19) 1.04 (0.85, 1.31) 1.18 (0.99, 1.38) 
241 Groningen Netherlands 1.00 (0.79, 1.25) 1.04 (0.81, 1.38) 1.18 (0.95, 1.45) 
327 Madeira Portugal 0.94 (0.72, 1.22) 0.88 (0.61, 1.29) 1.17 (0.82, 1.70) 
123 Kymi Finland 0.95 (0.75, 1.20) 0.83 (0.64, 1.10) 0.82 (0.61, 1.07) 
119 Ahvenanmaa Finland 0.93 (0.76, 1.14) 0.83 (0.63, 1.09) 0.81 (0.61, 1.06) 
129 Uusimaa Finland 0.96 (0.80, 1.14) 0.83 (0.66, 1.06) 0.81 (0.62, 1.02) 
120 Harne Finland 0.92 (0.77, 1.10) 0.81 (0.65, 1.04) 0.79 (0.61, 1.00) 
126 Ouiu Finland 0.91 (0.76, 1.09) 0.81 (0.64, 1.06) 0.79 (0.60, 1.02) 
124 Lappi Finland 0.91 (0.70, 1.20) 0.81 (0.60, 1.11) 0.79 (0.57, 1.07) 
125 Mikkeli Finland 0.90 (0.76, 1.06) 0.81 (0.64, 1.04) 0.79 (0.61, 1.01) 
127 Pohjois-Karjala Finland 0.93 (0.76, 1.13) 0.81 (0.63, 1.06) 0.79 (0.59, 1.02) 
121 Keski-Suomi Finland 0.90 (0.76, 1.07) 0.79 (0.63, 1.02) 0.78 (0.59, 0.99) 
122 Kuopio Finland 0.89 (0.73, 1.09) 0.79 (0.61, 1.03) 0.77 (0.59, 0.99) 
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Figure 6.12 Map ofRRs from fully Bayesian model (three-level , no covariates) 
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Figure 6.13 Map ofRRs from fully Bayesian model (three-level , all covariates) 
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Figure 6.14 Plot of Latitude against Relative Risks from fully Bayesian 
model (three-level, no covariates) 
Plot of latitude against Relative Risks (3 level null model) 
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Figure 6.15 Plot of Latitude against Relative Risks from fully Bayesian model 
(three-level, all covariates) 
Plot of latitude against Relative Risks (3 level full model) 
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Chapter 7 
7 Spatial Model Comparisons 
7.1 Spatial Models 
It has been shown that modelling the underlying spatial structure to produce 
smoothed disease maps has its advantages. An effective way to do so is through 
the use of random effects modelling and so far a spatial multilevel model allowing 
for correlation between regional and spatial random effects has been explored. To 
fit these models it is necessary to use either iterative procedures, such as iterative 
generalised least squares (IGLS (124», or simulation based methods, such as 
Gibbs sampling (137). MCMC simulation based methods have been becoming 
more common in recent years due to the increasing ability and speed of 
computers. These methods are popular for fitting complex models and have been 
used to develop multilevel models with a complex underlying structure. 
A set of multilevel models whose complex structure does not fit into the 
standard multilevel framework are multiple membership models. These models do 
not strictly follow the nested structure of the data in multilevel models but can be 
fitted using IGLS methods with constraints (138). However, Browne at al (139) 
discuss the problems associated with fitting such models and how using MCMC 
methods proves very useful. Fitting such models in a spatial disease context will 
be compared with the models fitted in Chapters 5 and 6. 
Also, a spatial model commonly used for disease outcomes IS the 
conditional autoregressive (CAR) model. This will also be fitted to the EU cancer 
mortality dataset and will be compared with the various spatial multilevel model 
structures. 
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7.2 Multiple Membership Model 
A multiple membership model is an extension to the standard multilevel 
framework and considers the case when the lowest level unit is a member of more 
than one higher classification unit. This family of models was first used by Hill 
and Goldstein (140) and further developed by Browne et al (139). They are 
actually part of the larger family of generalised linear mixed models (GLMM); 
these are a combination of the linear mixed model (141) and the generalised linear 
model framework (142). An extension to these models (139) is to use them in a 
spatial context (5) by considering the areas as one classification and the 
neighbours as another multiple-membership classification; this is known as a 
multiple-membership multiple-classification (MMMC) model. This is very similar 
to the spatial multilevel model described previously but does not allow correlation 
between the area and neighbour residuals. Using the notation developed by 
Browne et al (139), modelling the observed counts of cancer deaths in 1991 for 
187 regions with known neighbourhood structure can be written as 
Yi ,.., Poisson(Ai ), 
log(AJ = log(EJ + Po + X iPl + ... + XiPk 
+ u (2! + ~ W~3!U ~3) 
a[/] I,J J ' 
jEiJ i] (7.1) 
In (7.1), Yi is the count of cancer deaths for the ith region in the dataset; a[i] is the 
area from which the observed count was taken, and 8[i] is the set of neighbouring 
areas to the area from which the count was taken. fJ is a vector of fixed effect 
parameters, and uP), uP) are the vectors of residuals for random effects for 
classifications 2 (area) and 3 (neighbours) respectively. 
Similar to the spatial multilevel model described in Chapters 5 and 6, the 
observed counts of cancer deaths are affected by k covariates, the area where the 
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counts came from and the neighbouring areas. The weights used in this model are 
such that 
and all neighbours are given equal weights so that 
(3) _ 1 
Wi)' --, 
, n· 
l 
where ni is the number of neighbours to a[i]. 
The multiple-membership multiple-classification model was fitted using 
MCMC methods; the prior distributions for the fixed effect parameters are flat, 
for the inverse of the classification 3 variance term (~:~3»)' a Gamma prior was 
allocated: 
~:~3) ,.., Gamma (0.001,0.001), 
and similarly for the classification 2 variance matrix: 
~:~2) ,.., Gamma (0.001,0.001) . 
The MCMC algorithm that is used to fit the model is based on a combination of 
univariate Metropolis Hastings (MH) steps and Gibbs steps and has been 
implemented in MLwiN (143). The model can also be run in WinBUGS (7) and 
the code to do so is given in Appendix A2.1. 
7.3 Conditional Autoregressive Model 
A set of Bayesian spatial models that have been frequently used to model disease 
counts are based on the conditional autoregressive (CAR) prior (110); these were 
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described in more detail in Chapter 4 (see equations (4.18) to (4.22». The version 
of this model appropriate for the ED cancer dataset can be written as follows: 
Y i ...... Poisson (Ai)' 
10g(Ai) = 10g(E;) + XJ31 + ... + XJJk + U i + Vi' 
U i ...... N(O,a;), Vi ...... N(vi' a: In;) 
where Vi = I Vj Ini • 
jEo(i) 
(7.2) 
Again, ni is the number of neighbouring regions for region i. The same priors are 
used to fit the CAR model using MCMC methods as were used in the MMMC 
model. As can be seen the model is similar to the MMMC model as it has two sets 
of random effects; the difference is that spatial correlation is achieved through the 
variance structure instead of through the multiple membership relationship 
resulting in the neighbourhood random effects not being independent. Whilst the 
MMMC model has ra[t1 random effects for each observation, where ra[t1 is the 
number of neighbours for region i, the CAR model has one random effect for each 
observation. These random effects have the average of the surrounding random 
effects as their expected value. The CAR distribution is improper, and in order to 
produce a model that has a unique solution, a constraint has to be made on the 
model. This model was fitted in MLwiN and the common procedure when fitting 
the model in the package is to remove the intercept term to make the model 
identifiable (5). The code for running this model in WinBDGS is given in 
Appendix A2.2. 
7.4 Model Comparisons 
It is of interest to compare the spatial multilevel model with correlation between 
random effects with the MMMC model and the CAR model. The results from 
fitting these models using MCMC methods will be presented along with results of 
fitting a variance components and spatial multilevel model using quasi-likelihood 
methods in a frequentist setting, as described in Chapter 5. 
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7.4.1 Parameter estimates 
For an initial comparison, the parameter estimates for each model are given in 
Table 7.1. The estimates along with the respective confidence or posterior credible 
intervals are presented for the five different models: 
Model A: the variance components model fitted usmg empirical Bayes 
methods 
Model B: the spatial multilevel model with correlated residuals fitted using 
empirical Bayes 
Model C: the spatial multilevel model with correlated residuals fitted using 
fully Bayesian techniques 
Model D: the multiple-membership multiple-classification model fitted using 
fully Bayesian methods 
Model E: the conditional autoregressive model fitted by full y Bayesian 
methods. 
The significant variables in each model are presented in bold and it can be seen 
that the significant fixed parameter estimates are similar in models A to D, with 
the only discrepancy being that /33 is just non-significant in model B. Model E, 
however, shows differences in the magnitudes and signs of some of the fixed 
parameter estimates; /32 has a lesser effect on cancer mortality than in the other 
models and /33 has the opposite effect. As expected, the confidence intervals for 
the fixed parameters in model E cover different values than in the case of the other 
models. They are also generally wider, covering a larger range of values than all 
the other models. The confidence intervals for models A to D cover much of the 
same values. When comparing the intervals for models A and B, the intervals are 
about double the width in model B; since model A has ignored the positive 
autocorrelation that has been shown to exist, it is likely that incorrect inference 
has occurred; in particular standard errors will have been underestimated. Models 
C and D have attached similar errors for the fixed parameters; one would expect 
these models to produce the most similar results since these models are very 
similar in principle. The errors or ranges in the confidence intervals in these two 
models are also smaller than in the empirical Bayes estimated model B. Since 
models B and C are exactly the same except for the method of model fitting, it 
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suggests that the fully Bayesian method IS more preCIse ill estimating the 
parameters. 
If we look at the random parameters, models C and D again are in close 
agreement both in estimates and confidence intervals. However, the random 
parameter estimates of models Band C are very different. Model B has a larger 
total variance and also attributes a higher percentage of this to the spatial effects, 
(J/. Overall there appears to be more variability when fitting model B, as, along 
with a higher total variance, the confidence intervals attached to these estimates 
are also wider. In addition to this, a negative estimate is suggested as a plausible 
value for (Ju2• This is obviously not plausible and possibly shows a fault in this 
model-fitting procedure which allows such estimates to be produced. Finally, it 
would appear that model E has less total variation and has less variation 
attributable to spatial heterogeneity; however, it should be noted that the variance 
terms are not directly comparable due to the different use of weights. The variance 
terms are not actually very different from those in models C and D, after taking 
account of the average number of neighbours possessed by a region. 
It should be noted that, for models A and B, the confidence intervals are 
obtained from the estimate ± 1.96 x standard error. The model estimation that is 
being used for these models is based on an iterative generalised least squares 
(IGLS) framework which uses penalised quasilikelihood (PQL) estimation to 
approximate the Poisson distribution (6). This may lead to inaccuracy in the 
estimation of standard errors resulting in the confidence intervals not being 
estimated well which may account for some of the discrepancies between the 
width of the model intervals. 
7.4.2 Residuals 
The set of models that have been fitted can also be compared by examining 
residuals. This method is used in disease mapping as local goodness of fit 
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measures to help assess how well the model fits the data (5). The composite 
residuals can be written as 
for models B, C and D and 
r i = U i + I wiju j 
j 
r. = u. + V. I I I 
(7.3) 
(7.4) 
for model E. To make these residuals comparable to the other models, ~ can be 
subtracted from (7.4): 
r. = u. + (v. - v. ) • I I I I (7.5) 
Model A, the variance components model, has one set of residuals representing 
heterogeneity effects. Composite residuals are calculated for model B 
incorporating the heterogeneity residuals and the spatial residuals taking account 
of the number of neighbours each region has. In the Bayesian settings the 
residuals were simply formed at each iteration of a posterior sampler and averaged 
over the converged sample (144). Composite residuals, similar to those calculated 
for model B, were examined for models C and D and for E, the composite 
residuals that were examined are shown in equation (7.5). 
Table 7.2 presents the residuals for each of the five models; these are given 
in decreasing order of the residuals from model C, the fully Bayesian spatial 
multilevel model. It can be seen that the residuals vary somewhat across the 
models; however, the trends in the estimates for models A to D are fairly similar 
with no particular pattern emerging, such as one model having obviously higher 
or lower residuals. Model E appears to show more differences in the residuals 
values and this can be seen more clearly from the matrix plot in Figure 7.1. This 
plots all of the residuals from models A to E. In each of the plots, except for the 
bottom row, the points tend to lie along the diagonal indicating agreement in the 
residuals for the models A to D. However, there is evidently variability between 
the models and the best agreement is between models C and D, the two multilevel 
models fitted using fully Bayesian methods, with most points lying close to the 
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line of equality. The plots comparing the residuals from models A to D with 
model E show much different pictures. The points do not appear to follow a 
similar pattern as the other models despite the initial adjustment of the residuals. 
It is more informative to compare the confidence or posterior credible 
intervals for residuals from the models. These are presented for the four spatial 
models in Table 7.3. Looking across models B to D, it can now be seen that the 
intervals for each of the regions do overlap somewhat, covering the same range of 
values. Model B, the empirical Bayes spatial multilevel model, appears to have 
the widest intervals in most cases. The intervals for Model C (fully Bayes 
equivalent of C) and D (fully Bayes MMMC), as well as covering similar values, 
have similar ranges of the residuals. As expected, more discrepancies occur when 
comparing the intervals with those from model E. There is some overlap but also 
many of the intervals are very different in the values covered and in the width of 
the intervals. More of the intervals from model E, than from the other models, do 
not include zero. 
Figures 7.2 to 7.6 display maps of the residuals from models A to E 
respectively. If the spatial model fits well and all relevant covariates are included, 
the result should be a spatially smooth map. Examining these "smooth" maps as a 
diagnostic technique should display unusual features that are inevitably not 
accounted for by the model; these will be highlighted by clusters of high positive 
or negative residuals. Figure 7.2 shows a map with a lot of variability and little 
smoothing, which is expected because model A does not incorporate the spatial 
structuring of the data into the modelling. Looking at Figure 7.3 it is clear that the 
map of residuals is much more smooth and an area with a particularly high 
residual can be clearly identified from this map. The range of the residuals has 
also reduced by 28% (model A: -0.253 to 0.253, model B: -0.150 to 0.215) and 
definite clustering of the residuals is evident within countries. Overall this map 
suggests model B to be more useful at modelling the disease than model A. 
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Table 7.1 Parameter estimates and confidence intervals: models A-E 
Empirical Bayes (RIGLS) Full Bayes (MCMC) 
Parameters Variance Spatial Spatial Multiple Conditional 
Com onents (A) Multilevel (B) Multilevel (C) Membershi (D) Autore ressive (E) 
Po 6.83 6.83 6.88 6.92 
(6.69 , 6.98) (6.53 , 7.13) (6.67 , 7.08) (6.71, 7.13) 
PI 0.0005 0.0005 0.0006 0.0005 0.0007 
Smoking (0.0004 , 0.0006) (0.0003 , 0.0007) (0.0004 , 0.007) (0.0004,0.0006) (-0.0002,0.0016) 
P2 -0.0076 -0.0075 -0.0086 -0.0079 -0.0030 
Fruit (-0.0086 , -0.0065) (-0.0096 , -0.0054) (-0.0098 , -0.0071) (-0.0095 , -0.0064) (-0.0057 , -0.0003) 
P3 -0.0011 -0.0011 -0.0014 -0.0011 0.0082 
Vegetable (-0.0017 , -0.0006) (-0.0022, 0.00002) (-0.0022 , -0.0005) (-0.0018, -0.0004) (0.0022,0.0142) 
P4 0.0264 0.0260 0.0305 0.0280 0.0258 
Animal Fat (0.0194,0.0333) (0.0120 , 0.0400) (0.0227 , 0.0369) (0.0199 , 0.0360) (-0.0184 , 0.0699) 
P5 0.0006 0.0007 -0.0009 -0.0003 -0.0007 
Alcohol (-0.0002,0.0014) (-0.0009 , 0.0023) (-0.0019 , 0.0002) (-0.0013 , 0.0007) (-0.0033 , 0.0018) 
P6 2.00e-7 3.27e-7 1.47e-7 -8.86e-7 -6.30e-8 
GDP (-4.51e-6 ,4.91e-6) (-9.2e-6 ,9.ge-6) (-3.76e-6 ,3.13e-6) (-4.13e-6 ,2.35e-6) (-3.41e-6 , 3.2ge-6) 
cru
2 0.0135 0.0018 0.0038 0.0027 0.0028 
(0.0106 , 0.0164) (-0.0136 , 0.0173) (0.0026 , 0.0057) (0.0015 , 0.0039) (0.0013 , 0.0044) 
cr/ 0.0436 0.0270 0.0283 0.0060 
(0.0113 , 0.0759) (0.0178 , 0.0390) (0.0185 , 0.0381) (-0.0012 , 0.0130) 
cruv 0.0114 0.0052 
(-0.0003,0.0231) (0.0023 , 0.0086) 
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Table 7.2 Model residuals (ordered by decreasing residuals from model C) 
Country Region RA RB Rc Ito RE 
Portugal Madeira 0.1468 0.1689 0.2513 0.1293 -0.0475 
France Nord-Pas-de-Calais 0.2528 0.3984 0.1860 0.1611 0.0547 
Denmark Copenhagen * 0.1596 0.0562 0.1792 0.1170 0.2889 
France Corsica 0.1840 0.2010 0.1642 0.0599 -0.0049 
Greece Macedonia Central 0.0750 0.0081 0.1472 0.0941 0.0958 
France Picardie 0.1924 0.2467 0.1386 0.1254 -0.2879 
Portugal Azores 0.2243 0.2032 0.1338 0.1039 0.0532 
UK West Midlands 0.0272 -0.0130 0.1243 0.0460 0.0768 
UK Northern Ireland -0.0535 0.0115 0.1240 0.1324 -0.0957 
Austria Lower Austria 0.0735 0.1015 0.1180 0.0659 0.0098 
UK Bedfordshire -0.0233 -0.0758 0.0015 -0.0279 0.0038 
France Poitou-Charentes 0.0766 0.1884 0.0015 0.0554 -0.0430 
UK Humberside 0:0662 0.0277 0.00004 0.0150 0.0587 
France Midi-Pyrenees -0.0171 0.1420 -0.0004 0.0468 -0.1235 
Germany Saarland -0.0433 0.0642 -0.0032 -0.0481 0.0330 
Germany Baden-Wurttemberg -0.2105 -0.0259 -0.0040 -0.0860 -0.0643 
UK Dyfed -0.0495 -0.0136 -0.0056 -0.0062 -0.0676 
Denmark Ringkobing -0.0792 -0.1451 -0.0070 -0.0149 -0.1904 
UK Hampshire -0.0628 -0.0782 -0.0098 -0.0195 0.0156 
Greece Thessaly 0.0400 -0.0893 -0.0110 -0.0179 0.0965 
Finland Mikkeli -0.1093 -0.2191 -0.1042 -0.0554 0.2209 
Greece Aegean South -0.1100 -0.1164 -0.1100 -0.1021 -0.0697 
Finland Kuopio -0.1849 -0.2466 -0.1159 -0.0700 0.3683 
Germany Bremen 0.0096 -0.0563 -0.1210 -0.0224 0.0522 
Finland Oulu -0.1512 -0.2148 -0.1236 -0.0733 -0.0184 
Greece Greece West -0.1072 -0.1355 -0.1310 -0.1103 -0.0052 
Portugal Norte 0.0220 0.1026 -0.1315 -0.0334 0.0382 
Greece Epirus -0.2461 -0.1194 -0.1399 -0.1463 -0.1678 
Greece Ionian Islands -0.0346 -0.1786 -0.1492 -0.1635 0.0247 
Greece Aegean North -0.1393 -0.1693 -0.1599 -0.1263 -0.0586 
*Copenhagen and Frederiksberg (city) 
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Looking at the residuals from model C (Figure 7.4), it can again be seen that 
a smoothed map is displayed with two regions of high positive residuals and one 
with high negative residuals; thus this model is also useful for highlighting 
extreme residuals. Despite the majority of regions having residuals close to zero ie 
orange, yellow or green, there is slightly more variability within countries perhaps 
reflecting a more similar picture of the true distribution of the residuals. The 
overall range in the residuals from model C (-0.160 to 0.251) is actually slightly 
wider than those from model B. 
Examining Figure 7.5, the residuals from model D, it can be seen that the 
range of residuals (-0.160 to 0.161) is slightly narrower than any of the other 
models. However, comparing the map with Figure 7.4, a very similar picture can 
be seen; a spatially smoothed map is evident with two areas standing out as 
having extreme residuals. Both maps display a picture whereby the models have 
clead y smoothed the data well, reduced the variability and hopefully provided a 
picture that is close to the true residual surface. 
Finally, looking at the map from model E (Figure 7.6) we can see that the 
overall range in residuals is much wider than from the other models. For the 
purpose of comparison, the residuals have been split into similar categories as for 
Figures 7.2 to 7.5, but this is perhaps not the most ideal choice of ranges due to 
the wider spread of the residuals. However, as can be seen from the map, the 
majority of regions do have residuals which still lie close to zero. There are much 
more 'extreme' residuals (blue and red areas) than were evident on the other map, 
but this could be explained by the residuals not being directly comparable and 
being grouped wrongly. 
As previously mentioned, few regions have residual confidence intervals 
that do not include zero (see Table 7.3). This indicates that few regions actually 
have relative risks significantly different from unity and from examining the maps 
for models B, C and D (Figures 7.3, 7.4 and 7.5) it can be seen that they also only 
suggest one or two areas with particularly high residuals. This suggests these 
disease maps are useful for detecting disease 'hotspots' where the populations are 
at significant risk of mortality. 
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Table 7.3 Residual confidence intervals (ordered as in Table 7.2) 
Region CI95% (B) PI95% (C) CI95% (D) CI95% (E) 
Madeira (-0.046,0.476) (-0.008 ,0.497) (-0.082,0.341) (-0.144,0.049) 
Nord-Pas-de-Calais (-0.304,0.564) (-0.112,0.567) (-0.158,0.480) (-0.031 .0.140) 
Copenhagen * (-0.409 ,0.453) (-0.133 ,0.545) (-0.248 ,0.482) (0.115 .0.463) 
Corsica (-0.349 ,0.502) (-0.114,0.453) (-0.264,0.384) (-0.106.0.096) 
Macedonia Central (-0.132,0.232) (-0.035 ,0.317) (-0.062,0.251) (0.017 ,0.175) 
Picardie (0.135 ,0.243) (0.022 ,0.243) (0.035 ,0.216) (-0.363 ,-0.213) 
Azores (-0.106,0.416) (-0.117 ,0.408) (-0.114,0.321) (-0.052,0.158) 
West Midlands (-0.198,0.208) (-0.064,0.329) (-0.177 ,0.269) (-0.011 ,0.165) 
Northern Ireland (-0.401 ,0.448) (-0.206 ,0.507) (-0.255 ,0.520) (-0.190,-0.002) 
Lower Austria (-0.059,0.191) (-0.021 ,0.248) (-0.041 ,0.172) (-0.061 ,0.080) 
Bedfordshire (-0.191 ,0.151) (-0.165 ,0.163) (-0.163,0.107) (-0.079 .0.086) 
Poitou-Charentes (-0.103,0.221) (-0.112,0.122) (-0.084,0.195) (-0.088 ,0.002) 
Humberside (-0.163,0.175) (-0.132,0.149) (-0.126,0.156) (-0.015 ,0.132) 
Midi-Pyrenees (-0.107 ,0.215) (-0.118,0.153) (-0.058,0.152) (-0.142,-0.105) 
Saarland (-0.181 ,0.211) (-0.146,0.157) (-0.193,0.097) (-0.064,0.130) 
Baden-Wurttemberg (-0.173 ,0.166) (-0.117 ,0.132) (-0.220 ,0.048) (-0.129,0.001) 
Dyfed (-0.192,0.184) (-0.183,0.182) (-0.158,0.146) (-0.154,0.018) 
Ringkobing (-0.218 ,0.098) (-0.152 ,0.135) (-0.172,0.142) (-0.320,-0.061) 
Hampshire (-0.160,0.104) (-0.130,0.111) (-0.124 ,0.085) (-0.061 ,0.092) 
Thessaly (-0.168,0.128) (-0.136,0.123) (-0.162,0.126) (0.012,0.181) 
Mikkeli (-0.225 ,0.030) (-0.230 ,0.021) (-0.178,0.067) (0.192,0.250) 
Aegean South (-0.211 ,0.160) (-0.264 ,0.042) (-0.268,0.064) (-0.152,0.012) 
Kuopio (-0.251 ,0.079) (-0.274,0.044) (-0.220 ,0.080) (0.419 ,0.318) 
Bremen (-0.459 ,0.428) (-0.565 ,0.272) (-0.376,0.331) (-0.025 ,0.129) 
Oulu (-0.257 ,0.040) (-0.275 ,0.019) (-0.212 ,0.065) (-0.089 ,0.053) 
Greece West (-0.227 ,0.040) (-0.263 ,0.013) (-0.241 ,0.021) (-0.083 ,0.072) 
Norte (-0.426 ,0.435) (-0.467 ,0.211) (-0.358,0.291) (-0.072,0.148) 
Epirus (-0.192,0.091) (-0.283,-0.011) (-0.279,-0.014) (-0.260,-0.075) 
Ionian Islands (-0.318,0.205) (-0.391 ,0.097) (-0.400,0.073) (-0.079,0.128) 
Aegean North (-0.249 ,0.062) (-0.306 ,-0.024) (-0.263.0.011) (-0.133,0.016) 
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Figure 7.1 
Matrix plot of residuals from models A, B, C, D and E 
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Figure 7.2 Map of residuals from model A eve fitted using EB) 
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Figure 7.3 Map of residuals from model B (Spatial fitted using EB) 
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Figure 7.4 Map of residuals from model C (Spatial fitted using FB) 
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Figure 7.5 Map of residuals from model D (MMMC fitted using FB) 
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Figure 7.6 Map of residuals from model E (CAR fitted using FB) 
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7.4.3 Deviance Information Criterion (DIC) 
The complexity and fit of the fully Bayesian models were compared using the 
deviance information criterion (DIC) (145). This is based on the posterior 
distribution of D( C) and consists of two components, a term that measures 
goodness-of-fit and a penalty term for increasing model complexity; it is written 
as 
DIC =D + PD. (7.6) 
The first term is a Bayesian measure of model fit and is defined as the posterior 
expectation of the deviance 
(7.7) 
where f (yIO) is the likelihood function ie the joint conditional probability 
function of the observations given the unknown parameters. The better the model 
fits the data, the larger the values for the likelihood. Since D is defined using 
minus twice the log-likelihood, smaller values represent 'better' models. 
The second term, PD' is an estimate of the 'effective' number of parameters 
and can be thought of as a penalty term reflecting the model complexity or 
degrees of freedom. P D is defined as the difference between the posterior mean 
-
of the deviance and the deviance evaluated at the posterior mean e of the 
parameters 
PD = D - D(e) = Ee1y [D(e)]- D{Eely [e]) (7.8) 
= Ee1y [- 21n f(Yle )]+ 21n f~le y 
PD should capture the amount of shrinkage obtained by the hierarchical prior. A 
PD value that is small relative to the number of data points indicates that the prior 
provides a lot of information, and therefore there has been little borrowing of 
strength across the regions. It makes sense to compare the estimated P D for each 
model to gain some knowledge of the amount of important structural information 
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provided by the second stage prior. On the other hand, models with negligible 
prior information will have a PD approximately equal to the number of 
parameters. In this case the DIC will be close to Akaike's Information Criterion 
(AlC); later in this section the AlC will be used to compare the empirical Bayes 
models. 
The DIC will be used to compare the performance of the given disease 
mapping models; it is effectively a method of selecting the model that leads to the 
best prediction of the risk surface in the areas of interest. For each of the models 
fitted using fully Bayesian methods, the DIC is presented in Table 7.4. The table 
also presents the separate contributions of fit (D), complexity (PD) and deviance 
-(D(B) ). 
Table 7.4 DIC for models fitted using fully Bayesian 
Models -D D(B) PD DIe 
Spatial (C) 1939.0 1770.0 
Multilevel 
168.4 2107.4 
Multiple (D) 1938.6 1771.0 
Membership 
167.6 2106.2 
Conditional (E) 1945.2 1779.3 
Autoregressive 
166.0 2111.2 
Firstly it should be seen that all three models are highly complex leading to a 
considerable borrowing of strength, with between 166 and 168 'effective' 
parameters being needed to fit the 187 data points. The DIC values indicate that 
model D (MMMC model) is the 'best' model out of the three considered here as it 
has the lowest DIC value. However, Spiegelhalter et al (145) suggested that 
models with DIC values within 1 or 2 of the 'best' model should be strongly 
supported, those within 3 and 7 should be weakly supported and those with a DIC 
more than 7 higher than the 'best' are very much inferior. This suggests model E 
is weaker than models C and D which are effectively equal in terms of their fit 
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and performance and have priors providing appropriate information about the 
spatial structure. 
To compare the empirical Bayes models, where the prior is completely 
specificied with no hyperparameters, the Akaike Information Criterion can be 
used. The Ale can be written as 
AIC=D(e) + 2p, (7.9) 
where p is the number of parameters and B denotes the maximum likelihood 
estimate, or in this case the quasi-likelihood equivalent. In fact, equation (7.8) can 
be rearranged and written as D = D( B) + P D, then the DIC defined in equation 
(7.6) can then be re-written as 
DIC = D(8) + 2PD. (7.10) 
which is the same as equation (7.9) but with the posterior mean 8 substituted by 
the ML, or QL, estimate ofe. Thus, the DIe can be seen as a generalisation of the 
Ale and, in the special case where the prior is flat, such as with the empirical 
Bayes analysis, Ale equals DIC since the ML estimate coincides with the 
posterior mean. This is also approximately true for QL estimates since the 
estimates may not maximise the likelihood but should approximate it. It follows 
that a model with a smaller Ale is favoured and comparing the empirical Bayes 
estimates would suggest that the variance components model, with a lower AlC, is 
the 'best' model. However, in this case, model B is favoured since A ignores 
important information about the spatial structure. Also, if the QL estimates are a 
good approximation of ML estimates, the -2In( f (YIB) ) value for model B should 
be lower than that of model A. This is not true, as can be seen from Table 7.5, and 
is a disadvantage of using model fitting using quasilikelihood methods. Looking 
at the two sets of models using the DIe and Ale values gives a crude comparison 
of all the models and it is clear the fully Bayesian model should be supported. 
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Table 7.5 AlC for models fitted using empirical Bayes 
Models 
-2ln( f (yIO) ) 2p AlC 
Variance 
Components (A) 2547.5 16 2563.5 
Spatial 
Multilevel (B) 2669.2 20 2689.2 
7.4.4 Iterations 
A final factor that should be considered when making model choices, especially 
when MCMC methods are being used to fit complex models, is the time it takes to 
run the required number of iterations. Actual times have not been given here but 
Table 7.6 displays the number of iterations required for each of the models to 
reach convergence (see Appendix A3.1-A3.2 for convergence diagnostics). For 
models C to E, that were fitted using MCMC techniques, a bum-in period plus 
further iterations, as described in Chapter 6, was required. As can be seen, model 
E required the most iterations in total, with a bum-in period of 2,000,000 being 
needed followed by 100,000 further iterations. As a result this model took the 
longest time to run. Model D required fewer iterations in total followed by model 
C which required the least overall; which took much less time to run. However, it 
should be noted that all models required many hours of simulation time before 
suitable posterior distributions were obtained. 
Finally, due to the computational intensity of the MCMC simulations, 
iterative quasi-likelihood procedures have an advantage. From Table 7.6 it can be 
seen that both models A and B required very few iterations before convergence of 
parameters. These took minutes to run and therefore have the advantage of much 
less time being needed to fit the models. 
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Table 7.6 Number of iterations required for convergence 
Models Bum-in Further Iterations 
Variance 
Components * (A) 6 
Spatial 
Multilevel * (B) 8 
Spatial (C) 
Multilevel 200,000 50,000 
Multiple (D) 
Membership 1,000,000 100,000 
Conditional (E) 
Autoregressive 
2,000,000 100,000 
* models fitted using empirical Bayes methods so only the number of iterations 
required until convergence presented 
7.5 Model Choice 
The main goal of disease mapping is to remove random noise and any natural 
variation in the human population allowing identification of areas with high or 
low rates. To accurately produce such a map a model can be used that allows the 
borrowing of strength across the whole of the study region and reduces the 
variance through the use of shrinkage estimators. In this chapter five such models 
were examined in an attempt to find the ''best'' model for mapping regional level 
cancer mortality. 
Examining the parameter estimates initially showed the importance of 
taking account of spatial autocorrelation. Comparing the fixed parameters from 
the spatial models suggested that, with the exception of the CAR model, the fully 
Bayesian methods gave more precise estimates. The random parameter estimates 
for the fully Bayesian spatial multilevel model (C) and MMMC model (D) were 
very similar but discrepancies were evident when comparing them to the 
empirical Bayes spatial multilevel model (B); different estimates, wider intervals 
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and a negative variance being included in the confidence interval all suggested C 
and D were superior. The differences in the fIxed parameter estimates in the CAR 
model (E) lead to concerns about its uses for modelling this type of data. 
The best agreement in the residuals was between models C and D. With the 
exception of the CAR model, which again was not directly comparable, the 
variance components model (A) produced the most extreme residuals. Comparing 
the residuals' confidence intervals for models B, C and D again showed model B 
to cover the widest range of values; models C and D were narrower and very 
similar. The maps of the residuals for models C and D appeared to produce the 
most smoothed maps and were the most useful diagnostic tools. The map of 
model D showed that the residuals covered the narrowest range overall. 
Examining the Deviance Information Criterions suggests models C and D 
were equally superior to model E and both provided appropriate information 
about the spatial structure in the data through the use of adequate priors. 
Comparing the Akaike Information Criterion for the models fItted using Empirical 
Bayes methods suggested that the variance components model should be 
favoured, but, this ignores the spatial structure and therefore has its disadvantages. 
Using the AlC and the DIC values to give a crude comparison of model fIt across 
the empirical and fully Bayesian methods showed that models C and D had much 
lower information criterion values, again suggesting 'better' models. 
Finally, time taken to fIt the various models was considered when choosing 
a model. As discussed, the empirical Bayes models required much less time than 
the fully Bayes models. Among the MCMC models, that all required numerous 
iterations, model C required the least and could be fItted in less time than models 
D and E. In fact, this was one of the main deciding factors in model choice 
between the two favoured disease mapping models. As described in this section, 
models C and D, the fully Bayesian spatial multilevel model and the multiple-
membership model, are superior in different manners to the others. Both provide 
similar estimates and are very useful for disease mapping, but, model C could be 
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fitted in about a fifth of the time of that for model D making it a more favourable 
choice. 
It should also be noted that model C provides an additional pIece of 
information, namely a correlation between the two sets of random effects, u and v. 
From the parameter estimates (Table 7.1) it can be seen that this term is 
significant showing a positive correlation between the two terms and suggesting it 
is useful to incorporate it in the modelling. Also, because they were fitted using 
MCMC methods, model C, and effectively model D, have another advantage of 
allowing more complex multilevel modelling structures to be fitted, such as the 
addition of higher geographical levels; these modelling extensions proved difficult 
using empirical Bayes methods. 
For the above reasons the natural decision was to model and disease map 
further similar data using model C, the fully Bayesian spatial multilevel model. 
This model will be used to explore the spatial distributions of various specific 
cancers in Chapter 8. 
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8 Specific Cancers 
8.1 Examining Specific Cancer Rates 
Examining all cancers grouped together has proved informative and is commonly 
used to measure variation in health across regions and countries. However, it is a 
fairly crude measure of analysis and so far has ignored the fact that specific 
cancers may follow different spatial patterns in the EU. Also, literature suggests 
that relationships with various risk factors vary for different cancers, and therefore 
it makes sense to consider different cancers individually. 
The mortality data used in previous Chapters are all malignant neoplasms 
(ICD-9 140-208) for 187 regions in 11 EU countries (Table 3.3). This dataset can 
be broken down further into specific cancers by regions. The malignant neoplasms 
that will be examined further in this chapter are i) malignant neoplasm of trachea, 
bronchus and lung (which will be referred to as lung cancer from now on), ICD-9 
162; ii) malignant neoplasm of oesophagus (oesophageal cancer), ICD-9 150; and 
iii) malignant neoplasm of the colon, rectum rectosigmoid junction and anus 
(colorectal cancer) ICD-9 153,154. 
8.2 Lung Cancer Mortality 
In 1998, 32% of the world's lung cancer deaths occurred in Europe (146) despite 
Europe comprising approximately an eighth of the world's population (147). Lung 
cancer is the most common cause of death from cancer in European men; in 1995 
29% of the total male cancer burden was due to lung cancer (2). Recent studies 
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have shown an increase in both incidence of and mortality from lung cancer 
among woman in Europe (148-151). There has been a "rapid increase" in female 
lung cancer mortality in some countries in Europe (150) and rates in EU countries 
appear to have doubled in the period 1955-1994 (148). 
8.2.1 Modelling Lung Cancer Mortality 
Previous studies such as these have examined lung cancer mortality patterns and 
trends in Europe at a country level (2, 152, 153). It is of interest to evaluate 
whether these patterns remain after taking regional variations into account. Also, 
using modelling methods that allow adjustment for spatial patterning and potential 
risk factors may produce a different picture of European lung cancer mortality 
rates and more accurately quantify the burden of the disease. 
Again, 187 regions in 11 EU countries in 1991 are examined. The data are 
modelled using the fully Bayesian spatial multilevel model (equations (6.5) and 
(6.6)). The full model fitted the same explanatory variables as were used when 
examining all cancers together. Convergence was monitored using time series 
plots and Gelman-Rubin plots for each parameter from simultaneous runs of the 
model resulting in a bum-in period of 50,000 being needed for the two-level null 
model. The number of further iterations required was determined by examining the 
Monte Carlo error in relation to the posterior standard deviation for each 
parameter, and the two-level null model required 10,000 further iterations until a 
suitable posterior distribution was available from which to sample. The two-level 
full model required a bum-in of 200,000 iterations and 300,000 further iterations. 
The full three-level model took 500,000 iterations until convergence and a further 
300,000 iterations were then required. 
8.2.2 Model Results: Lung Cancer 
Tables 8.1 and 8.2 give estimates of relative risks of lung cancer mortality for 
selected regions; extreme (two maximum and two minimum) rates are given for 
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each country (except Luxembourg where onI y country level data are available), 
ordered by declining posterior relative risk estimates within each country. Table 
8.1 gives the standardised mortality ratios and 95% confidence intervals based on 
the Poisson distribution, and the relative risks (posterior means) obtained from the 
two-level model with no covariates and corresponding 95% credible intervals 
(posterior 0.025 and 0.975 quantiles). Table 8.2 gives the relative risks and 95% 
posterior credible intervals from the two-level and three-level models with all six 
covariates included. Table 8.3 gives the country level SMRs and relative risks 
from the three-level full model. Table 8.4 gives the parameter estimates (posterior 
means and 95% posterior credible intervals) from the three previously mentioned 
models. Relative risks were calculated from the fIxed effect parameter estimates to 
compare regions with high and low levels of exposure to the given risk factors and 
these are given in Table 8.5. Figures 8.1-8.4 are maps of the SMRs and the 
predicted relative risks from the three models. 
8.2.2.1 Two-Level Null Model: Lung Cancer 
Table 8.1 gives the two highest and the two lowest relative risks within each 
country, predicted from the two-level spatial model with no covariates. The SMR 
for each of these regions is also given. The predicted relative risks are taking into 
account the spatial patterning of lung cancer mortality and any extra-Poisson 
variation and the estimates show that the area with the highest relative risk of lung 
cancer mortality is Northern Ireland in the United Kingdom with a RR of 1.59, 
followed by Copenhagen and Frederiksberg (city) (RR=1.53) and Northumberland 
in the UK (RR=1.46). Therefore, lung cancer mortality in Northern Ireland is 59% 
higher than expected. Before taking account of risk factors, areas with the lowest 
relative risk of lung cancer mortality in the EU countries under investigation are 
Norte in Portugal (RR=0.60) and Vasterbotten in Sweden (RR=0.67); this means 
that lung cancer mortality is 40% lower than expected in Norte and 33% lower 
than expected in Vasterbotten. Regions in Portugal display the widest range in 
relative risks (0.60 - 1.33) closely followed by the UK (0.88 - 1.59). The 
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Netherlands have the smallest range in relative risks (0.97 - 1.16) followed by 
Austria (0.84 - 1.08). 
8.2.2.2 Lung Cancer SMRs 
Also, for each region given in Table 8.1, the corresponding SMRs are presented. 
The disadvantages of examining these have already been discussed but they are 
shown here for comparison purposes. Examining SMRs alone ignores population 
sizes at risk, spatial patterning etc and gives a different picture of the risk of lung 
cancer mortality in the EU. For example, Northern Ireland has the highest 
predicted relative risk from the two-level null spatial model. However, looking at 
the SMR alone suggests that the risk of lung cancer mortality is only 21 % higher 
than expected (compared to 59%). Looking at Norte, the region with the lowest 
predicted relative risk, it can be seen the SMR has again dropped. Also, the 
confidence interval for the SMR (based on the Poisson distribution) suggests that 
Norte has a significantly lower than expected risk of lung cancer mortality; 42% -
49% lower, whereas the model predicts that this region's relative risk does not 
differ significantly from unity. This pattern emerges for many regions. 
8.2.2.3 Lung Cancer Disease Maps I (SMRs and Two-Level Null Model RRs) 
The map of SMRs (Figure 8.1) shows that there is a very high amount of variation 
within the EU, ranging from 0.33 to 2.16. It can also be seen that within some 
countries there is a high amount of clustering, with the UK and the Netherlands 
general 1 y having high SMRs and Sweden and Portugal having low SMRs. 
Estimating the relative risks from the two-level null spatial model reduces 
the number of regions with extreme rates (see Figure 8.2). Here, the within-area 
effects are modelled with a Poisson distribution, and relative risks between areas 
are considered as having a log-normal distribution with the mean for each area 
being centred on the mean of its neighbours. This, in effect, is providing a 
smoother map and is getting closer to the true picture of lung cancer mortality in 
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the EU. Areas that stood out as having extreme rates on the disease map of 
mortality previous to modelling may have high variability in their estimates due to 
having smaller population sizes. In such a case, one cannot confidently identify a 
region as, for example, a disease 'hotspot'. Modelling the data to remove this 
variability produces estimates of the 'true' risk of the disease, therefore extreme 
rates that dominate this map can be more accurately interpreted as lung cancer 
mortality 'hotspots'. From the map it can be seen that areas with a particularly 
high risk of lung cancer mortality are some UK regions, Lorraine in France and 
two regions in east Greece. Those areas now standing out as having particularly 
low risk of lung cancer mortality are regions in Portugal, Bavaria in Germany and 
some parts of Sweden. 
8.2.2.4 Two-Level Full Model: Lung Cancer 
As discussed in Chapter 2, there are other factors affecting the risk of lung cancer 
mortality that so far have not been taken into account. It is of interest to examine 
the risk of mortality from this disease after taking into account measures of risk 
and protective factors and also after taking into account the within-country 
clustering that was evident from the map of SMRs (Figure 8.1). Table 8.2 gives the 
estimated relative risks of lung cancer mortality from the two-level spatial model 
including the six covariates used in previous model fitting: fruit, vegetable, animal 
fat and alcohol consumption, cigarette smoking and gross domestic product. The 
two highest and the two lowest relative risks within each country are given. The 
estimates are also given for the three-level model, incorporating country as a 
higher level to account for the fact that regions within a country are more likely to 
be homogeneous than regions from different countries. 
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Table 8.1 Relative risks (SMR and RR from two-level null model) of mortality from lung cancer 
for each count extreme rates . ven, ordered b decreasin RR 
i Country Region OJ Ej SMR CI9s%(SMR) RRmean PI9S % 
3 Carinthia 284 253.6 1.12 (0.99 ,1.26) 1.08 (0.78 , 1.51) 7 Styria 497 560.9 0.89 (0.81 ,0.97) 1.06 (0.83 , 1.35) 
... Austria 
2 Burgenland 136 129.6 1.05 (0.88 ,1.24) 0.91 (0.59 , 1.40) 5 UQQer Austria 476 579.8 0.82 (0.75,0.90) 0.84 (0.64 , 1.11) 85 Copenhagen * 549 312.9 1.75 (1.61 ,1.91) 1.53 (0.82 , 2.91) 86 Copenhagen 400 298.0 1.34 (1.21 ,1.48) 1.28 (1.01 , 1.65) 
... Denmark 
94 Ribe 136 107.9 1.26 (1.06 , 1.49) 0.96 (0.68 , 1.37) 
98 Viborg 133 127.7 1.04 {0.87 ,1.23} 0.94 {0.66 , 1.32} 
126 Oulu 166 174.8 0.95 (0.81 ,1.11) 1.17 (0.87 , 1.57) 
124 Lappi 81 82.4 0.98 (0.78,1.22) 1.03 (0.69 , 1.55) 
... Finland 
120 Harne 230 312.2 0.74 (0.64 ,0.84) 0.90 (0.67 , 1.21) 
130 Vassa 166 214.9 0.77 {0.66 ,0.90} 0.87 {0.61 , 1.24} 
139 Lorraine 1156 843.1 1.37 (1.29 , 1.45) 1.22 (0.96 , 1.56) 
134 Haute-Normandie 714 629.7 1.13 (1.05 ,1.22) 1.13 (0.86 , 1.48) 
... France 
142 Pays de la Loire 851 1207.0 0.71 (0.66 ,0.75) 0.84 (0.62 , 1.11) 
143 Bretagne 964 1159.8 0.83 {0.78,0.89} 0.84 {0.54 , 1.31} 
77 Saarland 639 520.5 1.23 (1.13 ,1.33) 1.14 (0.78 , 1.68) 
74 Rheinland-Palatinate 1905 1869.1 1.02 (0.97 ,1.07) 1.08 (0.85 , 1.37) 
... Germany 
76 Bavaria 3900 5466.4 0.71 (0.69,0.74) 0.79 (0.65 , 0.96) 
71 Bremen 367 361.0 1.02 {0.92 ,1.13} 0.76 {0.36 , 1.53} 
157 Macedonia East+ 323 271.6 1.19 (1.06 , 1.33) 1.24 (0.85 , 1.83) 
158 Macedonia Central 874 765.4 1.14 (1.07 ,1.22) 1.20 (0.88 , 1.67) 
... Greece 
163 Greece West 335 359.7 0.93 (0.83 ,1.04) 0.88 (0.69 , 1.13) 
166 Attica 1619 1545.0 1.05 {1.00 ,1.10} 0.83 {0.62 , 1.10} 
238 Luxembourg 184 175.7 1.05 {0.90 , 1.21} 1.10 {0.75 , 1.61} 
242 Friesland 326 280.8 1.16 (1.04 , 1.29) 1.16 (0.86 , 1.59) 
248 Limburg 651 489.4 1.33 (1.23 ,1.44) 1.15 (0.83 , 1.60) 
... Netherlands 
246 Flevoland 108 76.9 1.40 (1.15 ,1.70) 0.98 (0.69 , 1.39) 
241 Groningen 337 262.4 1.28 {1.15 ,1.43} 0.97 {0.68 , 1.38} 
327 Madeira 74 93.8 0.79 (0.62 ,0.99) 1.33 (0.82 , 2.14) 
326 Azores 78 95.9 0.81 (0.64,1.01) 1.28 (0.80 , 2.06) 
... Portugal 
323 Lisboa e Vale do Tejo 787 1490.6 0.53 (0.49 ,0.57) 0.72 (0.50 , 1.01) 
321 Norte 733 1347.4 0.54 {0.51 ,0.58} 0.60 {0.32 , 1.1O} 
462 Orebro 112 169.1 0.66 (0.55 ,0.80) 1.01 (0.77 , 1.34) 
467 Uppsala 85 138.4 0.61 (0.49,0.76) 0.99 (0.74 , 1.34) 
... Sweden 
454 lamtland 32 88.5 0.36 (0.25 ,0.51) 0.71 (0.51 , 0.99) 
469 Vasterbotten 50 141.7 0.35 {0.26,0.47} 0.67 {0.47 , 0.94} 
565 Northern Ireland 788 650.9 1.21 (1.13 ,1.30) 1.59 (0.83 , 3.13) 
513 Northumberland 252 164.2 1.53 (1.35,1.74) 1.46 (1.10 , 1.98) 
... UK 
532 East Sussex 515 464.7 1.11 (1.01 ,1.21) 0.90 (0.64 , 1.27) 
521 Leicestershire 428 428.4 1.00 {0.91 ,1.I0} 0.88 (0.69 , 1.10) 
*Copenhagen and Frederiksberg (city), +Macedonia East and Thrace 
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Figure 8.1 Map of lung cancer SMRs 
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Figure 8.2 Map of lung cancer RRs from null two-level model 
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The estimates from the two-level model, taking into account potential risk 
factors, show that the region with the highest relative risk of cancer mortality in 
the EU countries under investigation is Madeira in Portugal (RR=1.48) closely 
followed by Copenhagen and Frederiksberg (city) (RR=1.45) and Northern Ireland 
in the UK (RR=1.44). The lowest relative risks were found in Norte in Portugal 
(RR=O.70), Bavaria in Germany (RR=O.72) and Vasterbotten in Sweden 
(RR=O.78). The regions with extreme risks are similar to those identified from the 
model with no covariates, but the actual estimates have changed somewhat. They 
are now closer to unity, which is due to the risk and protective factors being 
measured at the level of country and are therefore helping explain some of the 
differences between countries. 
When comparing the 95% Bayesian credible intervals from the null and full 
model, it can be seen that after adding covariates many more of the intervals are 
significantly different from unity. Therefore, these regions have a significantly 
greater or lesser risk of lung cancer mortality after adjusting for known risk 
factors. This suggests that there are other factors, not taken account of here, which 
are affecting lung cancer mortality in areas of the EU or perhaps the distribution of 
the risk factors within these counties is not constant and it reflects particularly high 
(or low) regional levels of exposure to the covariates. 
8.2.2.5 Lung Cancer Disease Maps II (Two and Three-Level Full Model RRs) 
Looking at the maps of relative risks from the null model (Figure 8.2), most of the 
regions that stand out as 'hotspots' are not actually significant using this modelling 
method, and since they dominate the map visually they may be misinterpreted as 
being significant. However, looking at Figure 8.3, in which the significant regions 
have been named, it can be seen that these tend to be the areas that stand out 
visually on this smoother map, showing the usefulness of modelling and mapping 
the lung cancer mortality data in this manner. 
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Figure 8.4 maps the relative risks from the three-level model. The estimates 
in the regions within countries that had high overall risks are now closer to country 
level risk. This creates a different picture of the distribution of lung cancer, with 
relative risks within some countries now appearing more similar. For example, all 
of the regions in the UK have risks close to or greater than unity, whereas using 
the two-level model there was more variation with some regions having relative 
risks less than 0.9. Similarly, all relative risks in Germany are lower than 1 (Figure 
8.4) but before accounting for the higher level they varied much more around 
unity. 
8.2.2.6 Three-level Full Model: Lung Cancer 
Looking at the final columns of Table 8.2, the results from adding a further 
geographical level to the model, as expected it can be seen here that the estimates 
change. The same picture that emerged on the map is evident, but what is also 
noticeable is that the 95% credible intervals get much wider. Here we are 
incorporating spatial clustering effects into the model indirectly by adding a third 
level that accounts for the fact that regions within a country are more likely to be 
homogeneous than regions from different countries. The introduction of country-
level random effects appears to result in the covariates being measured with more 
error; this causes uncertainty in the estimation of the parameters associated with 
the covariates which in tum introduces uncertainty into the residual estimation. 
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Table 8.2 Relative risks (two and three.level full models) of mortality from lung cancer (for 
each country extreme rates S:!ven, ordered by decreasing RR from three-level model} 
i Country Region OJ Ej RRmean(2) PI95 % (2) RR.nean(3) PI95 %(3) 3 Carinthia 284 253.6 1.23 (1.03 , 1.65) 1.30 (0.75 , 2.27) 7 Styria 497 560.9 1.14 (0.98 , 1.43) 1.21 (0.75 , 1.98) 
... Austria 
2 Burgenland 136 129.6 0.99 (0.83 1.51) 1.12 (0.57 , 2.19) 5 UQQer Austria 476 579.8 0.94 (0.81 , 1.22) 1.01 ~60 -,-~J.71} 85 Copenhagen * 549 312.9 1.45 (1.20 , 2.75) 1.38 (0.57 , 3.59) 86 Copenhagen 400 298.0 1.25 (1.06 , 1.61) 1.19 (0.71 , 2.09) Denmark 
87 Frederiksborg 174 156.3 0.96 (0.81 , lAO) 0.91 (0047 , 1.82) 98 Viborg 133 127.7 0.94 (0.79 , 1.30) 0.90 (0.50 , 1.70) 
126 Oulu 166 174.8 1.14 (0.96 , 1.49) 1.19 (0.74 , 2.01) 
124 Lappi 81 8204 1.08 (0.90 , 1.60) 1.13 (0.63 , 2.14) Finland 
120 Harne 230 312.2 0.92 (0.78 , 1.19) 0.97 (0.62 , 1.60) 
130 Vassa 166 214.9 0.92 (0.77 , 1.28) 0.97 (0.57 , 1. 71) 
139 Lorraine 1156 843.1 1.23 (1.06 , 1.52) 1.25 (0.82 , 2.08) 
134 Haute-Normandie 714 629.7 1.14 (0.98 , 1.46) 1.18 (0.75 , 2.02) 
France 
143 Bretagne 964 1159.8 0.85 (0.71 , 1.28) 0.89 (0.48 , 1.77) 
142 Pays de la Loire 851 1207.0 0.80 (0.68 , 1.04) 0.84 (0.52 , 1.45) 
72 Nth Rhine_Westphalia 9518 8234.9 1.10 (0.97 , 1.33) 0.94 (0.62 , 1.40) 
77 Saarland 639 520.5 1.10 (0.92 , 1.53) 0.95 (0.55 , 1.61) 
Germany 
75 Baden-Wurttemberg 3181 4548.3 0.78 (0.66 , 1.02) 0.67 (0.41 , 1.07) 
76 Bavaria 3900 5466.4 0.72 (0.62 , 0.86) 0.64 (0.43 , 0.94) 
157 Macedonia East + 323 271.6 1.23 (1.02 , 1.81) 1.19 (0.57 , 2.42) 
158 Macedonia Central 874 76504 1.18 (0.99 , 1.60) 1.14 (0.58 , 2.14) 
Greece 
166 Attica 1619 1545.0 0.90 (0.76 , 1.18) 0.88 (0046 , 1.59) 
163 Greece West 335 359.7 0.90 (0.76 , 1.13) 0.88 (0.48 , 1.52) 
238 Luxembourg 184 175.7 1.25 (1.03 , 1.77) 1.22 (0.64 , 2.26) 
248 Limburg 651 489.4 1.10 (0.94 , 1.49) 1.00 (0.47 , 1.81) 
252 Zeeland 209 187.0 1.06 (0.87 , 2.01) 0.98 (0.33 , 2.47) 
Netherlands 
241 Groningen 337 262.4 0.96 (0.81 , 1.32) 0.88 (0040 , 1.60) 
249 Utrecht 531 423.1 0.95 (0.80 , 1.29) 0.88 (0.41 , 1.59) 
327 Madeira 74 93.8 1048 (1.23 , 2.43) 1.57 (0.73 , 3.59) 
326 Azores 78 95.9 1.42 (1.18 , 2.35) 1.51 (0.70 , 3047) 
Portugal 
323 Lisboa e Vale do Tejo 787 1490.6 0.82 (0.71 , 1.15) 0.87 (0.47 , 1.70) 
321 Norte 733 1347.4 0.70 (0.58 , 1.28) 0.74 (0.31 , 1.88) 
462 Orebro 112 169.1 1.10 (0.93 , 1.42) 1.09 (0.66 , 1.77) 
467 Uppsala 85 13804 1.09 (0.91 , 1.43) 1.09 (0.65 , 1.80) 
Sweden 
1.31 455 Jonkoping 73 187.1 0.80 (0.67 1.03) 0.82 (0.49 
469 Vasterbotten 50 141.7 0.78 (0.64 , 1.07) 0.79 (0.44 , 1.36} 
565 Northern Ireland 788 650.9 1.44 (1.17 , 2.75) 1.59 (0.68 , 4.13) 
513 Northumberland 252 164.2 1.32 (1.12 , 1.71) 1.45 (0.90 , 2.57) 
UK 
534 West Sussex 432 437.5 0.86 (0.73 , 1.11) 0.95 (0.59 , 1.67) 
521 Leicestershire 428 428.4 0.83 (0.72 , 1.02) 0.93 (0.61 . 1.56} 
*Copenhagen and Frederiksberg (city), +Macedonia East and Thrace 
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Figure 8.3 Map of lung cancer RRs from full two-level model 
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Figure 8.4 Map of lung cancer RRs from full three-level model 
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8.2.2.7 Lung Cancer Country Level Results 
Table 8.3 gives the SMRs and corresponding confidence intervals for each country 
along with the relative risks and posterior intervals from fitting the 3-level full 
spatial model. From the modelling results it can be seen that Germany has the 
lowest lung cancer mortality relative risk (RR=0.83) and Austria has the highest 
(RR=1.14), closely followed by the UK (RR=1.12). None of the posterior credible 
intervals exclude unity indicating no country has a risk of lung cancer mortality 
significantly higher or lower than expected. This is because the within country 
variation is large for most countries and looking at regional level relative risks 
within these countries does prove more informative. 
Table 8.3 Relative risks of mortality from lung cancer at country level 
Country Oi Ei SMR CI95 % (SMR) RRmean PI95 % 
Austria 3278 3633.2 0.90 (0.87 , 0.93) 1.14 (0.87 , 1.49) 
Germany 35037 37653 0.93 (0.92 , 0.94) 0.83 (0.66 , 1.01) 
Denmark 3206 2649.6 1.21 (1.17 , 1.25) 0.96 (0.72 , 1.32) 
Finland 1820 2223.1 0.82 (0.78 , 0.86) 1.04 (0.85 , 1.34) 
France 22232 22458 0.99 (0.98 , 1.00) 1.04 (0.84 , 1.40) 
Greece 4877 5091.1 0.96 (0.93 , 0.99) 0.97 (0.66 , 1.35) 
Luxembourg 184 175.7 1.05 (0.90 , 1.21) 1.05 (0.77 , 1.39) 
Netherlands 8416 6632.7 1.27 (1.24 , 1.30) 0.92 (0.58 , 1.24) 
Portugal 2270 4459.4 0.51 (0.49 , 0.53) 1.04 (0.78 , 1.46) 
Sweden 2812 4944.9 0.57 (0.55 , 0.59) 0.98 (0.75 , 1.25) 
UK 39121 28663 1.36 (1.35 , 1.38) 1.12 (0.89 , 1.54) 
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8.2.2.8 Lung Cancer Parameter Estimates 
The parameter estimates from fitting the three models are given in Table 8.4. The 
estimates and 95% credible intervals are given for the two-level spatial model with 
no explanatory variables, then after including all six explanatory variables and 
finally including the higher country level. The overall intercept flo represents a 
logarithm of the average number of lung cancer deaths in all regions included in 
the study in addition to the centred logarithm of the expected deaths, when all 
other fixed coefficients are zero. The estimates of the intercept are not particularly 
informative as they reflect an unlikely situation where-by an area has zero 
exposure to any of the risk or protective factors. 
Looking at the full two-level model first, the estimate of fli is the mean, or 
fixed slope for the explanatory variable smoke and it can be seen the estimate is 
positive and, judging significance from the 95% posterior credible intervals, 
significant. This implies that when taking the other variables into account an 
increase in cigarette consumption increases lung cancer mortality on average in the 
EU. The parameter estimate of 0.001 is a log relative risk of lung cancer mortality 
for each one unit/cigarette smoked increase per person per year. This suggests that 
every 100 increase in cigarettes smoked per person per year is associated with an 
increase in the risk of lung cancer mortality of about 11% (RR=exp{O.l }=1.105). 
It can be seen that other variables which significantly affect cancer mortality are 
fruit and vegetable consumptions, both showing an inverse association with lung 
cancer mortality. The actual effect size of these variables will be discussed later 
on. 
Looking at the random parts of the models it can be seen that, for the null 
and full two-level models, the variance has been partitioned into that which is due 
to differences between regions, au 2, and that which arises due to the spatial 
structure in lung cancer mortality, a/. To interpret the spatial effects, the average 
number of neighbours a region has should be taken into account, and after doing so 
the adjusted variance from the spatial part of the model is 0.046 (CT; rii = 
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0.19114.128) and the total variance under the null model is then 0.065 ( = a; + 
a; / n = 0.019 + 0.046). Seventy-one percent (0.046/0.065 *100) of this variance 
arises from spatial effects. Looking at au2 and a/ from the full two-level model , 
the total variance decreases to 0.033 (0.013 + 0.08114.128). Therefore, taking into 
account the measures of exposure to risk and protective factors has reduced the 
variation by around 50%. Of this remaining variance (0.033), 61 % is attributable 
to spatial patterning in the data. Finally looking at the results from the three-level 
model, it can be seen that the significant fixed parameter estimates do not change 
very much from the two-level model. However, the random part has now been 
partitioned further and a/ now represents the variance that is due to differences 
between countries. The total variance is now around 0.058, which has nearly 
doubled after adding a third higher level. Now, 18% of the total variance is due to 
heterogeneity between regions, 30% is attributable to spatial effects and 52% is 
due to differences between countries. 
8.2.2.9 Lung Cancer Risk Factor Effect Size 
It is also of interest to quantify the effect size of the risk or protective factors when 
examining lung cancer mortality rates. Using both the two-level and three-level 
models, relative risks were calculated for each variable comparing countries with 
high and low levels of exposure to risk factors and are given in Table 8.5. Firstly, 
looking at the two-level model and the smoking variable, the table is showing that 
Greece has the highest level of cigarette consumption in these eleven countries and 
Sweden has the lowest. The relative risk of 7.69 suggests that consuming, on 
average, the same amount of cigarettes as Greece leads to a relative risk of lung 
cancer mortality that is 7.7 times as high as if smoking was on the same level as 
Sweden. Also, looking at the fruit variable suggests that a population consuming, 
on average, the same amount of fruit as Greece has a risk of lung cancer mortality 
that is 51 % lower than if consumption was on the same level as the UK. The final 
significant variable is vegetable consumption and the parameter estimates from the 
two-level model suggest that consuming the same level of vegetables as Greece 
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leads to a risk of lung cancer mortality that is 57% less than if consumption was on 
the same level as Finland. 
The results are also given for the three-level model and as can be seen the 
estimates change slightly. Also, as noted for the parameter estimates, the 95% 
posterior credible intervals are wider. Adding a third higher level to the model 
results in increasing the variation, hence reducing the precision of the relative 
risks. 
There may be implications for ignoring (or even including) country in the 
multilevel structure when fitting such spatial models. The non-independence of 
regional mortality within countries has been taken into account, firstly through 
allowing for spatial autocorrelation between neighbouring areas and secondly by 
using country level covariates. It has been shown that both aspects of the 
modelling are important; we have seen that there is significant spatial variation 
existing in the data suggesting there is evidence that spatial patterning of the 
disease does exist and the importance of the country effects shows that there are 
discontinuities between countries. The results seen so far in this chapter, along 
with those from Chapter 6, suggest that different models may be useful for the 
estimation of different effects. Adding a third level appears to be a useful model 
for explaining differences between countries; and, at least for lung cancer 
mortality, there is a higher level of heterogeneity between countries than between 
regions within countries. The spatial model, without the additional level, appears 
more useful at detecting differences between regions, such as disease 'hotspots' 
before and after adjusting for covariates, and gives more precise estimates of the 
fixed effects. 
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Table 8.4 Parameter estimates from modelling lung cancer mortality rates 
Parameters Null two-level Model Full two-level Model Full three-level Model 
Estimate Credible Interval Estimate Credible Interval Estimate Credible Interval 
fJo 5.85 (5.76 , 5.93) 4.93 (4.43, 5.39) 4.49 (3.47 , 5.42) 
fJ1 (smoke) 0.0010 (0.0007, 0.0013) 0.0011 (0.0006 , 0.0014) 
fJ2 (fruit) -0.0104 (-0.0135, -0.0076) -0.0100 (-0.0156 , -0.0024) 
fJ3 (veg) -0.0035 (-0.0051, -0.0021) -0.0040 (-0.0069 , -0.0013) 
fJ4 (animal) 0.0085 (-0.0100, 0.0272) 0.0120 (-0.0090 , 0.0464) 
fJ5 (alcohol) -0.0003 (-0.0026, 0.0020) -0.0003 (-0.0046 , 0.0038) 
fJ6 (gdp) 3.44e-6 (-3.16e-6, 1.02e-5) 2.55e-6 (-3.42e-6 , 8.62e-6) 
(ju 2 0.0185 (0.0102 , 0.0294) 0.0125 (0.0075, 0.0190) 0.0105 (0.0062 , 0.0162) 
(jUY 0.0496 (0.0328 , 0.0708) 0.0198 (0.0108, 0.0315) 0.0164 (0.0081 , 0.0268) 
(j} 0.1909 (0.1392 , 0.2585) 0.0814 (0.0484, 0.1236) 0.0728 (0.0432 , 0.1109) 
(jy 2 0.0298 (0.0034 , 0.1134) 
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Table 8.5 Effect size of covariates from two- and three-level full lung cancer models 
Covariate Min (country/ Max (country/ Two-level model Three-level model 
region) region) RR 95% CI RR 95% CI 
Smoking 1550 (Sweden) 3590 (Greece) 7.69 (4.15 , 12.7) 9.43 (3.61 , 19.3) 
Fruit 74.5 (UK) 142.6 (Greece) 0.49 (0.40 , 0.60) 0.51 (0.34 , 0.85) 
Vegetable 58.8 (Finland) 300.4 (Greece) 0.43 (0.29 , 0.60) 0.38 (0.19 , 0.73) 
Animal fat 2.3 (Greece) 26.8 (Luxembourg) 1.23 (0.78 , 1.95) 1.61 (0.80 , 3.12) 
Alcohol 60.0 (Greece) 173.9 (Germany) 0.97 (0.75 , 1.25) 0.97 (0.60 , 1.55) 
GDP 5611 (Epims - 44711 (Copenhagen and 1.14 (0.88 , 1.49) 1.10 (0.87 , 1.40) 
Frederikberg (city) -
Greeece) Denmark) 
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8.2.3 Lung Cancer Discussion 
It has been shown that spatial variation in lung cancer mortality exists both within 
and between countries throughout the EU. Whilst a large part of the variation can 
be accounted for by adjusting for known risk and protective factors for lung 
cancer, variation still clearly exists throughout the European countries under 
examination. Some regions in Portugal, Germany and Sweden display particularly 
low lung cancer mortality rates, so it may be of interest to investigate why these 
areas avoid lung cancer mortality. Probably of more interest are the areas that 
stand out as lung cancer mortality 'hotspots' after taking account of factors that 
are known to affect the disease rates. There are twelve regions in the Austria, 
Denmark, France, Germany, Greece and the UK that show a particularly high risk 
of lung cancer mortality and it may be of a public health interest to investigate 
these areas further. 
It is of obvious public health advantage to promote smoking cessation in the 
EU countries for the prevention of many diseases, particularly lung cancer, and 
similarly with healthy eating promotions. However, it is of interest to determine 
any other factors that are affecting EU lung cancer mortality rates. A possible 
cause of the lung cancer 'hotspots' remaining after adjusting for country level 
smoking and dietary habits is that exposure to the factors may be particularly high 
or low within these countries. This could be determined by carrying out smaller 
scale studies within these countries and specific smoking cessation promotion 
focus may then have to be made in these 'hotspot' areas. 
Current information does not support screening for lung cancer (154). A 
recent lung cancer screening recommendation statement (155) suggested that 
some types of screening would be more likely to detect lung cancer at an early 
stage than would be detected in an unscreened population; however, they also 
found poor evidence that any screening strategy for lung cancer decreases 
mortality. Therefore, geographical differences in the provision of scree rung 
programmes is not a factor that is likely to be affecting the EU pattern of lung 
cancer mortality. Because of the very high fatality from the disease other health 
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care provisions, such as variations in treatment, are also unlikely to be affecting 
the mortality rates. 
The association between lung cancer and specific occupations is well 
established in reports dating back to the 1950s (44). The IARC Monographs 
Programme (156) has reviewed many of the associations between occupational 
agents and different types of cancers and it can be seen that risk is increased 
among workers employed in a number of industries and occupations. The types of 
occupations are too specific to be taken into account of in a population based 
study; however, this risk factor may explain some of the lung cancer 'hotpots'. 
There is abundant evidence in existing literature of the strong associations 
lung cancer has with smoking, fruit and vegetable consumption. These are also the 
factors that have been shown in this study to have a significant association with 
lung cancer mortality at the population level. It was seen that around half of the 
variation that exists between regions in the EU can be explained by taking into 
account faid y crude measures of exposure to the above significant risk and 
protective factors. 
Further modelling showed that around 60% of the remaining variance is 
spatially patterned and this suggests that there are other factors not included in this 
study which are spatially patterned that also influence lung cancer mortality. Such 
factors which may be affecting these spatial patterns of mortality could be factors 
previously discussed or genetic predisposition to lung cancer. It has been 
established that a gene that predisposes lung cancer does exist and recent research 
in the area identified the location on the chromosomes that carry this gene (157). 
The precise gene has yet to be pinpointed but this research complements other 
work that suggests that genetic predisposition is a risk factor for lung cancer. This 
risk factor is likely to be affecting mortality rates in the EU in some form. Many 
gene frequencies are spatially patterned (158) and this leads to the possibility that 
this is a risk factor that may be causing some of the unexplained spatially 
patterned variance. Further research is necessary in this area. 
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8.3 Colorectal Cancer Mortality 
Cancer of the colon and rectum is the second most common cancer in both men 
and woman in Europe (146). In men, colorectal cancer comprises 22% of all 
cancer cases and 14% in woman (2). There are major between-country differences 
in colorectal cancer survival rates in Europe (159). The countries with highest 
survival have a five-year survival rate which is less than 60% (160) and the 
overall European five-year survival is very similar in colon cancer (51%) and 
rectal cancer (48%). European deaths from colorectal cancer are ranked the 
second most common cause of cancer deaths, with around 11 % of all cancer 
mortality being due to neoplasms in these sites (2). Second to cancer of the lung, 
colorectal cancer demonstrates one of the most serious cancer burdens in Europe. 
8.3.1 Modelling Colorectal Cancer Mortality 
It is of interest to examine the true distribution of colorectal cancer both within 
and between countries in Europe. Again, we are able to do so by modelling 
colorectal cancer mortality relative risks after adjusting for spatial patterning and 
potential risk factors. 
As discussed in chapter 2, alcohol intake and different dietary components 
have been shown to be the main risk factors for the disease and data reflecting 
levels of these have been modelled. There is conflicting evidence on the effect 
smoking has on colorectal cancer mortality; this has been included as a covariate 
in the latter models to determine its effect on European colorectal cancer mortality 
rates. There is no evidence of socio-economic status affecting colorectal cancer, 
and GDP has not been included in the model results shown in this section as 
adding this covariate slowed convergence time substantially. The variables were 
fitted as covariates when fitting the fully Bayesian spatial multilevel models. The 
same sets of models are fitted as were examined for lung cancer mortality. 
Running simultaneous models and monitoring convergence resulted in a bum-in 
period of 200,000 being needed for the two-level null model. These samples were 
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discarded and 100,000 further iterations were run; at this stage the Monte Carlo 
error as a percentage of the posterior standard deviation was much less than 5% so 
fewer further iterations were actually required to obtain a suitable sample of 
reliable posterior estimates. The full two-level model required a bum-in of 
200,000 iterations and 100,000 further iterations. For the full three-level model 
900,000 iterations were discarded as a bum-in period and it took a further 300,000 
iterations until a suitable posterior distribution was available. 
8.3.2 Model Results: Colorectal Cancer 
Relative risks for colorectal cancer mortality are presented in Tables 8.6 and 8.8. 
As with the lung cancer results, estimates are given for selected regions within 
each country. Table 8.6 shows the standardised mortality ratios and respective 
95% confidence intervals and the posterior mean relative risks obtained from the 
null two-level model and corresponding 95% posterior credible intervals. 
Similarly Table 8.8 gives the relative risks and credible intervals from the two-
level and three-level models including the five covariates discussed previously. 
Table 8.7 gives the eleven country level SMRs and relative risks from the 
posterior estimates from the full three-level model. Table 8.9 presents the 
posterior means and 95% credible intervals for each of the parameters from these 
three models. Table 8.10 shows effect sizes of the parameter estimates by giving 
relative risks comparing areas with high and low levels of exposure to the risk 
factors. Figures 8.5-8.8 are maps of the SMRs and posterior relative risks from the 
three models. 
8.3.2.1 Two Level Null Model: Colorectal cancer Model 
Table 8.6 give the two highest and two lowest relative risks within each country 
and corresponding intervals in brackets from the two-level spatial model with no 
covariates. It can be seen that the area with the highest relative risk of colorectal 
cancer mortality is Nord-Pas-de-Calais in France, with a relative risk of 1.61, 
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followed by Burgenland in Austria (RR=1.43), Cornwall in the UK (RR=I.43) 
and Storstr~m in Denmark (RR=I.42). Before taking account of risk factors, the 
areas with the lowest risk of colorectal cancer mortality is Norte in Portugal 
(RR=0.28) followed by the Algarve in Portugal (RR=0.48) and Dytiki Ellada and 
Ionian Islands in Greece (RR=0.50). Regions in Portugal show the most 
variability in relative risks ranging from 0.28 to 1.17. Finland have the smallest 
range in relative risks (0.73 - 0.98) closely followed by Sweden (0.81-1.07). 
8.3.2.2 Colorectal Cancer SMRs 
Standardised mortality ratios are given for each region and presented in Table 8.6. 
As previously discussed, the relative risks can be much more reliably interpreted 
as close to the true risk of cancer mortality; however, they are presented here for 
comparison purposes. It is of interest to show the discrepancies between the 
'traditional' measure of disease risk and the modern spatial modelling approaches 
to estimate the risk. Most of the extreme predicted posterior risks differ 
substantially from the SMRs, often giving risk estimates on the opposite side of 
unity for the same region. This emphasises the importance of using accurate 
modelling methods to examine disease distribution. 
8.3.2.3 Colorectal Cancer Disease Maps I (SMRs and Two-Level Null Model RRs) 
Figure 8.5 presents the map of the SMRs and it appears to indicate that colorectal 
cancer mortality is generally low in the EU. The SMRs range from 0.13 to 1.27 
and it can be seen that the blue regions (SMR < 0.89) tend to dominate the map. 
The few regions with high rates are confined to France and Denmark. Again, 
clustering within countries is evident from this map. However, it is more 
informative to examine the modelled rates. 
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Table 8.6 Relative Risks (SMR and RR from two-level null model) of mortality from colorecta1 
cancer for each countr extreme rates iven, ordered b decreasin RR 
i Country Region Oi Ei SMR CI95 % (SMR) RR..-n PI95 % 2 Burgenland 115 112.8 1.02 (0.84,1.22) 1.43 (0.91, 2.26) 4 Lower Austria 615 620.6 0.99 (0.91 ,1.07) 1.22 (0.96, 1.56) Austria 
7 Styria 389 486.1 0.80 (0.72,0.88) 0.98 (0.78, 1.23) 3 Carinthia 164 216.6 0.76 (0.65 ,0.88) 0.85 {0.61 , 1.18} 90 Storstr~m 112 125.5 0.89 (0.73,1.07) 1.42 (1.03, 1.97) 85 Copenhagen 318 308.1 1.03 (0.92 ,1.15) 1.38 (0.73, 2.69) Denmark 
99 Nordjylland 229 212.0 1.08 (0.94 , 1.23) 0.91 (0.54, 1.52) 96 Ringkobing 94 105.6 0.89 (0.72,1.09} 0.88 (0.66, 1.16} 
129 Uusimaa 225 409.1 0.55 (0.48,0.63) 0.98 (0.74, 1.32) 
121 Keski-Suomi 54 92.9 0.58 (0.44,0.76) 0.95 (0.71, 1.28) 
Finland 
126 QuIu 61 135.9 0.45 (0.34 ,0.58) 0.78 (0.57 , 1.08) 
122 Pohjois-Savo 35 96.3 0.36 (0.25 ,0.51} 0.73 (0.50, 1.04} 
138 Nord - Pas-de-Calais 1114 927.3 1.20 (1.13 ,1.27) 1.61 (0.73, 3.58) 
141 Franche-Comte 279 285.7 0.98 (0.87 ,1.10) 1.31 (0.99, 1.70) 
France 
134 Haute-Normandie 427 422.6 1.01 (0.92,1.11) 1.04 (0.80, 1.35) 
143 Bretagne 864 801.2 1.08 (1.01 ,1.15} 1.02 (0.65, 1.66} 
84 Thuringen 878 988.8 0.89 (0.83 ,0.95) 1.26 (0.98, 1.63) 
75 Baden-Wurttemberg 3429 3961.7 0.87 (0.84 ,0.89) 1.19 (0.88, 1.60) 
Germany 
69 Hamburg 745 813.7 0.92 (0.85 ,0.98) 0.91 (0.60, 1.38) 
78 Berlin 1211 1439.4 0.84 (0.79,0.89} 0.91 (0.42, 1.93} 
158 Macedonia Central 241 582.7 0.41 (0.36 ,0.47) 0.96 (0.68, 1.38) 
165 Peloponnese 77 360.7 0.21 (0.17 ,0.27) 0.93 (0.58, 1.48) 
Greece 
162 Ionian Islands 21 109.1 0.19 (0.12 ,0.29) 0.50 (0.28, 0.86) 
163 PeloQonnese 59 299.5 0.20 (0.15 ,0.25} 0.50 (0.37, 0.67) 
238 Luxembourg 110 146.0 0.75 (0.62 ,0.91} 1.01 (0.65, 1.52} 
252 Zeeland 104 157.3 0.66 (0.54 ,0.80) 1.23 (0.57, 2.69) 
248 Umburg 320 378.0 0.85 (0.76,0.94) 1.18 (0.85, 1.63) 
Netherlands 
242 Friesland 159 234.5 0.68 (0.58,0.79) 0.93 (0.67, 1.28) 
250 Noord-Holland 648 899.3 0.72 (0.67,0.78} 0.87 (0.54, 1.39} 
323 Lisboa e Vale do Tejo 894 1170.3 0.76 (0.71 ,0.82) 1.17 (0.86, 1.59) 
322 Centro 364 742.1 0.49 (0.44,0.54) 1.01 (0.85, 1.20) 
Portugal 
(0.37 ,0.60) 0.48 (0.26, 0.89) 325 Algarve 73 153.6 0.48 
321 Norte 594 1066.3 0.56 (0.51 ,0.60} 0.28 (0.16, 0.50} 
460 Malmohus 258 386.4 0.67 (0.59,0.75) 1.07 (0.62, 1.85) 
470 Vasternorrland 85 137.9 0.62 (0.49,0.76) 1.06 (0.70, 1.60) 
Sweden 
448 Alvsborg 130 218.1 0.60 (0.50 0.71) 0.82 (0.61 1.09) 
469 Vasterbotten 78 114.5 0.68 (0.54 ,0.85} 0.81 (0.57, 1.14} 
543 Cornwall 189 246.2 0.77 (0.66 ,0.89) 1.43 (0.69, 3.06) 
565 Northern Ireland 427 536.3 0.80 (0.72,0.88) 1.35 (0.67, 2.73) 
UK 
546 Somerset 163 236.4 0.69 (0.59 ,0.80) 0.95 (0.71 , 1.25) 
528 Hertfordshire 266 389.0 0.68 (0.60 ,0. 77} 0.90 (0.66, 1.19} 
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Figure 8.6 maps the relative risks estimated from the two-level null spatial 
model and a very different picture of the distribution of colorectal cancer is 
evident. The relative risks range from 0.28 to 1.61 and the pattern on the overall 
map is displaying a high amount of variation both within and between counties. 
The map is now showing fewer areas with extreme low risk of cancer mortality 
and more areas with high risks of this disease (RR > 1.1). Countries that appear to 
have areas with very high risk (RR > 1.2) of colorectal cancer mortality before 
taking into account potential risk factors for the disease are France, Germany, 
Austria, Denmark and the UK. These regions could now be viewed as colorectal 
cancer mortality 'hotspots'. Some regions in Finland, Greece and Portugal display 
very low risk of colorectal cancer mortality (RR < 0.8). Taking into account risk 
and protective factors of colorectal cancer will hopefully help explain some of the 
variation that is clearly evident on this map. 
8.3.2.4 Two-Level Full Model: Colorectal Cancer 
As previously discussed, there are risk factors that have been shown to affect the 
risk of colorectal cancer mortality but so far these have been ignored in the 
modelling. Table 8.8 gives the estimated relative risks of colorectal cancer from 
the two-level spatial model including five of the covariates used in previous 
model fitting; fruit, vegetable, animal fat and alcohol consumption and cigarette 
smoking. Again, the two highest and two lowest relative risks within each country 
are given. The table also shows the estimates from the full three-level model; 
these estimates take account of the within country clustering that was evident 
from the initial map of SMRs. 
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Figure 8.5 Map of colorectal cancer SMRs 
• 1.20 to 1.27 
• l. 1 0 to l.1 9 
• 0.90 to 1.09 
• 0.80 to 0.89 
• 0.13toO.79 
r 
. :::- -
,-...,'-" ,-.:!.. (-
r--'" ... f -IJ 
"2- _I.~_\ __ /. ~\ 
Specific Cancers 
, 
'f 
• , 
. / ". 
.. ( 
". 
189 
Chapter 8 Specific Callcer 
Figure 8.6 Map of colorectal cancer RRs from null two-level model 
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The estimates from the two-level model taking the covariates into account 
show that the region with the highest relative risk of mortality in the EU countries 
under investigation is Lisbon and Vale do Tejo in Portugal (RR=1.49), followed 
by Nord-Pas-de-Calais in France (RR=1.39) and Lower Austria (RR=1.33). The 
lowest relative risks were found in Norte in Portugal (RR=0.54) followed by 
Greece West (RR=0.69) and Ionian Islands (RR=0.72) in Greece. Many of the 
regions identified as extreme before adding the covariates to the model remain as 
extreme within their country. However, they now tend to be less extreme as the 
covariates are helping to explain some of the country level variation. 
Regions within Portugal still show the most variability, with the relative risk 
of cancer mortality ranging from 0.54 to 1.49. Regions within Finland display the 
least variability, with all relative risks ranging from 0.91 to 1.06. 
8.3.2.5 Three-level Full Model: Colorectal Cancer 
Looking at the final columns of Table 8.8, which are the relative risks from 
adding a third level to the model (country), it can be seen both the estimates and 
the credible intervals have changed somewhat when compared with the two-level 
full results. The relative risks now take into account the fact that regions within a 
country are more homogenous than regions from different countries. The 
estimates are shrunk towards the overall relative risk of the country. All regions in 
France, which displayed the most areas with very high risks (see Figure 8.6), now 
have predicted relative risks which are fairly high. On the other hand, Finland's 
relative risks have shrunk somewhat based on the fact that they had many regions 
with very low risk of colorectal cancer mortality; the variability between regions 
has reduced through the addition of country as a level resulting in there is now 
being less variability within countries. 
The 95% credible intervals for these relative risks again appear to have 
widened so there is now much more uncertainty attached to the risks, which is 
likely to be due to the covariance that exists between the country level random 
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effects and fIXed effects; this will be causing uncertainty in the estimation of the 
parameters associated with the covariates which leads to uncertainty in the relative 
risks. 
8.3.2.6 Colorectal Cancer Disease Maps II (Two and Three-Level Full Model RRs) 
Figure 8.7 maps the relative risks from the full two-level model. The relative risks 
that stand out on the map are the bright red regions (RR > 1.2) and these are areas 
that possibly need further investigation into why they remain as colorectal cancer 
mortality 'hotspots' after adjusting for the potential risk and protective factors. 
There are ten such regions in Portugal, France, Austria and Greece, and areas of 
low risk also stand out on the map; there are such regions in Finland, Portugal and 
Greece. 
The 'hotspot' areas can now be clearly identified on the map because the 
map that has been produced has been spatially smoothed and variation has been 
reduced through adjusting for colorectal cancer risk factors. The smooth map is 
dominated by purple regions in which the relative risks are close to unity; none of 
these risks are significantly different from unity based on 95% posterior credible 
intervals. In fact, the only relative risks significantly different from unity are the 
extreme risks, ie those greater than 1.2 or less than 0.80. 
Finally examining the map of relative risks from the three-level model 
(Figure 8.8) it can be seen that most countries now display a high amount of 
clustering within the country. So the regional relative risks have been drawn 
towards the overall country level risk. Countries that stand out as still having high 
variability within them are Portugal and Greece. Looking at the results from the 
two-level model (Table 8.8), the regions within these countries did have the 
highest amount of variability in relative risks, 0.54-1.49 and 0.69-1.27 
respectivel y. 
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Although this map is smooth in that it appears to be free of random noise 
and not dominated by natural variation it is of limited use for the purpose of 
identifying regional 'hotspots' of the disease. 
8.3.2.7 Colorectal Cancer Country Level Results 
The table below (Table 8.7) gives the SMRs and corresponding confidence 
intervals for each country and the relative risks and posterior intervals from fitting 
the three-level full model. The modelling results coincide with the map obtained 
from fitting the three-level model (Figure 8.8) in that France has the highest 
relative risk (RR=1.51) of colorectal cancer mortality by far. None of the other 
countries display RRs significantly different from unity based on the 95% 
posterior credible intervals. 
Table 8.7 Relative risks of mortality from colorectal cancer at country level 
Country Oi Ei SMR CI95 % (SMR) RR.nean PI95 % 
Austria 2785 3224.2 0.86 (0.83, 0.90) 1.09 (0.77, 1.67) 
Germany 29867 33190.8 0.90 (0.89, 0.91) 0.95 (0.71, 1.40) 
Denmark 2077 2207.8 0.94 (0.90, 0.98) 0.96 (0.65, 1.64) 
Finland 966 1843.6 0.52 (0.49, 0.56) 0.71 (0.50, 0.94) 
France 15778 15184.4 1.04 (1.02, 1.06) 1.51 (1.15, 2.08) 
Greece 1234 4087.3 0.30 (0.29, 0.32) 0.87 (0.4 7, 1.65) 
Luxembourg 110 146.0 0.75 (0.62, 0.91) 1.09 (0.71, 2.13) 
Netherlands 4090 5401.1 0.76 (0.73, 0.78) 1.01 (0.47, 1.59) 
Portugal 2151 3554.6 0.61 (0.58, 0.63) 1.03 (0.64, 1.64) 
Sweden 2499 4185.2 0.60 (0.57, 0.62) 1.01 (0.68, 1.46) 
UK 19220 24308.9 0.79 (0.78, 0.80) 0.98 (0.61, 1.41) 
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8.3.2.8 Colorectal Cancer Parameter Estimates 
The parameter estimates from fitting the three models are given in Table 8.9 along 
with their posterior credible intervals. Po represents the overall intercept, but 
however these values are not very informative as they reflect a situation where an 
area has zero exposure to all the risk factors. The other fIxed parameter estimates 
are of more interest. Looking at the full two-level model first it can be seen that 
the estimate of the fixed slope for the smoke variable is positive and, judging from 
the 95% posterior interval, signifIcant. Therefore, taking the other variables into 
account, an increase in cigarette smoking increases colorectal cancer on average 
in the EU. The parameter estimate of 0.0006 is a log relative risk of lung cancer 
mortality for each one cigarette smoked per person per year. This suggests that 
every increase of 100 cigarettes smoked per person per year is associated with an 
Increase In the risk of colorectal cancer mortality of about 6% 
(RR=exp{0.06}=1.06). It can be seen that other variables which significantly 
affect colorectal cancer mortality are fruit consumption (RR=0.91), vegetable 
consumption (RR=0.97) and animal fat consumption (RR=1.39); all are based on 
a 10kg increase in the food or drink per person per year. 
Looking at the random part of the null and two-level model, the variance has 
been partitioned into that which is due to regional differences, ou2, and that which 
is due to the spatial structure of colorectal cancer mortality, Ov 2• The spatial 
variance under the null model, after taking the regional average number of 
neighbours into account, is 0.040, resulting in the total variance being 0.056. 
Therefore, 71 % of the total variance in colorectal cancer mortality, before taking 
risk factors into account, arises from spatial effects. The total variance from the 
full two-level model is 0.028. Therefore, taking into account the measures of 
exposure to the various risk factors has reduced the overall variation in colorectal 
cancer mortality by 50%. Of this remaining variation 68% is attributable to spatial 
patterning in the data. 
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Table 8.8 Relative risks (RR from two- and three-level full models) of mortality from colorectal cancer 
for each count extreme rates . ven, ordered b decreasin RR from three-level model 
i Country Region OJ Ej RRmean(2) PI9S %(2) RR.ne.a(3) PI9S %(3) 4 Lower Austria 615 620.6 1.33 (1.07 , 1.67) 1.25 (0.76 , 2.28) 2 Burgenland 115 112.8 1.30 (0.90 , 1.91) 1.22 (0.67 , 2.47) Austria 
6 Salzburg 119 172.3 1.06 (0.84, 1.34) 1.02 (0.61, 1.86) 3 Carinthea 164 216.6 1.01 (0.78 , 1.33) 1.01 (0.59 u'_u 1.811-90 Storstrom 112 125.5 1.09 (0.83 , 1.43) 1.04 (0.57 , 2.19) 85 Copenhagen * 318 308.1 1.00 (0.57 , 1.73) 1.03 (0.47 , 2.65) Denmark 
93 SonderjyUand 76 106.7 0.84 (0.66 , 1.07) 0.89 (0.50 , 1.82) 96 Ringkobing 94 105.6 0.80 {0.62 , 1.02) 0.88 {0.49 , 1.81) 
129 Uusimaa 225 409.1 0.91 (0.72 , 1.14) 0.74 (0.44 , 1.16) 120 Harne 154 264.6 0.88 (0.69 , 1.13) 0.74 (0.44 , 1.17) 
Finland 
124 Lappi 31 62.6 0.81 (0.56 , 1.16) 0.66 (0.35 , 1.13) 
122 Kuo~io 35 96.3 0.77 {0.57 , 1.01) 0.65 {0.37 , 1.04) 
138 Nord-Pas-de-Calais 1114 927.3 1.39 (0.77 , 2.54) 1.68 (0.86 , 3.50) 
140 Alsace 495 390.6 1.22 (0.97 , 1.57) 1.63 (1.04 , 2.67) 
France 
151 Provence-Alpes-Cote d'Azur 1179 1313.4 1.04 (0.85 , 1.27) 1.35 (0.86 , 2.21) 
152 Corsica 64 75.9 1.03 {0.60 , 1.78) 1.30 (0.67 , 2.64) 
72 Nth-Rhine Westphalia 6841 7209.2 1.09 (0.91 , 1.29) 1.00 (0.66 , 1.67) 
83 Saxony-Anhalt 1078 1114.9 1.07 (0.85 , 1.35) 1.00 (0.63 , 1.73) 
Germany 
76 Bavaria 4085 4757.4 0.94 (0.81 , 1.10) 0.92 (0.61 , 1.52) 
78 Berlin 1211 1439.4 0.85 {0.47 , 1.54) 0.85 {0.42 , 1.86) 
158 Central Macedonia 241 582.7 1.27 (0.94 , 1.72) 1.10 (0.48 , 2.66) 
157 Macedonia East+ 83 208.1 1.04 (0.71 , 1.53) 1.01 (0.42 , 2.53) 
Greece 
162 Ionian Islands 21 109.1 0.72 (0.46 , 1.10) 0.75 (0.30 , 1.89) 
163 Greece West 59 299.5 0.69 (0.53 , 0.87) 0.72 {0.32 , 1.62) 
238 Luxembourg 110 146.0 0.99 (0.72 , 1.35) 1.09 {0.57 , 2.68) 
248 Limburg 320 378.0 1.17 (0.90 , 1.55) 1.11 (0.43 , 2.13) 
244 Overijssel 311 362.3 1.08 (0.90 , 1.32) 1.06 (0.43 , 1.93) 
Netherlands 
249 Utrecht 238 350.2 0.99 (0.74 , 1.31) 0.94 (0.36 , 1.81) 
250 Noord-Holland 648 899.3 0.90 {0.62 , 1.31) 0.93 {0.34 , 1.88) 
323 Lisboa e Vale do Tejo 894 1170.3 1.49 (1.10 , 2.04) 1.32 (0.64 , 2.75) 
324 Alentejo 157 268.6 1.19 (0.95 , 1.49) 1.11 (0.57 , 2.15) 
Portugal 
326 Azores 40 75.6 0.86 (0.53 , 1.40) 0.87 (0.37 , 2.01) 
321 Norte 594 1066.3 0.54 {0.31 , 0.92) 0.73 {0.29 , 1.77) 
466 Stockholm 473 706.3 1.04 (0.75 , 1.43) 1.06 (0.58 , 1.90) 
470 Vastemorrland 85 137.9 1.06 (0.77 , 1.46) 1.05 (0.57 , 1.89) 
Sweden 
471 Vastmanland 63 122.1 0.92 (0.72 1.17) 0.97 (0.55 1.67) 
464 Skaraborg 69 140.7 0.94 (0.73 , 1.20) 0.97 (0.55 , 1.67) 
552 Cheshire 343 384.1 1.12 (0.92 , 1.37) 1.08 (0.58 . 1.79) 
511 Durham 222 251.2 1.10 (0.90 , 1.36) 1.07 (0.57 , 1.79) 
UK (0.49 . 1.54) 533 Surrey 322 463.5 0.94 (0.75 , 1.16) 0.93 
528 Hertfordshire 266 389.0 0.89 {0.71 , 1.12) 0.91 {0.48 , 1.52) 
*Copenbagen and Frederiksberg (city), +Macedonia East and Thrace 
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Figure 8.7 Map of colorectal RRs cancer from full two-level model 
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Figure 8.8 Map of colorectal cancer RRs from full three-level model 
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Finally, looking at the three-level model it can be seen that the parameter 
estimates are now all non-significant based on the 95% posterior intervals. More 
uncertainty appears to be attached to the estimates, which was also evident in the 
relative risks (Table 8.8). In contrast to lung cancer, the differences in colorectal 
cancer between countries cannot be explained, to a great extent, by the various 
risk factors, hence, the non-significant parameter estimates. In fact, the large 
differences between countries remain after taking account of the risk factors; see 
Figure 8.8. 
8.3.2.9 Colorectal Cancer Risk Factor Effect Size 
The parameter estimates for the fixed effects were explained in the previous 
section. However, to give a clearer picture of the actual effect size of these 
estimates, relative risks were calculated comparing countries with high and low 
levels of exposure to each of the risk factors. These are presented for the two-level 
and three-level models in Table 8.10. Concentrating on the two-level model 
results and looking at the smoking variable first it can be seen that smoking, on 
average, the same amount of cigarettes as in Greece leads to a relative risk of 
colorectal cancer mortality that is 3.4 times as high as if smoking was on the same 
level as in Sweden. Consideration of the dietary variables leads to the following 
conclusions: consuming, on average, the same amount of fruit as in Greece has a 
risk of colorectal cancer mortality that is 49% lower than if consumption was on 
the same level as in the UK; vegetable consumption on the same level as in 
Greece gives a risk of mortality 55% lower than if consuming as much as Finland; 
and animal fat consumption on the same level as Luxembourg results in a 
colorectal cancer mortality risk 2.3 times as high than if consumption was similar 
to Greece. 
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8.3.3 Colorectal Cancer Discussion 
As was evident from studying all cancers and lung cancer, spatial variation in 
colorectal cancer mortality exists both within and between countries in the EU. 
About half of this variation can be accounted for by taking into account the known 
risk and protective factors for the disease; however, variation still exists 
throughout the eleven countries. Portugal, Finland and Greece have regions in 
which very low risks of mortality exist; further investigations in these areas may 
help determine ways to prevent colorectal cancer mortality. However, areas of 
high risk tend to be of more interest from the viewpoint of public health 
interventions and those which exist for colorectal cancer mortality after 
accounting for the risk factors are ten regions across France, Austria, Portugal and 
Greece. 
It would be interest to investigate further why these 'hotspot' areas exist 
after accounting for the various risk and protective factors. As with lung cancer, 
differing within-country exposure to one or more of the risk factors could account 
for the high risks. For example, people in the 'hotspot' regions in France may 
smoke more than in the rest of the country but this has not been adjusted for so 
instead it shows as a very high risk area on the map. There is abundant evidence 
supporting the benefits of early screening on colorectal cancer survival (161-166) 
and it has been estimated that more than one third of deaths from colorectal cancer 
could be prevented if those over fifty were screened regularly for the disease 
(167). The availability of screening for colorectal cancer in these 'hotspot' areas 
may be affecting rates. Accurate diagnosis and effective surgery for early-stage 
cancer has also been shown to improve colorectal cancer mortality (168), and 
variations in the provisions of these within countries may also be affecting the 
rates. 
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Table 8.9 Parameter estimates from modelling colorectal cancer mortality rates 
Parameters Null two-level Model Full two-level Model Full three-level Model 
Estimate Credible Interval Estimate Credible Interval Estimate Credible Interval 
fJo 5.36 (5.28, 5.44) 4.92 (4.50, 5.39) 4.84 (3.68, 6.08) 
PI (smoke) 0.0006 (0.0003, 0.0009) 0.0004 (-0.0002, 0.0009) 
P2 (fruit) -0.0099 (-0.0131, -0.0069) -0.0061 (-0.0128, 0.0012) 
P3 (veg) -0.0033 (-0.0048, -0.0019) -0.0033 (-0.0089, 0.0005) 
P4 (animal) 0.0331 (0.0167, 0.0498) 0.0155 (-0.0312, 0.0561) 
fJ5 (alcohol) -0.0003 (-0.0027, 0.0019) 0.0031 (-0.0034, 0.0092) 
fJ6 (gdp) 3.ge-07 (-4.1e-06, 4.ge-06) 
O'u 
2 0.0163 (0.0090, 0.0255) 0.0090 (0.0049, 0.0145) 0.0047 (0.0023, 0.0080) 
O'uv 0.0479 (0.0326, 0.0673) 0.0226 (0.0138, 0.0339) 0.0065 (0.0023, 0.0121) 
O'v 
2 0.1630 (0.1187, 0.2178) 0.0795 (0.0521, 0.1146) 0.0260 (0.0122, 0.0454) 
0'2 y 0.0867 (0.0204, 0.2968) 
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Table 8.10 Effect size of covariates from two-and three-level full colorectal cancer models 
Covariate Min (country) Max (country) 2 level model 3 level model 
RR 95% CI RR 95% CI 
Smoking 1550 (Sweden) 3590 (Greece) 3.40 (1.84, 6.27) 2.26 (0.66, 6.27) 
Fruit 74.5 (UK) 142.6 (Greece) 0.51 (0.41, 0.63) 0.66 (0.42, 1.09) 
Vegetable 58.8 (Finland) 300.4 (Greece) 0.45 (0.31, 0.63) 0.45 (0.12, 1.13) 
Animal fat 2.3 (Greece) 26.8 (Luxembourg) 2.25 (1.51, 3.39) 1.46 (0.47, 3.95) 
Alcohol 60.0 (Greece) 173.9 (Germany) 0.97 (0.74, 1.24) 1.42 (0.68, 2.85) 
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In this study, the factors that were shown to have a significant association 
with European colorectal cancer mortality rates complemented other research on 
the disease (as discussed in Chapter 2). Smoking and animal fat consumption 
were shown to be strong risk factors for the disease, and fruit and vegetable 
consumption exert a protective effect on colorectal cancer mortality. Around 50% 
of the variation that was seen to exist between regions in the EU can be explained 
by taking account of these fairly crude measures of exposure to the given risk and 
protective factors. 
There was still a fairly high amount of variance evident even after adjusting 
for covariates, and modelling showed that around 68% of this is spatially 
patterned. This suggests that there are other factors not included in the study that 
are also spatially patterned that also influence colorectal cancer mortality. About 
75% of patients with colorectal cancer have sporadic disease in that there is no 
apparent evidence of having inherited the disorder (169), and the remaining 
patients have a family history suggesting a genetic contribution, common 
exposures among family members, or a combination of both. It is well established 
that gene frequency varies considerably from place to place, but usually there is 
little difference between neighbouring populations (158). Therefore, genetic 
susceptibility to the disease may be one of the underlying spatial factors showing 
a strong relationship with colorectal cancer. Some genetic mutations have been 
identified as the cause of inherited cancer risk; these mutations are estimated to 
account for only 5% to 6% of colorectal cancer cases overall and therefore it is 
likely that other undiscovered major genes and background genetic factors 
contribute to the development of colorectal cancer, along with nongenetic risk 
factors such as those previously discussed (169). It was noted that different types 
of health care provision play an important role in colorectal cancer incidence and 
mortality; this also may be a factor that is spatially patterned and could account 
for some of the unexplained spatially patterned variation. Similarly, the 
importance of country may relate to countrywide differences in screening 
practices. 
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8.4 Oesophageal Cancer Mortality 
Oesophageal cancer is one of the most deadly malignancies (58). In Europe, five-
year relative survival rates are around 10% with significant between country 
survival differences existing (170). Worldwide, cancer of the oesophagus is the 
sixth highest malignancy amongst men and ninth highest amongst woman (171). 
Cases of the disease are much more common in economically less developed 
regions and, although around 80% occur in such areas, it should still be 
approached as a public health concern in Europe. Substantial variation in 
incidence, and therefore mortality due to poor prognosis, has been observed in 
Europe; in Sweden, a low-risk country, the age adjusted incidence rates are 3.1 
and 1.0, in England and Wales 7.6 and 3.2, in Scotland 9.4 and 5.0 and in 
Calvados in France 22.3 and 1.1 per 100,000 person-years for men and woman 
respectively (172). The high between country variation within Europe and the 
very high fatality of oesophageal cancer patients emphasises the need for further 
investigation into its true distribution and the reasons for such patterns existing. 
8.4.1 Modelling Oesophageal Cancer Mortality 
As with previous cancers examined, spatial multilevel modelling techniques are 
used to examine the oesophageal cancer mortality patterns throughout eleven EU 
countries. As previously discussed, cancer of the oesophagus has been strongly 
associated with smoking and alcohol intake, and dietary factors (mainly the 
protective effects of fruit and vegetable consumption) have been shown to 
influence the patterns of the disease. Again, data that reflects different levels of 
these within the EU countries has been included in the models. The same group of 
models have been fitted as in previous sections; bum-in periods of 20,000, 
300,000 and 800,000 were needed for the null, two-level and three-level spatial 
models respectively. Further iterations of 100,000, 100,000, and 400,000 were run 
for the three models, respectively, to gain a suitable posterior distribution from 
which to sample from. It should be noted that, as with modelling colorectal 
cancer, many fewer further iterations would have sufficed for the null model. 
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8.4.2 Model Results: Oesophageal Cancer 
Tables 8.11 and 8.12 present the standardised mortality ratios and relative risks 
from fitting the 3 models. As in the previous sections the most extreme rates 
within each country are given. Table 8.13 shows the country-level SMRs and 
relative risks from fitting the three-level model. Table 8.14 gives the fIxed and 
random parameter estimates from each of the models and Table 8.15 shows 
relative risks comparing high and low levels of exposure to each of the covariates. 
The SMRs and relative risks from each model have been mapped and are 
displayed in Figures 8.9-8.12. 
8.4.2.1 Two-Level Null Model: Oesophageal Cancer 
Looking at Table 8.11 it can be seen that, based on the relative risks from the null 
model, the region with the highest risk of oesophageal cancer in the EU countries 
being examined is Copenhagen in Denmark with a very high relative risk of 4.40. 
This is followed by Nord-Pas-de-Calasis in France (RR=2.94) and Northern 
Ireland in the UK (RR=2.79) who, despite having a risk of oesophageal cancer 
much lower than Copenhagen, before taking account of any risk factors, still have 
a very high relative risk of the disease. The region with the lowest relative risk 
emerges to be the Algarve in Portugal with a risk of oesophageal cancer mortality 
70% lower than what is expected for that area. This is closely followed by 
Bornholm in Denmark (RR=0.35) and Vienna in Austria (RR=0.37). These 
figures alone display the very high variability of the disease both within and 
between countries in the EU. It is clear that regions within Denmark show the 
most variability in risks of oesophageal cancer mortality, and the country 
displaying the least amount of variability is Greece with very low relative risks 
ranging from 0.46 to 0.74. 
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8.4.2.2 Oesophageal Cancer SMRs 
Comparing the relative risks to the SMRs displayed in table 8.11 it can again be 
seen that there are many discrepancies between the two. Much research on 
variability of disease within countries and across numerous countries often looks 
solely at age and sex standardised rates. This table, along with the similar tables 
for other cancers, clearly shows that spatially modelled risks, which should be 
closer to the true distribution of the disease, often differ very much from the 'raw' 
rates emphasising that such rates should be taken with caution. 
8.4.2.3 Oesophageal Cancer Disease Maps I (SMRs and Two-Level Null Model RRs) 
Figure 8.9 clearly shows that there is much clustering of SMRs within countries in 
the EU and also displays much variation between countries. The SMRs range 
from 0 to 5.33; this is an example of another problem when using these ratios. 
Since oesophageal cancer is not as common a form of malignancy as cancers such 
as lung cancer, sometimes an area, probably with a small population, will observe 
no deaths from the disease. In this case it is a fairly small region in Finland. The 
popUlation in this area is then presented as having zero risk of mortality from 
oesophageal cancer. This is however false and the modelling approaches 
subsequently used take this into account through modelling extra-Poisson 
variation. 
Figure 8.10 shows a much different picture of the distribution of 
oesophageal cancer mortality. The relative risks before taking account of risk and 
protective factors now show more variation within most of the countries. The 
relative risks range from 0.29 to 4.40. However, there are now fewer areas of 
extreme risk. Most of the high relative risks can be found in Denmark, France and 
the UK. Most of the regions with lower risk of oesophageal cancer than expected 
before taking account of risk factors are in Greece, West Germany, Sweden and 
Finland. 
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8.4.2.4 Two-Level Full Model: Oesophageal Cancer 
Mer adjusting for risk and protective factors (Table 8.12) shows that the relative 
risks for oesophageal cancer mortality predicted from the two-level model change 
somewhat. The most extreme risk of the disease can now be found in Azores , 
Portugal; taking into account Portugal's smoking and drinking habits and average 
fruit and vegetable consumption the risk of oesophageal cancer mortality is 3.9 
times higher than expected. Centro in Portugal has the second highest risk of 
oesophageal cancer mortality (RR=1.95), followed by Zeeland in the Netherlands 
(RR=1.70). Provence-AIpes-Cote d'Azur in France has the lowest risk of 
mortality after adjusting for covariates with a relative risk of 0.63, closely 
followed by Bremen in Germany (RR=0.66; not evident from table) and Uusimaa 
in Finland (RR=0.69). Regions within Finland display the least amount of 
variability in relative risks with a range of 0.69 to 0.98. 
Some extreme regions tend to be less extreme after adding the covariates; 
the relative risks in Copenhagen and Frederiksberg (city) and Stn?)rstrom reduce 
considerably after adjusting for the covariates. Therefore, after taking into account 
the fact that people living in Denmark have low fruit and vegetable consumption 
and high animal fat and alcohol intake, they actually have a much lower risk of 
oesophageal cancer mortality. Greece's relative risks, which were very low 
previously, grew closer to unity after adding the covariates. Greece have a 
"healthy" lifestyle in general, except for their smoking habits, in that they have 
very high fruit and vegetable consumption and very low animal fat and alcohol 
consumption; after taking this into account the relative risks of oesophageal 
cancer mortality are much higher. 
8.4.2.5 Three-level Full Model: Oesophageal Cancer 
Again it can be seen that the uncertainty attached to the relative risks is much 
greater after adding a third hierarchical level to the model. Many of the 
confidence intervals more than double in size. 
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As expected, the estimates of the relative risks in countries which generally 
had high risks previously increase somewhat; this can be seen for example in 
Denmark and the Netherlands. Similarly, those countries with clustering of low 
relative risks prior to adding the higher level such as Finland and Germany now 
have lower estimates. 
8.4.2.6 Oesophageal Cancer Disease Maps II (Two and Three-Level Full Model RRs) 
Again, adding the covariates gives a different picture of oesophageal cancer 
mortality (Figure 8.11). There is still a high amount of variation within and 
between countries. However, fewer regions now have very high (RR > 1.2) risk of 
mortality, due to the risk and protective factors explaining the reasons for some 
areas having such high risks. There are twenty nine regions that remain 
oesophageal cancer 'hotspots' and possibly need further investigation into why 
they are so. Apart from those in the UK and Sweden, these tend to be small 
clusters within France, the Netherlands, Austria, Denmark and Portugal. The areas 
of low risk that stand out on the map are regions in Finland, Portugal and Greece 
and clusters within France, Germany and Sweden. Again, it may be of interest to 
look at these areas on a smaller scale to try and determine why they have such low 
oesophageal cancer mortality after taking into account country level exposures to 
the significant risk factors. 
Finally, looking at the map of the relative risks, after adding country as a 
higher level to the model (Figure 8.12), there is more clustering evident within 
countries. All the regions within some countries are very homogeneous, eg 
Germany, Finland, Netherlands and Denmark, and some countries show two or 
three distinct clusters within the country, eg France, Austria and Greece. The last 
two maps give a smoother picture of the distribution of oesophageal cancer 
mortality in the EU. 
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i Region Oi SMR CI95%(SMR) RRme.n PI95 % 8 Tirol 18 0.49 (0.29, 0.78) 0.98 (0.51, 1.86) 2 Burgenland 17 0.94 (0.54, 1.50) 0.98 (0.37, 2.65) Austria 
5 Upper Austria 38 81.1 0.47 (0.33, 0.64) 0.65 (0.36, 1.15) 10 Vienna 51 113.8 0.45 (0.33, 0.59) 0.37 
_JQ.11 ,_!.08t 85 Copenhagen * 231 43.3 5.33 (4.67, 6.07) 4.40 (1.49, 13.8) 90 Storstrom 77 20.7 3.73 (2.94, 4.66) 2.67 (1.58, 4.87) Denmark 
99 Nordjylland 159 35.2 4.51 (3.84, 5.27) 1.25 (0.52, 3.35) 91 Bornholm 16 3.7 4.34 (2.48, 7.04) 0.35 (0.14, 1.01) 
123 Kymi 11 23.1 0.48 (0.24, 0.85) 1.14 (0.50, 2.50) 
130 Vassa 20 29.9 0.67 (0.41, 1.03) 0.97 (0.44, 2.08) 
Finland 
121 Keski -Suomi 6 16.1 0.37 (0.14, 0.81) 0.70 (0.37, 1.22) 
124 La,e,ei 10 11.7 0.85 (0.41, 1.57) 0.59 (0.22, 1.50) 
138 Nord-Pas-de-Calais 526 194.5 2.70 (2.48, 2.95) 2.94 (0.63, 13.8) 
141 Franche-Comte 83 61.2 1.36 (1.08, 1.68) 1.87 (0.99, 3.10) 
France 
151 Provence-Alpes-Cote d'Azur 271 271.5 1.00 (0.88, 1.12) 0.77 (0.49, 1.20) 
145 Aguitaine 215 178.9 1.20 (1.05, 1.37) 0.74 (0.37, 1.59) 
75 Baden-Wurttemberg 431 641.1 0.67 (0.61, 0.74) 1.15 (0.62, 2.03) 
78 Berlin 136 219.2 0.62 (0.52, 0.73) 1.12 (0.22, 5.36) 
Germany 
83 Saxony-Anhalt 106 179.8 0.59 (0.48, 0.71) 0.67 (0.37, 1.20) 
69 Hamburg 96 123.0 0.78 (0.63, 0.95) 0.51 (0.21, 1.232 
159 Macedonia West 8 18.2 0.44 (0.19, 0.87) 0.74 (0.33, 1.63) 
167 Aegean South 7 17.0 0.41 (0.16, 0.85) 0.72 (0.36, 1.43) 
Greece 
168 Segean North 3 18.7 0.16 (0.03, 0.47) 0.50 (0.25, 0.94) 
169 Crete 5 41.5 0.12 (0.04, 0.282 0.46 (0.14, 1.342 
238 Luxembourg 20 24.7 0.81 {0.49, 1.25} 0.90 {O.4l, 1.85} 
252 Zeeland 27 25.6 1.05 (0.69, 1.53) 1.46 (0.28, 8.02) 
243 Drenthe 22 29.5 0.75 (0.47, 1.13) 1.26 (0.64, 2.41) 
Netherlands 
241 Groningen 36 36.4 0.99 (0.69, 1.37) 0.75 (0.35, 1.68) 
246 Flevoland 5 10.9 0.46 (0.15, 1.07) 0.73 (0.35, 1.45) 
326 Azores 7 13.1 0.53 (0.21, 1.10) 1.83 (0.84, 4.03) 
322 Centro 81 121.8 0.67 (0.53, 0.83) 1.03 (0.75, 1.41) 
Portugal 
327 Madeira 19 12.8 1.49 (0.89, 2.32) 0.48 (0.17, 1.20) 
325 Algarve 9 26.0 0.35 (0.16, 0.66) 0.30 (0.07, 1.14) 
460 Malmohus 36 61.1 0.59 (0.41, 0.82) 2.63 (0.87, 7.50) 
458 Kristianstad 12 24.4 0.49 (0.25, 0.86) 1.14 (0.64, 1.92) 
Sweden 
469 Vasterbotten 9 19.1 0.47 (0.21, 0.89) 0.52 (0.24, 1.04) 
455 Jonko,eing 8 25.1 0.32 (0.14, 0.63} 0.51 (0.28, 0.87} 
565 Northern Ireland 126 90.3 1.40 (1.16, 1.66) 2.79 (0.63, 11.8) 
555 Merseyside 185 97.1 1.91 (1.64, 2.20) 1.64 (0.79, 3.32) 
UK 
529 Berkshire 48 45.0 1.07 (0.79, 1.41) 0.90 (0.55, 1.41) 
563 West Glamorgan 33 27.1 1.22 (0.84, 1.712 0.82 (0.41 , 1.57) 
*Copenbagen and Frederiksberg (city) 
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Figure 8.9 Map of oesophageal cancer SMRs 
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Figure 8.10 Map of oesophageal cancer RRs from null two-level model 
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Table 8.12 Relative risks (from two-and three-level full models) of mortality from oesophageal 
cancer for each countr extreme rates iven, ordered b decreasin RR from three-level model 
i Country Region 0; E; RRmean(2) PI95 %(2) RRmean(3) PI95 %(3) 7 Styria 53 77.4 1.41 (0.98, 2.09) 1.06 (0.40, 3.07) 2 Burgenland 17 18.2 1.17 (0.60, 2.32) 1.00 (0.31, 3.54) Austria 
5 Upper Austria 38 81.1 0.90 (0.58, 1.38) 0.82 (0.30. 2.42) 10 UQQer Austria 51 113.8 0.76 (0.38, 1.51) 0.73 (0.~2,~A2) 85 Copenhagen * 231 43.3 1.63 (0.71, 3.82) 1.85 (0.38, 9.96) 90 Storstrom 77 20.7 1.59 (1.02, 2.50) 1.82 (0.51, 7.09) Denmark 
87 Frederiksborg 78 22.0 1.08 (0.61, 1.87) 1.36 (0.35, 5.64) 93 Sondeg,Ylland 42 17.8 0.96 (0.65, 1.41) 1.30 (0.37, 4.81) 119 Ahvenanmaa 0 1.8 0.98 (0.62, 1.53) 0.66 (0.22, 1.86) 127 Pohjois-Karjala 14 11.7 0.89 (0.55, 1.42) 0.64 (0.21, 1.84) 
Finland 
129 Uusimaa 41 70.8 0.69 (0.45, 1.03) 0.57 (0.19, 1.53) 
121 Keski-Suomi 6 16.1 0.72 (0.45, 1.09) 0.56 (0.19, 1.52) 
138 Nord - Pas-de-Calais 526 194.5 1.51 (0.56, 4.17) 1.51 (0.39, 6.42) 
136 Basse-Normandie 180 78.3 1.41 (0.97, 2.11) 1.45 (0.57, 3.88) 
France 
152 Corsica 9 16.1 0.71 (0.29, 1.73) 0.74 (0.19, 2.90) 
151 Provence-Alpes-Cote d'Azur 271 271.5 0.63 (0.42, 0.92) 0.71 (0.27, 1.90) 
74 Rheinland-Palatinate 215 262.5 0.99 (0.71, 1.37) 0.75 (0.29, 2.18) 
70 Lower Saxony 378 514.7 0.97 (0.79, 1.19) 0.73 (0.31, 1.96) 
Germany 
84 Thuringen 76 160.5 0.76 (0.52, 1.08) 0.54 (0.20, 1.61) 
82 Saxon,Y 140 318.4 0.71 (0.46, 1.06) 0.53 (0.19, 1.65) 
157 Macedonia East and Thrace 16 37.3 1.06 (0.55, 2.07) 1.05 (0.18, 5.64) 
158 Macedonia Central 33 105.0 1.07 (0.63, 1.81) 1.04 (0.20, 5.02) 
Greece 
168 Aegean North 3 18.7 0.77 (0.47 , 1.24) 0.80 (0.15, 3.71) 
169 Crete 5 41.5 0.74 (0.36, 1.50) 0.77 (0.13, 4.10) 
238 Luxembourg 20 24.7 1.05 (0.61, 1.82) 1.20 (0.35, 4.26) 
252 Zeeland 27 25.6 1.70 (0.62, 4.87) 2.04 (0.42, 12.3) 
249 Utrecht 59 59.9 1.30 (0.80, 2.17) 1.76 (0.52, 7.10) 
Netherlands 
246 Flevoland 5 10.9 1.04 (0.60, 1.77) 1.44 (0.41, 5.97) 
248 Limburg 35 69.2 0.84 (0.52, 1.33) 1.30 (0.38, 5.18) 
326 Azores 7 13.1 3.90 (1.69, 9.33) 1.95 (0.34, 9.34) 
322 Centro 81 121.8 1.85 (1.29, 2.78) 1.39 (0.34, 4.52) 
Portugal 
324 Alentejo 21 44.2 1.14 (0.75, 1.73) 0.93 (0.22, 3.04) 
325 Algarve 9 26.0 0.76 (0.27, 2.03) 0.82 (0.13, 3.97) 
449 Blekinge 15 12.6 1.21 (0.69, 2.18) 1.12 (0.26, 4.29) 
466 Stockholm 80 115.8 1.13 (0.65, 1.98) 1.10 (0.26, 4.08) 
Sweden 
0.82 (0.21 , 2.73) 463 Ostergotland 8 31.8 0.78 (0.50, 1.17) 
455 Jonkoping 8 25.1 0.73 (0.47, 1.09) 0.81 (0.21, 2.70} 
565 Northern Ireland 126 90.3 1.51 (0.58, 3.95) 1.32 (0.29, 5.77) 
553 Greater Manchester 326 168.2 1.28 (0.87, 1.89) 1.25 (0.43, 3.43) 
UK 
529 Berkshire 48 45.0 0.81 (0.56, 1.14) 0.86 (0.30, 2.33) 
563 West Glamorgan 33 27.1 0.77 (0.46, 1.24) 0.85 (0.26, 2.56) 
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Figure 8.11 Map of oesophageal cancer RRs from full two-level model 
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Figure 8.12 Map of oesophageal cancer RRs from full three-level model 
• 1.20 to 2.04 
• 1. 1 0 to 1. 1 9 
• 0.90 to 1.09 
• 0.80 to 0.89 
• 0.53 to 0.79 
'. ,/ " 
.. ( 
•• 
Lnapler ?5 Specific Cancers 
8.4.2.7 Country Level Oesophageal Cancer Results 
Comparing the country level relative risks obtained from fitting the full three-level 
multilevel model (Table 8.13) it can be seen that the Netherlands and Denmark 
have by far the highest risks of oesophageal cancer mortality (RR of 1.55 and 1.50 
respectively). The country with the overall lowest relative risk is, as expected, 
Finland (RR=0.62), followed by Germany (RR= 0.67). 
Table 8.13 Relative risks of mortality from oesophageal cancer at country level 
Country OJ Ej SMR CI95 % (SMR) RRmean PI95 % 
Austria 255 506.6 0.50 (0.44, 0.57) 0.88 (0.45, 1.84) 
Germany 3690 5316.7 0.69 (0.67, 0.72) 0.67 (0.34, 1.52) 
Denmark 1423 365.2 3.90 (3.70, 4.10) 1.50 (0.60, 4.05) 
Finland 192 314.7 0.61 (0.53, 0.70) 0.62 (0.29, 1.20) 
France 4835 3203.9 1.51 (1.47, 1.55) 1.01 (0.54, 1.96) 
Greece 181 690.3 0.26 (0.23, 0.30) 0.91 (0.26, 2.91) 
Luxembourg 20 24.7 0.81 (0.49, 1.25) 1.14 (0.51, 2.68) 
Netherlands 773 931.4 0.83 (0.77, 0.89) 1.55 (0.67, 4.27) 
Portugal 460 611.1 0.75 (0.69, 0.82) 1.16 (0.40, 2.67) 
Sweden 346 671.8 0.52 (0.46, 0.57) 0.96 (0.35, 2.35) 
UK 6071 3957.1 1.53 (1.50, 1.57) 1.02 (0.47, 2.12) 
8.4.2.8 Oesophageal Cancer Parameter Estimates 
The fixed parameter estimates from the full two-level model (Table 8.14) show 
that the country level covariates that are significantly affecting oesophageal 
cancer mortality whilst taking the other variables into account are smoking and 
fruit, vegetable and animal fat consumption. The estimate for smoking suggests 
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that every increase of 100 cigarettes smoked per person per year is associated with 
an increase in the risk of oesophageal cancer mortality of about 17% 
(RR=exp{0.16}=1.17}. An increase in fruit consumption of 10 kg per person per 
year reduces the risk of oesophageal cancer by 28% (RR=0.72). A similar increase 
in vegetable consumption results in a relative risk of 0.63 and in animal fat 
consumption gives a relative risk of 2.16. 
The random part of the null model shows that the spatial variance, a
v 
2, after 
taking the average number of nearest neighbours (n = 4.128) into account is 
0.180, resulting in a total variance of 0.228. Therefore, 79% of the total variance 
in oesophageal cancer mortality, before taking risk factors into account, arises 
from spatial effects. The total variance from the full two-level model is 0.078. 
Therefore, taking into account the measures of country level exposure to cigarette 
smoking and fruit, vegetable and animal fat consumption has reduced the overall 
variation in oesophageal cancer mortality by 66%. Sixty four percent of this 
remaining variation can then be attributed to spatial patterning in the data. 
Looking at the three-level model, it can be seen-that the parameter estimate 
for fruit consumption is the only variable that remains significant. After adding 
country as a level to the hierarchical model it can again be seen that there is more 
error attached to all the fixed parameter estimates with the posterior credible 
intervals being around three times wider in most cases. The intervals for the 
random parameters actually reduce in size; however, a large amount of the 
variation is now attributable to the third level, country. Partitioning the variance 
so that it includes a/ results in the total variance increasing to 0.353. The 
majority of the variance from this model is attributable to the differences between 
countries. 
8.4.2.8 Oesophageal Cancer Risk Factor Effect Size 
Concentrating on the significant parameter estimate relative risks from the two-
level model, Table 8.15, shows that smoking on average the same amount of 
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cigarettes as in Greece leads to a relative risk that is 26 times as high than if 
smoking was on the same level as in Sweden. Consuming an equivalent average 
amount of fruit as Greece reduces the risk of oesophageal cancer mortality by 
89% compared to the UK. Vegetable consumption on the same level as in Greece 
has a risk of mortality that is 67% lower than if consumption was on the same 
level as in Finland. Finally, animal fat consumption on the same level as in 
Luxembourg leads to a relative risk of oesophageal cancer 6.6 times what it would 
be if consumption was similar to Greece. 
8.4.3 Oesophageal Cancer Discussion 
Mortality patterns of oesophageal cancer are similar to other cancers in that it is 
clear from disease maps and estimates of relative risks that much variation exists 
both within and between countries in the EU. Some of this variation can be 
accounted for by taking into account country level risk and protective factors for 
the disease. This changes the pattern of mortality: it smoothes the distribution of 
the disease more and makes small clusters of extreme risks more evident. Mer 
such modelling, the most prominent areas with very low risk of the disease are 
South France, West Germany and some Scandinavian regions. Clusters of high 
risk that are clearly visible from this smoothed map are in North Portugal, North 
France, West Denmark, South Austria, the Netherlands and a few UK regions. 
It may be of public health interest to investigate why some regions in the EU 
remain as oesophageal 'hotspots' after accounting for exposure to known risk and 
protective factors. It could simply be that there are variations in levels of these 
factors within countries; this has not been taken into account, due to data 
availability, and may reflect the within country variations. Levels of exposure to 
the various factors would have to be examined at the regional level, at least, 
within these countries, and, if particularly high or low levels of exposure exist, 
specific countries may wish to aim public health promotions, specific to this 
disease, in these areas. 
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Table 8.14 Parameter estimates from modelling oesophageal cancer mortality rates 
Parameters Null 2 level Model Full 2 level Model Full 3 level Model 
Estimate Credible Interval Estimate Credible Interval Estimate Credible Interval 
Po 3.87 (3.71 , 4.03) 3.04 (2.31, 3.78) 3.34 (0.28 , 6.98) 
PI (smoke) 0.0016 (0.0011, 0.0021) 0.0010 (-0.0008 , 0.0020) 
P2 (fruit) -0.0326 (-0.0378, -0.0276) -0.0267 (-0.0444 , -0.0054) 
P3 (veg) -0.0046 (-0.0072, -0.0021) -0.0022 (-0.0095 , 0.0070) 
P4 (animal) 0.0768 (0.0495, 0.1058) 0.0481 (-0.0613 , 0.1342) 
Ps (alcohol) -0.0015 (-0.0052, 0.0022) 0.0045 (-0.0090 , 0.0154) 
P6 (gdp) 
(Ju2 0.0475 (0.0171 , 0.1007) 0.0278 (0.0124, 0.0478) 0.0166 (0.0072 , 0.0290) 
(Juv 0.1659 (0.0970 , 0.2530) 0.0675 (0.0413, 0.1012) 0.0298 (0.0150 , 0.0491) 
(Jv 2 0.7436 (0.5046 , 1.0130) 0.2052 (0.1292, 0.3065) 0.0890 (0.0465 , 0.1483) 
(J2 y 0.3145 (0.0618 , 1.0790) 
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Table 8.15 Effect size of covariates from 2 and 3 level full oesophageal cancer models 
2 level model 3 level model 
Covariate Min (country) Max (country) 
RR 95% CI RR 95% CI 
Smoking 1550 (Sweden) 3590 (Greece) 26.10 (10.19, 69.49) 7.06 (0.20, 62.62) 
Fruit 74.5 (UK) 142.6 (Greece) 0.11 (0.08, 0.15) 0.16 (0.05, 0.69) 
Vegetable 58.8 (Finland) 300.4 (Greece) 0.33 (0.17, 0.61) 0.59 (0.10, 5.38) 
Animal fat 2.3 (Greece) 26.8 (Luxembourg) 6.57 (3.36, 13.36) 3.25 (0.22, 26.79) 
Alcohol 60.0 (Greece) 173.9 (Germany) 0.84 (0.55, 1.28) 1.66 (0.36, 5.80) 
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Some areas stood out visually on the disease map before adjusting for the 
various covariates, but after doing so the relative risks shrunk closer to unity. 
Therefore the risk of oesophageal cancer in these areas is affected by the 
significant risk factors in the modelling. These regions or clusters are also areas of 
public health concern; they may benefit further from health promotion in the areas 
of smoking and healthy eating. 
There is reasonable evidence that screening would result in no (or minimal) 
decrease in mortality from oesophageal cancer in the US population (173). After 
examining European survival rates, Faivre et al (170) concluded that stage of 
diagnosis and different types of surgery are likely to improve survival. However, 
there is no evidence of such health provisions affecting mortality rates, and 
therefore will not be affecting variations in European rates. This suggests that, if 
attempting to reduce oesophageal cancer mortality in 'hotspot' areas, prevention 
should be the focus. 
Obesity has emerged as a major risk factor for this disease with a positive 
association being shown to exist between BMI or relative weight and oesophageal 
cancer (59-63). Due to the unavailability of consistent obesity or BMI data across 
the various populations, this risk factor was not included in modelling. Hopefully 
the dietary factors will reflect levels of obesity in some manner. However, the 
unaccounted for BMI levels in the populations may explain some of the 
oesophageal cancer mortality 'hotspots'. 
It is somewhat surprising that alcohol intake is not a significant risk factor, 
at the population level, for oesophageal cancer mortality in the EU. As previously 
discussed (Chapter 2), the positive association between alcohol use and the risk of 
oesophageal cancer is well established, and many studies have shown it to be a 
strong risk factor. This suggests that alcohol levels within countries would be 
associated with the disease rates and this again may account for the clusters of 
very high (or low) rates. 
It was observed that the factors that have a significant positive association 
with European oesophageal cancer mortality rates were smoking and animal fat 
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consumption. The risk of dying from the disease was much higher in areas with 
high smoking level compared to low; the risk factor, 26.1, demonstrates the huge 
burden smoking has on this disease. Animal fat consumption also increases the 
risk of oesophageal cancer by a great amount and should be considered as an area 
on which to focus if aiming for prevention of the disease. As with all other 
cancers examined at the population level, fruit and vegetable consumption has a 
strong protective effect against this malignancy. Taking account of the country 
level measures of exposure to these diseases explained about 66% of the variation 
that existed between regions in the ED. 
The disease maps and model results showed that there was still a high 
amount of variation after adjusting for covariates and that around 64% of this is 
spatially patterned. The unexplained spatially-patterned variation again suggests 
there are other spatially-patterned risk factors for oesophageal cancer. The factors 
that may be causing the disease 'hotspots' could also be spatially patterned and 
account for some of this variation. Since gene frequency is often spatially 
patterned (158) it is not unreasonable to consider this flS an unaccounted for factor 
that is affecting the disease. It has been reported that there is apparent familial 
clustering of oesophageal cancer patients (174, 175) but it is unclear whether this 
represents a common exposure to environmental factors or a genetic 
predisposition. There is only one, rare, recognised genetic abnormality that 
predisposes patients to a type of cancer of the oesophagus (176). However, further 
research is needed in this area and it cannot be ruled out as a spatially patterned 
factor affecting the disease. 
8.5 Comparing Cancer Patterns 
To compare cancer mortality patterns across the ED, disease maps were examined 
and have proved a very useful tool for analysing the spatial patterns of cancer 
mortality throughout Europe. The maps provide a clear picture of the estimated 
risk of the specific cancers across the regions of interest. However, mapping 
estimates from different models can provide different pictures and interpretations 
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of the distribution of the disease. Maps were produced of the risk of the disease 
without adjusting for any covariates. These provide a true reflection of cancer 
rates across the EU and one can be fairly confident that areas which stand out as 
having extremely high rates are actually disease 'hotspots'. Such maps do not give 
explanations as to why areas have extremely high (or low) rates of the disease but 
do indicate where further public health intervention may be required. In an 
attempt to explain such patterning of the disease, relative risks were modelled 
after adjusting for various covariates that were thought to be influencing the rates 
of the disease. A comparison across both maps would show if the risk in areas that 
were previously standing out as 'hotspots' has reduced. If so, this would suggest 
the covariate( s) have explained these high rates, eg if smoking is a strong 
significant covariate in the model this would suggest the high rates of, say, lung 
cancer mortality can be explained by the country's smoking levels. This would 
then give scope to introduce public health policy on reducing smoking in that 
area. Areas that remain as hotspots after adjusting for risk factors gives an added 
piece of information in that some other factor, not accounted for in the modelling, 
is causing these areas of high risk. The region could perhaps have higher (or 
lower) levels of exposure to the covariates than the country on average or perhaps 
some other unaccounted for factor is causing the hotspot such as a social or 
lifestyle factor that has not been taken into account or an area of point-source 
pollution. Disease maps after adjusting for covariates may be useful to public 
health specialists who may be able to identify or recognise the patterns as those 
relating to other covariates. Overall, when modelling we wish to compare rates 
across regions allowing for varying age and sex structure of the populations as it 
is known these are affecting cancer mortality. However, there is obviously no 
wish to change the age and sex structure of a population to influence these rates. 
In contrast, it is often of public health interest to change the levels of other factors 
which vary across regions and influence the mortality rates. For this reason, it is 
appropriate to always standardise for age and sex but fit both unadjusted and 
adjusted models with regards to other factors such as diet and smoking. This 
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allows comparison and interpretation of various disease maps as discussed above 
and hopefully determines where and what public health interventions are needed. 
The three cancers examined in this chapter are different in many respects. 
The number of deaths within the eleven EU countries varies substantially between 
the malignancies; the total number of lung cancer deaths was 123,253 in 1991, 
colorectal cancer deaths totalled 80,777 and oesophageal cancer deaths totalled 
18,246. 
The risk/protective factors which were identified in this study as 
significantly affecting each of the cancers were smoking, fruit consumption and 
vegetable consumption, with smoking, as expected, being a risk factor and fruit 
and vegetable consumption exerting protective effects against the diseases. 
Animal fat consumption was shown to be a significant risk factor for colorectal 
and oesophageal cancer mortality. The effect sizes of these risk and protective 
factors differed between the three cancer types. Smoking, as expected, was a 
strong risk factor for each group of mortalities. However, the highest risk from 
smoking was observed with oesophageal cancer, which had a relative risk three 
times as high as the risk associated with lung cancer. The associations fruit 
consumption had with lung and colorectal cancer mortality rates were similar; this 
was also the case for vegetable consumption. Again, oesophageal cancer had the 
strongest relationship with both of these risk factors. Consumption of animal fats 
increased the risk of both colorectal and oesophageal cancer mortality, and again 
the association with the latter was the strongest. 
The covariates that were found to be associated with the specific cancers do, 
in general, tie in with existing literature on cancer mortality risk factors. However, 
as discussed in Chapter 2, several epidemiological studies have shown a link 
between oesophageal cancer and alcohol intake, but this was not found in this 
study. This could be due to the variable being used to account for alcohol intake 
not being the most appropriate, or the fact that the variable is at country level. A 
more specific type of alcohol, instead of all alcohols, or perhaps alcohol data 
which is of a lower form of aggregation would have to be examined to show 
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evidence of a significant effect. Other examples of strong associations that have 
been shown to exist in literature but are not apparent in this study are the link 
between socio-economic status and lung cancer and animal fat consumption and 
colorectal cancer. Again, more appropriate types of data may be needed to show 
such effects. On the other hand, we found an association between colorectal 
cancer mortality and smoking levels, but there is inconsistent evidence of an 
association in existing literature. It may also be useful to include other risk factors 
that were mentioned in Chapter 2 such as consumption levels of fish or fish oil 
which has been shown to have a protective effect on colorectal cancer. 
The variability across relative risks of cancer mortality also varied from site 
to site; the relative risks after taking into account the relevant risk and protective 
factors ranged from 0.70 to 1.48 for lung cancer, with an inter-quartile range of 
0.94 to 1.07, colorectal cancer was similar, ranging from 0.50 to 1.49 (inter-
quartile range 0.95 - 1.07), and oesophageal cancer ranged from 0.63 to 3.9 (inter-
quartile range 0.88 -1.14). Similar results were observed across cancer sites when 
examining the random part of the models, with the total variation in the specific 
cancer mortality relative risks being reduced by a half or more through adjusting 
for risk and protective factors. Of the remaining variation, around 60% is 
attributable to the spatial patterning of each of the diseases. 
Examining cancer mortality from all sites together (Chapter 5) gave relative 
risks, after adjusting for risk factors, which range from 0.85 to 1.29 (inter-quartile 
range 0.95 - 1.05). The risk factors shown to significantly affect all cancer 
mortality when comparing areas of high and low exposure were smoking 
(RR=2.99) and fruit (RR=0.58), vegetable (RR=0.72) and animal fat (RR=2.03) 
consumption. Modelling all cancer mortality together showed that there was a 
65% reduction in the total variation of relative risks after adjusting for the risk and 
protective factors. It also showed that 85% of the remaining variation was due to 
spatial effects. Despite the similarities these results have with those predicted 
from modelling the three specific cancers, grouping all cancers together is 
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concealing different patterns in mortality from individual cancer sites and 
different relationships these have with risk factors. 
Although similarities were observed, there is evidence of differences III 
European patterns of cancer mortality at the different cancer sites, suggesting that 
it makes sense to examine mortality patterns separately for specific malignancies. 
Examining the spatial mortality patterns for all cancers together is informative and 
is used as a way of determining cancer burden (177). However, most recent 
research in European cancer mortality also examines specific cancer mortality (2, 
10, 148, 149, 152, 160, 178-181). These studies complement the work carried out 
in this chapter by suggesting that examining specific cancer mortality allows the 
burden of cancer to be delineated in more detail. 
A final similarity that was observed across cancers was that Finland 
consistently had low risks of the disease. Effective measures were adopted on 
tobacco as well as on diet in Finland, and it has shown that total cancer mortality 
declined by over 40% in males aged 55 to 64 over a forty-year period up until 
1994 (182). This country is considered to have the most effective overall 
programmes to reduce cancer mortality (179) and indicates the importance and 
scope for intervention on cancer control on population level in the EU. Much of 
the European cancer mortality observed here is, at least in theory, highly 
preventable with some regions, previously mentioned, reqUlnng urgent 
preventative intervention on tobacco and diet modification. 
Although the main purpose of this chapter was to explore the spatial 
distribution of cancer mortality in the EU, examining the various datasets 
provided an opportunity to explore further the effects of introducing a third higher 
level to the spatial model. Adding country as a higher level (random effect) takes 
into account the fact that areas within a country are more likely to be 
homogeneous than regions from different countries. The fact that regions are not 
independent has been taken into account through the spatial part of the model but 
including a higher country level takes account of the fact that there may be added 
differences at the borders where neighbours may be more heterogeneous. This 
cnapler l5 Specific Cancers 
would probably be due to political and cultural differences and differences 
between health care systems across the nations. However, the disease maps from 
such models tended to over-smooth within countries and over-emphasize 
differences between countries and therefore appear to be useful for examining 
country level differences but are of limited use for determining the effect risk 
factors have on cancer rates in these countries and for providing smooth disease 
maps that enable cancer 'hotspots' to be identified. 
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9 Discussion 
9.1 Conclusions 
The general aim of this thesis is to develop existing spatial modelling methods to 
provide an accurate account of the spatial patterning of cancer mortality across 
Europe. This task was effectively split into two parts; an ecological analysis on 
the burden of cancer mortality in Europe and the development of spatial 
multilevel models to analyse regional mortality data across various countries. 
The ecological analysis initially involved identifying risk and protective 
factors for specific cancers and obtaining data that reflect the different levels of 
these factors. Examining the fixed parameter estimates from modelling these data 
allowed the relationship between the geographical variation of cancer mortality 
and the various explanatory covariates to be described. The random parameter 
estimates allowed the assessment of the contribution spatial factors have upon the 
disease. Relative risks of mortality were predicted from the models and used to 
provide smoothed disease maps of the risk of all cancer mortality and three 
specific cancer mortalities. Various maps were examined for each group of 
cancers enabling an overall assessment of the true underlying distribution of the 
disease. Variability within and between countries was evident across Europe for 
each of the cancer groups examined. Much of this variation could be accounted 
for by risk factors such as smoking and diet, which had strong yet differing effects 
on each of the cancer groups. Accounting for spatial effects was also shown to 
reduce variation in cancer mortality substantially across the EU. Cancer 'hotspots' 
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were identified and we provided evidence that urgent preventative public health 
intervention is required in many European regions. 
Developing the spatial multilevel model involved extending work by 
Langford et al (6) in which they proposed a model with correlated random effects. 
This model had been fitted using Empirical Bayes procedures and was further 
explored in this thesis by fitting it to cancer mortality data across various 
countries. Using iterative generalised least squares procedures to fit this model 
had its disadvantages, one being the restrictions on adding further hierarchical 
levels. To overcome this problem the model was further developed using Markov 
Chain Monte Carlo (MCMC) procedures and overall resulted in a more flexible 
set of disease mapping models. Using this fully Bayesian approach gave the 
means to extend the model by adding a higher geographical level and the effects 
of doing so were explored; there was the suggestion that, depending on the 
specific reason for producing the disease map, adding a higher level to the 
multilevel model, such as country, often proved not useful. The models proposed 
in this thesis were compared to existing spatial models that can be implemented in 
the software MlwiN; the multiple-membership multiple-classification (MMMC) 
model and the conditional autoregressive (CAR) model. Overall the fully 
Bayesian spatial multilevel model proved to be more accurate and efficient at 
disease-risk estimation. 
9.2 Limitations and Further Work 
There are limitations to this study in the form of data available to carry out the 
ecological analysis, methods used to describe cancer mortality risk and further 
modelling issues that were beyond the scope of this PhD. These are discussed 
below with indications of areas where further work would be of interest. 
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9.2.1 Limitations with Data and Methods 
There are some disadvantages to this type of ecological study even before any 
analysis has been carried out. All of the data are in the form of aggregate 
information, but an ideal situation would be to have data available at the 
individual level where, obviously, much more information would be available. 
However, this study was carried out on such a large scale geographically that 
obtaining this type of information is virtually impossible. The conclusions that 
have been drawn throughout the thesis on the burden of cancer mortality come 
under the risk of being affected by ecological fallacy whereby observations based 
on aggregate data are improperly inferred to an individual level. For these reasons 
it is important to make it clear that conclusions referring to the risk and 
distribution of cancer are being made about populations, mainly at a regional 
level. 
Due to data availability, most of the risk factor data were only available at 
country level. This high level of aggregation is again not ideal due to the loss of 
information. However, it was shown that these fairly crude measures of exposure 
to the various risk factors are very useful, as they were shown to be significant 
predictors of the disease and they helped to explain a high amount of variation in 
all of the models explored. Once again care should be taken when interpreting the 
results from modelling the data; the risk factors tend to explain the differences 
between the countries and variation that remains between regions within countries 
could reflect the regional differences in these risk factors. 
Another limitation was choosing which time period most closely reflects 
population's accumulated lifetime exposures to the risk factors. The time period 
chosen, approximately the same period as for the mortality data, was perhaps not 
ideal and it would be of interest to explore the effects of using different time 
, 
periods or perhaps more than one time period. 
There are issues concerning the quality of the mortality, population and risk 
factor data. When collecting health data over such a large geographical area, 
recording and handling of the data varies between countries and inevitably this 
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results in variations in data availability and accuracy. Organisations like WHO 
carry out vigorous data checking procedures to minimise poor data quality but, 
since we are relying on many sources of data collection, these problems will exist. 
In this study one should remain aware that conclusions being drawn are fairly 
crude and tend to be used as an exploratory tool and for the generation of 
hypotheses about individual risks from the disease. 
As discussed above, missing data are also inevitable in this type of study. 
From the initial mortality and population data discussed in Chapter 3 it was seen 
that data availability is very poor for eastern European countries. This was the 
main motivation for concentrating on western European countries, where data are 
much more abundant and more countries have data available at the lowest level of 
aggregation. However, missing data were still a problem when examining cancer 
mortality in the EU as three countries have missing data for the time point of 
interest. For the EU, population and mortality data tends to be available for at 
least two of the four time points, and further work incorporating time in the 
modelling would help to overcome some problems. Extending the models to 
examine spatiotemporal effects would use more of the information that is 
available and provide disease maps of the whole of the EU. Perhaps more 
importantly, considering an analysis with an added temporal dimension would 
allow the examination of the change in disease distribution and covariate effects 
over time. In theory, this could be easily implemented: the spatial multilevel 
model could be extended by adding a further lower level and modelling the 
temporal trend as a random effect. A further time/year level would enable the 
inclusion of up to four years of data per area. 
Examining only the EU data means much of the European mortality data is 
being discarded. It would be of interest to explore cancer patterns for the countries 
farther east in Europe. An initial analysis looking at Europe as a whole was 
carried out and briefly discussed in Chapter 5, and it emerged that the countries in 
Eastern and Western Europe behaved very differently in terms of distribution of 
the disease risk. This along with the fact that eastern Europeans have vcrv 
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different lifestyle habits to those in the EU suggests that it does not make sense to 
model all of the countries together. It would make sense to carry out separate 
analyses and compare the results for the different groups of countries. To do so 
one would have to consider where to split Europe. Choosing to examine the EU 
was simply based on geopolitical borders. However, this does not necessarily 
mean that comparing the EU with eastern and central Europe would be the best 
statistical comparison. An initial analysis would need to be carried out to 
determine which countries are the most similar in terms of cancer risk and 
lifestyle habits and comparison groups could be drawn from these. 
To provide a good overview of the spatial distribution of cancer mortality, 
all cancers grouped together were modelled and also two of the most common 
cancers, lung and colorectal, were examined along with oesophageal cancer which 
is one of those most deadly malignancies. However, there are other cancers that 
add to the burden of cancer mortality in Europe. Four other groups of malignant 
neoplasms are available from the WHO dataset, and examining the spatial patterns 
of these would provide a more comprehensive overv.iew of the European cancer 
risk. There are also other causes of death available from the WHO mortality 
dataset which pose a burden on health in Europe. Applying the same models to 
different causes of mortality would describe the distribution of risk from these 
other diseases and their relationships with certain risk factors, and would provide 
information on where further public health interventions may be required. A 
further extension to the spatial multilevel model is to predict more than one 
outcome simultaneously (102) and potentially, with the availability of various 
mortality data, multiple causes of death could be examined. 
As discussed in Chapter 8 there is abundant research suggesting that certain 
genes or gene mutations predispose people to cancers and with deadly cancers, 
such as lung or oesophageal, genetic predisposition is therefore related to 
mortality rates of the disease. There is much ongoing research into pinpointing 
specific genes that are related to specific cancers, and there is some existing 
research that suggests that gene frequencies have spatial patterning. However, 
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more work is needed with regards to the geographical patterning of the gene 
frequencies related to cancers and their interactions with the environment and 
lifestyles of popUlations. 
9.2.2 Modelling Issues 
The addition of further hierarchical levels to the initial spatial multilevel model 
was explored using an MCMC framework. Adding a higher geographical level 
takes account of the fact that regions within the same country are more 
homogeneous than regions in different countries. Multilevel modelling aims to 
produce more accurate estimates by taking account of the non-independence at the 
lower levels. However, in this case regional non-independence has already been 
taken account of by fitting the spatial model, and when country level is added it 
appears to cause further uncertainty in the residuals and parameter estimates. This 
was evident in each model that was fitted, but further exploration into why this is 
happening would be useful to determine when adding the higher geographical 
level is appropriate. It appears from this analysis that it may only be useful for 
determining country effects and in fact not useful for mapping the distribution of 
the disease. 
The deviance information criterion (DIC) was used to aid model selection 
but gives little help in assessing how well the models fitted the data. Residuals 
were examined to informally assess overall goodness-of-fit but there is a lack of 
literature on measuring model fit for complex multilevel models. There is scope to 
carry out further work on this set of models to determine a method of assessing 
model fit. 
It would be of interest to extend this study and carry out work that examines 
the effect different prior distributions have on model fit. Several different prior 
distributions for the variance parameters would have to be identified and fitted to 
the spatial multilevel model that was chosen as the 'best' disease mapping model. 
Various sets of priors could be fitted to the datasets already examined and 
parameter estimates and coverage of confidence intervals could then be compared. 
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Alternatively, a method that may be more informative is a simulation study. This 
would involve simulating many datasets from the same distributions and using 
each set of chosen priors, fit the model to these datasets. For each set of priors, 
parameter estimates are obtained by finding the mean values over the numerous 
simulations; these can then be compared on the basis of how biased the methods 
are and how well the confidence intervals they produce cover the data. This 
method has the advantage of the true 'answers' being known. 
A final limitation to the modelling methods is the length of time it takes to 
fit the spatial multilevel model with correlated random effects using MCMC 
methods. The number of iterations and time required to run a suitable number of 
simulations were very high. This situation is obviously not ideal, especially as 
there is scope to expand the data to include more countries and timepoints which 
would result in slowing the process down further. The model is complex and 
inevitably will take numerous MCMC runs to fit. However, it would be of interest 
to examine the effect different prior distributions have on modelling time 
required. This could be monitored whilst carrying out the simulation study 
discussed above. 
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Appendix 1: WHO European Region 
AI.I EU members 
EU Member States 
Previous to October 2004 After October 2004 
Austria 
Belguim 
Denmark 
Finland 
France 
Germany 
Greece 
Ireland 
Italy 
Luxembourg 
Netherlands 
Portugal 
Spain 
Sweden 
UK 
Cyprus 
Czech Republic 
Estonia 
Hungary 
Latvia 
Lithuania 
Malta 
Poland 
Slovakia 
Slovenia 
Appendix 1 
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A1.2 Region names for codes given in Tables 3.2 - 3.5 
Country Region name (WHO code) 
Austria Burgenland (ATOl) Vorarlberg (AT08) Vienna (AT09) 
Azerbaijan Other regions (AZOl) Nakhichevan (AZ03) Baku (AT04) 
Belarus Grodno (BY02) Minsk city (BY04OI) Vitebsk (BY06) 
Gomel (BY03) 
-
Belgium Flemish Region (BEl) Walloon Region (BE2) Brussels (BID) 
Bulgaria (BG02) Plovdiv (BGOS) Sofia city (BG07) 
Mikhaylovgrad (BG04) Razgrad (BG06) 
Czech Prague (CZOl) Jihomoravsky (CZ03) Severomora-vsky (eZ05) 
Re~ublic Jihoeesky (CZ02) Stredoeesky (CZ06) 
Denmark Copenhagen and (DKOll) Frederiksborg 
-------"- ---
(DK013) Bomholm (DK023) 
Frederiksberg (city) Roskilde (DK014) Sonderjylland (DK032) 
CoQenhagen (DKOl2) 
Finland Ahvenanmaa (FLOl) Mikkeli (FL07) Oulu (FLU) 
Lappi (FL06) Uusimaa (FL08) 
France TIe de France (FROl) limousin 
-- --
(FR63) 
----,----
Corsica (FR83) 
Pays de la Loire (FRSl) - ----~-- -
Germany Hamburg (DE2) Berden Wurttem-berg (DEB) Saxony 
(DEE) 
Bremen (DE4) Brandenburg (DEC) Berlin (West) (DEBW) 
North Rhine-WestJ>halia (DES) -- ------ ----- - ------
Greece Attica (GR3) Ionian Islands (GR22) Aegean North 
(GR42) 
Macedonia Central (GRI2) Aegean South (GR4l) 
Hungary Budapest (HU05) Komarom-Esztergom (HU12) 
Nograd (HU15) 
Fejer (HU07) Somogy ~l_~_ 
(HU16) 
Italy Lombary (IT2) Liguria (lT13) Puglia 
(IT9I) 
Valle d' Aosta (lTl2) (IT33) 
(IT93) 
Kazakstan South Kazakstan (KZ03) Atyrau 
(KZ06) 
_TurgC!}' (KZ16) 
--- ---
Kyrgystan Bishkek (KGOI) Issyk-Kul (KG04) 
Talas (KG07) 
Dzhalal-Abad (KG03) Osh 
(KG06) 
-
Netherlands Groningen (NUl) Noord-Brabant 
(NlSI) Zeeland (NL74) 
Flevoland (NU5) Zuid-Holland 
(NL73) 
-- --
Norway Finnmark (NOO3) 
Oslo og Akershus (NOlO) Rogalnd (NOI2) 
Hedmark (NOO4) 0stfold 
(NOll) 
---
Poland Chelm 
(PL05) Legnica (PL19) Nowy Sacz 
(PU4) 
Katowice 
(PU3) Lodz (PUI) Sieradz 
(pL36) 
(PU6) ------ (PT14) 
Portugal Azores 
(PT2) Norte (PT11) _A!entejo_ 
----
Romania Arad 
(ROO2) Bucharest (ROlO) Iasi 
(R025) 
(ROO4) Covasna (R0l6) Vaslui 
(R039) 
Bacau (ROO8) 
Brasov Moskow city (RU0314) 
Russian Tura (RUlOO5) 
Pskov (RU0203) 
Federation Chukotka 
(RUll09) St Petersb~ _ (RU0204) 
-
_ __ (SKO~ _ Za~doslove!1~ky (SK04) 
Slovakia Bratislava 
(Continued over page) 
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Spain Asturias (ES12) Extremadura 
- ----
(ES43) Ceutay Melilla (ES63) 
Madrid (ES3) Andalusia (ES6l) Canary Island (ES?) Sweden Gavleborg (SE04) Jamtland (SE07) Stockholm (SE19) 
Gotland (SE05) Norrbotten (SEl4) 
Switzerland Appenzell-Inner Rhoden (CH03) - - --Basle city (CH05) Zug (eH25) Basle (CH04) Uri (CH22) Zurich (CH26) 
Tajikistan Dushanke (nOl) Kuliabsk (rJ04) Other regions (f107) 
Gomo-Budakhshan (rJ02) Khudzand (rJ05) 
-----
-----Turkmenistan Ashgabat (fMOl) Tahauz (fM04) 
__ Otherr:~onli ___ (fM05) 
Ukraine Chernihiv (UAOlO2) Kiev city (UA01l4) Kirovohrad (UA0304) 
Chermihiv (UAOlO3) Donetsk (UA0302) 
_ ?-aP()rizlrya (UA0308) 
United Bedfordshire (UK511) East Sussex (UK53l) Powys (UK914) 
Kingdom Berkshire (UK52l) Greater London (UK55) Northen Ireland (UKB) 
Buckinghamshire (UK522) Isle of Wight (UK562) 
------- -----
Uzbekistan Dzhizak (UZ03) Syr-Darya (UZll) Tashkent city (UZ13) 
Samarkand (UZ09) 
Yugoslavia Montenegro (YUOl) Serbia (YU03) 
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Appendix 2: WinBugs code 
A2.1 Code for Multiple-Membership Multiple Classification (MMMC) model 
#----MO DEL Defin ition----------------
model 
{ 
# Level 1 definition 
for(i in 1 :N) { 
deaths[i] - dpois(mu[i]) 
log(mu[i]) <- offs[i] + beta[1] 
+ beta[2] * smoke[i] 
+ beta[3] * fruit[i] 
+ beta[4] * veg[i] 
+ beta[5] * animal[i] 
+ beta[6] * alcohol[i] 
+ beta[7] * GDP[i] 
+ u2[region[i]] 
+ weight1 [i] * u3[neigh1 [i]] 
+ weight2[i] * u3[neigh2[i]] 
+ weight3[i] * u3[neigh3[ij] 
+ weight4[i] * u3[neigh4[i]] 
+ weight5[~ * u3[neigh5[ij] 
+ weight6[i] * u3[neigh6[i]] 
+ weight7[i] * u3[neigh7[i]] 
+ weight8[i] * u3[neigh8[i]] 
+ weight9[i] * u3[neigh9[i]] 
+ weight10[i] * u3[neigh1 O[i]] 
+ weight11 [i] * u3[neigh11 [i]] 
+ weight12[i] * u3[neigh 12[i]] 
} 
# Higher level definitions 
for 0 in 1 :n2) { 
u2D] - dnorm(0,tau.u2) 
} 
for 0 in 1 :n3) { 
u3D] - dnorm(0,tau.u3) 
} 
# Priors for fixed effects 
for (k in 1 :7) { beta[k] - dflatO } 
# Priors for random terms 
tau.u2 - dgamma(0.001 000,0.001 000) 
sigma2.u2 <- 1/tau.u2 
tau.u3 - dgamma(0.001 000,0.001 000) 
sigma2.u3 <- 1/tau.u3 
} 
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A2.2 Code for Conditional Autoregressive (CAR) model 
#----MODEL Definition----------------
model 
{ 
# Level 1 definition 
for(i in 1 :N) { 
deaths[i] - dpois(mu[i]) 
log(mu[i]) <- offs[i] + beta[1] * smoke[i] 
+ beta[2] * fruit[i] 
+ beta[3] * veg [i] 
+ beta[4] * animal[i] 
+ beta[5] * alcohol[i] 
+ beta[6] * GDP[i] 
+ carmean + u2[region[i]] 
+ u3[region[i]] 
} 
# Higher level definitions 
for 0 in 1 :n2) { 
u2m - dnorm(0,tau.u2) 
} 
u3[1 :n3] - car.normal(adjD,weightsD,numD,tau.u3) 
# Priors for fixed effects 
for (k in 1 :6) { beta[k] - dflatO } 
carmean - dflatO 
# Priors for random terms 
tau.u2 - dgamma(0.001 000,0.001 000) 
sigma2.u2 <- 1/tau.u2 
tau.u3 - dgamma(0.001 000,0.001 000) 
sigma2.u3 <- 1/tau.u3 
Appendix 2 
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A2.3 Data file for spatial multilevel model fitted in equations (6.5) and (6.6) 
#----Data File------------------------------___ _ 
Iist(N= 187, 
R2 = structure( 
.Data = c(0.0055, 0.002, 
0.002, 0.055), 
.Dim = c(2,2)), 
region = c(1 ,2,3,4,5,6,7,8,9,10,11,12, ... ,187) 
neigh1 = c(6,8,9, 18, 18,8, 18, 18,8,61 ,12,92, .. .',186), 
neigh2 = c(3,7,8,6, 7,5,8,9,3,34,10,91, ... ,1), 
neigh3 = c(1 ,6,6,5,6,4,5,7,1 ,22,1 ,89, ... ,1), 
ne~gh4 = c(1 ,5,4,3,4,3,2,6,1 ,12,1 ,25, ... ,1), 
ne~gh5 = c(1 ,1 ,1 ,1,2,2,1 ,3,1 ,11,1 ,24, ... ,1), 
ne~gh6 = c(1,1,1,1,1,1,1 ,2,1,1,1,22, ... ,1), 
nelgh7 = c(1, 1,1,1,1,1,1,1,1,1,1,21, ... ,1), 
neigh8 = c(1 ,1,1,1,1,1,1,1,1,1,1,15, ... ,1), 
neigh9 = c(1,1,1,1,1,1,1,1,1,1,1 ,14, ... ,1), 
neigh10 = c(1 ,1 ,1 ,1 ,1 ,1 ,1 ,1 ,1 ,1 ,1 ,13, ... ,1), 
neigh11 = c(1,1,1,1,1,1,1,1,1,1,1 ,11 , ... ,1), 
neigh12 = c(1,1,1,1,1,1,1,1,1,1,1,10, ... , 1), 
weight1 = c(0.500,0.250,0.200,0.250,0.200,0.167 ,0.250,0.167 ,0.500,0.200,0.500.0.083 •... ,1 .000). 
weight2 = c(0.500,0.250.0.200,0.250,0.200,0.167.0.250,0.167,0.500.0.200,0.500,0.083 •... ,0.000), 
weight3 = c(0.000,0.250,0.200,0.250,0.200.0.167,0.250,0.167 .0.000,0.200.0.000,0.083, ... ,0.000). 
weight4 = c(0.000,0.250,0.200,0.250,0.200,0.167,0.250,0.167 .0.000,0.200,0.000,0.083 •... ,0.000), 
weight5 = c(0.000,0.000,0.200,0.000,0.200,0.167.0.000.0.167 ,0.000.0.200,0.000,0.083, ...• 0.000), 
weight6 = c(0.000.0.000,0.000,0.000,0.000,0.167 ,0.000,0.167 ,0.000,0.000,0.000.0.083 •... ,0.000), 
weight7 = c(O.OOO,O.OOO,O.OOO,O.OOO,O.OOO,O.OOO,O.OOO.O.OOO.O.Ooo,0.000,0.000,0.083, ... ,0.000), 
weight8 = c(O.OOO.O.OOO,O.OOO.O.OOO,O.OOO,O.OOO,O.OOO,O.OOO,O.OO0,0.000.0.000.0.083 •...• 0.000). 
weight9 = c(O.OOO,O.OOO,O.OOO,O.OOO,O.OOO.O.OOO,O.OOO,O.OOO,O.OO0,0.000,0.000,0.083, ... ,0.000), 
weight10 = c(O.OOO,O.OOO,O.OOO,O.OOO,O.OOO,O.OOO,O.OOO,O.OOO.O.OO0.0.000.0.000.0.083, ... ,0.000). 
weight11 = c(O.OOO,O.OOO,O.OOO.O.OOO,O.OOO.O.OOO,O.OOO.O.OOO.O.OO0.0.000.0.000.0.083 •...• 0.000). 
weight12 = c(O.OOO.O.OOO,O.OOO,O.OOO.O.OOO.O.OOO.O.OOO.O.OOO,O.OO0,0.000.0.000.0.083 •...• 0.000). 
smoke = c(221 0.0,221 0.0,221 0.0,221 0.0.221 0.0,221 0.0,221 0.0.221 0.0.221 0.0.2360.0.2360.0. 
2360.0,2360.0 •... ,221 0.0), 
fruit = c(139.2, 139.2,139.2,139.2,139.2,139.2.139.2,139.2.139.2,118.8,118.8.118.8 •...• 74.5). 
veg = c(80.6,80.6,80.6,80.6,80.6,80.6,80.6,80.6,80.6.78.6,78.1 ,78.1, '" .88.2). 
animal = c(21.1 ,21.1 ,21.1,21.1,21.1,21.1.21.1,21.1.21.1,19.9,19.9, 19.9 •...• 9.7), 
alcohol = c(166.0, 166.0, 166.0, 166.0, 166.0, 166.0, 166.0.166.0.166.0, 173.9, 173.9, 173.9, ... ,123.2), 
gdp = c(13756.0, 18239.0, 17338.0,2071 0.0,25118.0,17903.0,22431.0.22519.0.33902.0,22100.0. 
38689.0,21355.0, ... ,11461.0), 
offs = c(-0.998,-0.339,0.700,0.498,-0.551 ,0.461 ,-0.296,-1.015,0.886.1.337.0.943,2.355, ... ,0.593), 
deaths = c(769.0, 1407.0,3779.0,2875.0, 1012.0,2890.0,1267.0.642.0,4676.0,7379.0,5310.0. 
20009.0, ... ,3486.0)) 
The data file is shown for regions 1-12 and 187. The weight structure is given through the 
variables neigh 1 , ... ,neighl2 and weightl, ... weightl2. For example region 1 has 2 
neighbours (regions 6 and 3) and those neighbours are given equal weights of lIni = 0.5. 
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Appendix 3: Convergence Diagnostic Plots 
A3.1 Convergence plots for fixed parameters from MMMC model 
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A3.2 Convergence plots for fixed parameters from MMMC model 
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Convergence plots for each of the fixed parameters are given above . The Monte 
Carlo error is given on the Y-axis and the number of iterations is given on the x-
axis. The blue line plots how many iterations are needed to achie\'e a posterior 
mean parameter estimate with a desired Monte Carlo error value . The red line 
plots the MC error value that is 5% of the posterior standard de\i ation: hence (1 
suitable bum-in with an adequate number of further iterations ha been (1chie\ cd . 
Only the fixed parameters are given as prev ious mode l! ing hO\\'ed that these 
require the most number of iterations. 
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